image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
70ca4017de011a93ee2ccf5e9c70e52e6f6ac8c0073c2e5baf76c3ea7897ff9d.png | simple | <table><tr><td></td><td>All patients<i>N</i>= 14</td><td>Survivors<i>n</i>= 7</td><td>Nonsurvivors<i>n</i>= 7</td><td><i>P</i>value</td></tr><tr><td>Characteristics at ICU admission</td><td></td><td></td><td></td><td></td></tr><tr><td> Age</td><td>32 (22–51)</td><td>23 (21–44)</td><td>48 (30–58)</td><td>0.14</td></tr><tr><td> Male sex</td><td>8</td><td>4</td><td>4</td><td>1.00</td></tr><tr><td> CCI</td><td>2 (2–2)</td><td>2 (2–2)</td><td>2 (2–4)</td><td>0.48</td></tr><tr><td> SAPS II</td><td>51 (42–65)</td><td>56 (43–63)</td><td>45 (39–68)</td><td>0.90</td></tr><tr><td> Prior allogeneic stem cell transplantation</td><td>4</td><td>0</td><td>4</td><td><0.01</td></tr><tr><td> Days from diagnosis of HM to ECMO</td><td>87 (6–907)</td><td>0 ((−1)–116)</td><td>759 (69–1,228)</td><td>0.04</td></tr><tr><td> Days from ICU admission to ECMO</td><td>2 (0–3)</td><td>1 (0–2)</td><td>3 (1–11)</td><td>0.08</td></tr><tr><td> Days from intubation to ECMO</td><td>2 (1–5)</td><td>1 (0–2)</td><td>3 (1–9)</td><td>0.17</td></tr><tr><td>Characteristics at ECMO baseline</td><td></td><td></td><td></td><td></td></tr><tr><td> SOFA score</td><td>12 (11–13)</td><td>12 (12–19)</td><td>12 (11–15)</td><td>0.79</td></tr><tr><td> Lung injury score</td><td>3.3 (3.3–3.7)</td><td>3.3 (2.3–3.7)</td><td>3.5 (3.3–3.8)</td><td>0.09</td></tr><tr><td> PaO<sub>2</sub>/FiO<sub>2</sub> ratio</td><td>60 (53–65)</td><td>63 (51–106)</td><td>60 (48–61)</td><td>0.44</td></tr><tr><td> pH</td><td>7.29 (7.23–7.37)</td><td>7.29 (7.23–7.39)</td><td>7.37 (7.21–7.46)</td><td>0.52</td></tr><tr><td> PaCO<sub>2</sub>, mm Hg</td><td>49 (43–59)</td><td>41 (38–49)</td><td>55 (48–72)</td><td>0.05</td></tr><tr><td> Lactate, m<i>M</i></td><td>2.2 (1.6–4.8)</td><td>3.8 (1.6–7.1)</td><td>2.0 (1.0–5.0)</td><td>0.34</td></tr><tr><td> Hemoglobin, g/dl</td><td>9.4 (8.8–10.4)</td><td>9.4 (8.6–10.5)</td><td>9.8 (8.4–10.4)</td><td>0.90</td></tr><tr><td> Leukocytes, G/L</td><td>6.0 (2.5–12.6)</td><td>11.0 (3.6–17.0)</td><td>5.6 (2.0–12.8)</td><td>0.34</td></tr><tr><td> Platelets, G/L</td><td>38 (30–113)</td><td>64 (29–201)</td><td>35 (10–88)</td><td>0.21</td></tr><tr><td> Prothrombin time, %</td><td>70 (43–74)</td><td>50 (18–72)</td><td>73 (64–78)</td><td>0.22</td></tr><tr><td> Fibrinogen, mg/dl</td><td>436 (220–522)</td><td>473 (160–627)</td><td>421 (294–531)</td><td>1.00</td></tr><tr><td> Etiology of ARF determined<sup>a</sup></td><td>7</td><td>5</td><td>2</td><td>0.29</td></tr><tr><td> Clinical diagnosis of pneumonia</td><td>10</td><td>3</td><td>7</td><td>0.07</td></tr><tr><td>Characteristics during ECMO</td><td></td><td></td><td></td><td></td></tr><tr><td> Venoarterial ECMO</td><td>3</td><td>3</td><td>0</td><td>0.19</td></tr><tr><td> Duration of ECMO therapy, days</td><td>8.5 (4–16)</td><td>4 (3–9)</td><td>10 (7–28)</td><td>0.08</td></tr><tr><td> Diagnosis of HM on ECMO</td><td>4</td><td>4</td><td>0</td><td>0.07</td></tr><tr><td> Chemotherapy on ECMO</td><td>5</td><td>4</td><td>1</td><td>0.27</td></tr><tr><td> Vasopressors</td><td>14</td><td>7</td><td>7</td><td>na</td></tr><tr><td> Hemofiltration</td><td>5</td><td>2</td><td>3</td><td>1.00</td></tr><tr><td> Major bleeding events</td><td>5</td><td>1</td><td>4</td><td>0.27</td></tr><tr><td> Number of packed red blood cell units</td><td>8 (4–14)</td><td>4 (3–8)</td><td>14 (6–27)</td><td>0.02</td></tr><tr><td> Number of platelet concentrates</td><td>5 (1–17)</td><td>2 (0–5)</td><td>23 (14–26)</td><td>0.01</td></tr><tr><td>Outcome</td><td></td><td></td><td></td><td></td></tr><tr><td> ICU LOS, days</td><td>22 (14–42)</td><td>22 (21–77)</td><td>18 (11–40)</td><td>0.12</td></tr><tr><td> Hospital LOS, days</td><td>56 (44–101)</td><td>63 (49–110)</td><td>45 (15–133)</td><td>0.46</td></tr><tr><td> ICU and hospital survival, <i>n</i> (%)</td><td>7 (50%)</td><td></td><td></td><td></td></tr></table> |
666738745146b41cb8e579e2d31130299bca66ed717e46b4e730c78926cd712e.png | complex | <table><tr><td></td><td colspan="2">Sham-vehicle (pg/mL)</td><td colspan="2">Sham-EFX (pg/mL)</td><td colspan="2">TBI-vehicle (pg/mL)</td><td colspan="2">TBI-EFX (pg/mL)</td><td>TBI-vehicle vs. TBI-EFX</td></tr><tr><td></td><td>Ipsilateral</td><td>Contralateral</td><td>Ipsilateral</td><td>Contralateral</td><td>Ipsilateral</td><td>Contralateral</td><td>Ipsilateral</td><td>Contralateral</td><td>% decrease (ipsilateral side)</td></tr><tr><td colspan="9">Pro-inflammatory cytokines</td><td></td></tr><tr><td> IL-1α</td><td>5.75 ± 0.87</td><td>5.17 ± 0.22</td><td>5.53 ± 0.81</td><td>3.83 ± 0.88</td><td>40.41 ± 5.14***</td><td>3.27 ± 0.63</td><td>13.55 ± 2.65**</td><td>1.32 ± 0.77</td><td>33</td></tr><tr><td> IL-1β</td><td>45.14 ± 2.89</td><td>37.68 ± 2.43</td><td>56.58 ± 9.43</td><td>34.77 ± 3.25</td><td>382.88 ± 64.66***</td><td>33.98 ± 1.57</td><td>148.97 ± 25.50**</td><td>29.82 ± 1.72</td><td>39</td></tr><tr><td> IL-2</td><td>26.47 ± 0.75</td><td>24.84 ± 0.70</td><td>23.48 ± 0.50</td><td>22.89 ± 1.57</td><td>27.55 ± 4.42</td><td>21.55 ± 0.62</td><td>23.44 ± 1.64</td><td>20.46 ± 0.64</td><td>ns</td></tr><tr><td> IL-6</td><td>2.65 ± 0.33</td><td>1.76 ± 0.23</td><td>14.00 ± 8.89</td><td>3.21 ± 0.71</td><td>150.18 ± 21.25***</td><td>4.34 ± 0.64</td><td>41.97 ± 10.25**</td><td>1.86 ± 0.51</td><td>28</td></tr><tr><td> IL-12</td><td>8.87 ± 0.29</td><td>8.54 ± 0.38</td><td>7.50 ± 0.24</td><td>7.50 ± 0.95</td><td>7.41 ± 0.26</td><td>6.95 ± 0.38</td><td>6.95 ± 0.20</td><td>7.10 ± 0.20</td><td>ns</td></tr><tr><td> TNF-α</td><td>5.34 ± 0.35</td><td>1.30 ± 0.14</td><td>5.93 ± 0.36</td><td>4.48 ± 0.84</td><td>16.34 ± 1.71***</td><td>5.24 ± 0.62</td><td>9.91 ± 1.28**</td><td>5.91 ± 0.70</td><td>60</td></tr><tr><td> GM-CSF</td><td>2.49 ± 0.67</td><td>2.24 ± 0.49</td><td>2.06 ± 0.26</td><td>1.52 ± 0.29</td><td>1.20 ± 0.22</td><td>1.15 ± 0.17</td><td>1.07 ± 0.27</td><td>1.36 ± 0.14</td><td>ns</td></tr><tr><td colspan="9">Anti-inflammatory cytokines</td><td></td></tr><tr><td> IL-4</td><td>2.86 ± 0.13</td><td>2.50 ± 0.08</td><td>3.20 ± 0.53</td><td>2.85 ± 0.51</td><td>4.19 ± 0.78</td><td>2.54 ± 0.05</td><td>3.65 ± 0.72</td><td>2.32 ± 0.13</td><td>ns</td></tr><tr><td> IL-5</td><td>11.22 ± 0.24</td><td>10.74 ± 0.24</td><td>7.93 ± 0.31</td><td>6.72 ± 1.71</td><td>9.34 ± 0.63</td><td>9.24 ± 0.89</td><td>9.30 ± 1.18</td><td>9.00 ± 1.13</td><td>ns</td></tr><tr><td> IL-10</td><td>25.99 ± 1.60</td><td>24.13 ± 1.67</td><td>19.94 ± 2.04</td><td>19.66 ± 4.35</td><td>35.29 ± 4.98</td><td>17.52 ± 2.82</td><td>28.48 ± 2.45</td><td>23.12 ± 0.83</td><td>ns</td></tr><tr><td colspan="9">Macrophage-attracting chemokines</td><td></td></tr><tr><td> MIP-1α</td><td>1.71 ± 1.01</td><td>0.04 ± 0.04</td><td>2.64 ± 1.3</td><td>0.00 ± 0.00</td><td>90.42 ± 25.47***</td><td>0.00 ± 0.00</td><td>36.99 ± 4.51*</td><td>0.24 ± 0.21</td><td>41</td></tr><tr><td> MCP-1</td><td>7.50 ± 1.97</td><td>4.30 ± 0.63</td><td>12.82 ± 5.16</td><td>4.25 ± 0.64</td><td>93.82 ± 21.66***</td><td>5.53 ± 0.97</td><td>53.00 ± 7.45*</td><td>6.34 ± 1.55</td><td>56</td></tr></table> |
6c8d37e7e4fd59887a0ee55868466c7ec84f4ab9fd67b607ce05921755b255b6.png | simple | <table><tr><td></td><td></td><td>Enrichment score<sup>+</sup></td><td>Protein count (%)</td><td>Protein ID</td><td>P value</td></tr><tr><td>Biological process</td><td>Regulation of response to external stimulus</td><td>2.3</td><td>3 (27.27)</td><td>AHSG, C3, HRG</td><td>4.69e-3</td></tr><tr><td></td><td>Cellular iron ion homeostasis</td><td>2.13</td><td>3 (27.27)</td><td>HAP, HPX, TF</td><td>1.81e-4</td></tr><tr><td></td><td>Iron ion homeostasis</td><td>2.13</td><td>3 (27.27)</td><td>HAP, HPX, TF</td><td>2.45e-4</td></tr><tr><td></td><td>Cellular di-, tri-valent inorganic cation homeostasis</td><td>2.13</td><td>3 (27.27)</td><td>HAP, HPX, TF</td><td>9.34e.3</td></tr><tr><td></td><td>Di-, tri-valent inorganic cation homeostasis</td><td>2.13</td><td>3 (27.27)</td><td>HAP, HPX, TF</td><td>1.03e-2</td></tr><tr><td></td><td>Cellular cation homeostasis</td><td>2.13</td><td>3 (27.27)</td><td>HAP, HPX,TF</td><td>1.16e-2</td></tr><tr><td>Molecular function</td><td>Endopeptidase inhibitor activity</td><td>2.3</td><td>3 (27.27)</td><td>AHSG,C3, HRG</td><td>3.32e-3</td></tr><tr><td></td><td>Peptidase inhibitor activity</td><td>2.3</td><td>3 (27.27)</td><td>AHSG, C3, HRG</td><td>3.69e-3</td></tr><tr><td></td><td>Enzyme inhibitor activity</td><td>2.3</td><td>3 (27.27)</td><td>AHSG, C3, HRG</td><td>1.11e-2</td></tr><tr><td>Cellular component</td><td>Extracellular region</td><td>8.11</td><td>11 (100)</td><td>A1BG, AHSG, APOA1, AZGP1, C3, FGG, HAP, HPX, HRG, LRG1, TF</td><td>2.66e-11</td></tr><tr><td></td><td>Secretory granule</td><td>2.31</td><td>4 (36.36)</td><td>APOA1, FGG, HRG, TF</td><td>3.06e-4</td></tr><tr><td></td><td>Cytoplasmic membrane-bounded vesicle</td><td>2.31</td><td>4 (36.36)</td><td>APOA1, FGG, HRG, TF</td><td>7.58e-3</td></tr><tr><td></td><td>Membrane-bounded vesicle</td><td>2.31</td><td>4 (36.36)</td><td>APOA1, FGG, HRG, TF</td><td>8.29e-3</td></tr><tr><td></td><td>Cytoplasmic vesicle</td><td>2.31</td><td>4 (36.36)</td><td>APOA1, FGG, HRG, TF</td><td>1.16e-2</td></tr></table> |
d8f308e2f0a414e5569cfb21b6018be948f75df541aebaa952800a95b3a4278b.png | complex | <table><tr><td> </td><td> </td><td colspan="4">Assessment</td></tr><tr><td>Outcomes</td><td>Measures</td><td>t1</td><td>t2</td><td>t3</td><td>t4</td></tr><tr><td rowspan="2">Self-management competence (primary outcome)</td><td>Health education impact questionnaire heiQ, German version [29]. Subscales Self-monitoring and insight, Skill and technique acquisition</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Kansas City Cardiomyopathy Questionnaire KCCQ, German version [30]. Subscale self-efficacy</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Determinants of behavior:</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Intention, action and coping planning, action control</td><td>HAPA-scales [31,32]</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Medication beliefs</td><td>Beliefs about Medicine Questionnaire BMQ-D [33], German version</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Self-management behavior:</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Symptom control</td><td>Questionnaire will be developed by our research group</td><td>X</td><td>---</td><td>X</td><td>X</td></tr><tr><td>Physical activity</td><td>Godin Leisure-Time Exercise Questionnaire [34], German modified version</td><td>X</td><td>---</td><td>X</td><td>X</td></tr><tr><td>Medication adherence</td><td>Medication Adherence Report Scale MARS-D, German version [35]</td><td>X</td><td>---</td><td>X</td><td>X</td></tr><tr><td>Health-related quality of life (disease specific)</td><td>Kansas City Cardiomyopathy Questionnaire KCCQ, German version [30]</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Treatment satisfaction</td><td>Short questionnaire developed by our research group [36]</td><td>---</td><td>X</td><td>---</td><td>---</td></tr></table> |
680ca7816f8d4e6cd4064f17c21f45ccbedd9b8af99d9838740a5cd353d040c0.png | complex | <table><tr><td rowspan="2">Year of birth</td><td colspan="6">DHS</td><td colspan="2">Masakacohort</td><td colspan="2">Rakaicohort</td></tr><tr><td>1988</td><td>1995</td><td>2001</td><td>2006</td><td>Total</td><td>Median AFS†</td><td>N</td><td>Median AFS</td><td>N</td><td>Median AFS</td></tr><tr><td>1950–9</td><td>1158</td><td>1171</td><td>777</td><td>360</td><td>3466</td><td>15.9</td><td>581</td><td>16.6</td><td>1039</td><td>15.9</td></tr><tr><td>1960–9</td><td>1948</td><td>2273</td><td>1604</td><td>1553</td><td>7378</td><td>16.1</td><td>1030</td><td>16.8</td><td>2196</td><td>16.0</td></tr><tr><td>1970–9</td><td>947</td><td>3199</td><td>2805</td><td>2497</td><td>9448</td><td>16.4</td><td>1768</td><td>17.0</td><td>5606</td><td>16.6</td></tr><tr><td>1980–9</td><td>0</td><td>131</td><td>2060</td><td>3366</td><td>5557</td><td>17.1</td><td>3235</td><td>17.5</td><td>4853</td><td>16.5</td></tr><tr><td>1990–94</td><td>0</td><td>0</td><td>0</td><td>755*</td><td>755*</td><td>–</td><td>829</td><td>16.9</td><td>0</td><td>–</td></tr><tr><td>Total</td><td>4053</td><td>6774</td><td>7246</td><td>8531</td><td>26604</td><td>16.4</td><td>7443</td><td>17.1</td><td>13694</td><td>16.4</td></tr></table> |
29cb3f0e7893ab597aab46561e0a05f25f82bce5d17d1d6f0d75ce0198bba48c.png | simple | <table><tr><td></td><td>Hypermethylated</td><td>Hypomethylated</td></tr><tr><td>n</td><td>3925</td><td>4615</td></tr><tr><td>CpG island location</td><td>CpG islands</td><td>Non-CGI</td></tr><tr><td>Genomic location</td><td>TSS, 1st exon</td><td>Gene body, outside genes</td></tr><tr><td>Associated genes</td><td>1832</td><td>2057</td></tr><tr><td>GO function terms</td><td>36</td><td>27</td></tr><tr><td>GO process terms</td><td>265</td><td>53</td></tr><tr><td>Canonical pathways (IPA)</td><td>19</td><td>3</td></tr><tr><td>Transcription factors</td><td>24</td><td>1</td></tr></table> |
8d95d0c0471e62d68655ba12f515a815168f5b585c33d726f602a45f72f056db.png | complex | <table><tr><td></td><td>DNA binding consensus sequence</td><td>Putative binding site found in putative ATRX promoter</td><td>Biological roles</td><td>References</td></tr><tr><td colspan="5">5'UTR of ATRX (+215 to +1)</td></tr><tr><td>YY1(+38 to +29)</td><td>SNCCATNTT</td><td>CGCCATTTT</td><td>Activator/repressor involved in neural development with roles in the testis and meiosis</td><td>[35,36]</td></tr><tr><td colspan="5">ATRX promoter region</td></tr><tr><td>Inr element(-2 to +3)</td><td>CTTNACC</td><td>CTTAACC</td><td>Binds to basal transcription factor TFIID</td><td>[19]</td></tr><tr><td>CCAAT boxes(-2 to +3)(-38 to -34)(-69 to -65)</td><td>CCAAT</td><td>CCAAT</td><td>Binds NF-Y, C/EBP, GATA1, NF-E3</td><td>[42]</td></tr><tr><td>E2F(-6 to -1)</td><td>TTTGGCGC</td><td>ATTGGCGC</td><td>Family of TFs that regulate mitosis, apoptosis, DNA repair, development and differentiation</td><td>[52]</td></tr><tr><td>CREB(-122 to -117)</td><td>TGACGTCA</td><td>CGACGTCA</td><td>Mediation of basal and PKA-inducible transcription</td><td>[65]</td></tr><tr><td>HNF4(-173 to -168)</td><td>TGACCT</td><td>TGACCT</td><td>Liver factor involved in liver development and digestive function</td><td>[66]</td></tr><tr><td colspan="5">CR1</td></tr><tr><td>STAT5B(-963 to -956)</td><td>TTCN<sub>3</sub>GAA</td><td>TTCAAGAA</td><td>Involved in immune response, erythropoesis and mammary development</td><td>[67]</td></tr><tr><td>CP2(-1017 to -1003)</td><td>A/TCTGG-CNRGN<sub>6</sub>CNRS</td><td>CTATT-CCAGN<sub>6</sub>GCAG</td><td>Regulates transcription of <i>SRY</i>. Initially shown to bind murine alpha-globin gene</td><td>[50]</td></tr><tr><td>E2F (-796 to -791)</td><td>TTTGGCGC</td><td>TTTGGCTG</td><td>See E2F above</td><td>[52]</td></tr><tr><td colspan="5">CR2</td></tr><tr><td>HNF6(-1413 to -1408)</td><td>GAATCA</td><td>GAAGCY</td><td>Liver factor involved in regulation of HNF4 and pancreatic precursor cells</td><td>[68]</td></tr><tr><td colspan="5">CR3</td></tr><tr><td>FOXJ2/NKX2-5(-12720 to -12714)</td><td>TNAAGTG</td><td>TTAAGTA</td><td>Involved in regulation of cardiogenesis</td><td>[69]</td></tr></table> |
60d546ab259643f76441db8ae7c96804217c80fd0354e60c647ba91efccd1cab.png | complex | <table><tr><td rowspan="2">Titer of serum from one sheep infected intrapulmonarily with 300.000 TCID 50 of virus K796</td><td colspan="3">Virus strains</td></tr><tr><td>K796</td><td>10B</td><td>7W</td></tr><tr><td>Serum 13 months after infection with K796</td><td>128</td><td>16</td><td>8</td></tr><tr><td>Serum 3 years after infection with K796</td><td>256</td><td>32</td><td>16</td></tr><tr><td>Titer of serum from one naturally infected sheep in Cyprus</td><td>16</td><td>128</td><td>128</td></tr></table> |
46bd3b3d1179ae47f818c27abd6961b5fb77410a4c706727c1291fe9d91e653a.png | simple | <table><tr><td>Gene ID</td><td>Gene Product Description</td><td>Hilltop</td><td>Valley bottom</td></tr><tr><td>PF3D7_1121600</td><td>circumsporozoite-related antigen (CRA)</td><td>0.12 (0.05 - 0.19)</td><td>0.51 (0.39 - 0.63)</td></tr><tr><td>PF3D7_1035700</td><td>duffy binding-like merozoite surface protein (DBLMSP)</td><td>0.11 (0.05 - 0.17)</td><td>0.92 (0.33 - 1.51)</td></tr><tr><td>PF3D7_0108700</td><td>secreted ookinete protein, putative (PSOP24)</td><td>0.13 (0.01 - 0.25)</td><td>0.93 (0.41 - 1.44)</td></tr><tr><td>PF3D7_0206900.1</td><td>merozoite surface protein 5 (MSP5)</td><td>0.08 (0.05 - 0.11)</td><td>0.51 (0.26 - 0.76)</td></tr><tr><td>PF3D7_0501800</td><td>chromosome assembly factor 1 (CAF1), residues 692-1,239</td><td>0.09 (0.03 - 0.15)</td><td>0.47 (0.26 - 0.67)</td></tr><tr><td>PF3D7_0815500</td><td>conserved Plasmodium protein </td><td>0.05 (0.03 - 0.07)</td><td>0.34 (0.17 - 0.51)</td></tr><tr><td>PF3D7_1014100</td><td>conserved Plasmodium protein </td><td>0.14 (0.02 - 0.25)</td><td>0.92 (0.33 - 1.51)</td></tr><tr><td>PF3D7_0207000</td><td>merozoite surface protein 4 (MSP4), residues 1-164 (exon 1)</td><td>0.16 (0.01 - 0.30)</td><td>0.49 (0.38 - 0.60)</td></tr><tr><td>PF3D7_1002000</td><td>Plasmodium exported protein (hyp2) </td><td>0.07 (0.01 - 0.12)</td><td>0.33 (0.19 - 0.47)</td></tr><tr><td>PF3D7_0619000.1</td><td>conserved Plasmodium protein </td><td>0.05 (0.01 - 0.09)</td><td>0.37 (0.14 - 0.61)</td></tr><tr><td>PF3D7_1100800</td><td>Maurer's cleft two transmembrane protein (MC-2TM)</td><td>0.10 (0.04 - 0.16)</td><td>0.45 (0.21 - 0.68)</td></tr><tr><td>PF3D7_1134000</td><td>heat shock protein 70 (Hsp70-3)</td><td>0.13 (0.05 - 0.22)</td><td>0.40 (0.26 - 0.55)</td></tr></table> |
1531e52aadba335356f2ec49cfd195a538d76e5f25a9997b5597889b06cc83ea.png | simple | <table><tr><td>Traits/Disease</td><td>No. of Putative Associations</td></tr><tr><td>Conduct disorder (case status) *</td><td>11</td></tr><tr><td>Ischemic stroke</td><td>11</td></tr><tr><td>Atrial fibrillation/atrial flutter*</td><td>10</td></tr><tr><td>Permanent tooth development*</td><td>10</td></tr><tr><td>Conduct disorder (symptom count)*</td><td>9</td></tr><tr><td>Primary tooth development (time to first tooth eruption)*</td><td>8</td></tr><tr><td>Cleft lip*</td><td>7</td></tr><tr><td>Primary tooth development (number of teeth)*</td><td>5</td></tr><tr><td>Alcoholism (alcohol dependence factor score)*</td><td>4</td></tr><tr><td>Plasma coagulation factors*</td><td>3</td></tr><tr><td>Vitamin D insufficiency*</td><td>3</td></tr><tr><td>Vitamin D levels*</td><td>2</td></tr><tr><td>Atrial fibrillation*</td><td>1</td></tr><tr><td>Nonsyndromic cleft lip with or without cleft palate*</td><td>1</td></tr><tr><td>Plasma levels of Protein C*</td><td>1</td></tr><tr><td>Total</td><td>86</td></tr></table> |
22efd72395de644cf100ff1a0dbfa575c856e2af7df2bceecf1c4b4ba3023eaf.png | complex | <table><tr><td rowspan="2">Sentence duration</td><td rowspan="2"><i>N</i></td><td colspan="2">Plaque index</td><td colspan="2">Tartar index</td><td colspan="2">Total OHI</td></tr><tr><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td></tr><tr><td>Till 1 year</td><td>68</td><td>1.56</td><td>0.76</td><td>0.51</td><td>0.63</td><td>2.07</td><td>1.20</td></tr><tr><td>1–5 years</td><td>26</td><td>1.23</td><td>0.43</td><td>0.23</td><td>0.43</td><td>1.46</td><td>0.65</td></tr><tr><td>Over 5 years</td><td>6</td><td>1.00</td><td>0.00</td><td>0.00</td><td>0.00</td><td>1.00</td><td>0.00</td></tr><tr><td>Total</td><td>100</td><td>1.44</td><td>0.69</td><td>0.41</td><td>0.59</td><td>1.85</td><td>1.10</td></tr><tr><td colspan="2">Kruskal–Wallis test</td><td colspan="2"><i>P</i> < 0.05</td><td colspan="2"><i>P</i> < 0.05</td><td colspan="2"><i>P</i> < 0.05</td></tr></table> |
7a02b87600372d452fb70e72400d87c31ecbb664f0bd45cb8e87454b6f9cb32c.png | simple | <table><tr><td>HbB Genotype</td><td>Numbers (87)<sup>a</sup></td><td>G6PD Genotype</td><td>Numbers (84)<sup>a</sup></td><td>68 Status</td><td>126 Status</td><td>Deduced Phenotype<sup>b</sup></td></tr><tr><td></td><td></td><td>68–126</td><td></td><td></td><td></td><td></td></tr><tr><td>AA</td><td>75 (86%)</td><td>VV-NN<sup>c</sup></td><td>51 (61%)</td><td>Wildtype</td><td>Wildtype</td><td>G6PD B</td></tr><tr><td>SS</td><td>0</td><td>VV-DD<sup>d</sup></td><td>8 (10%)</td><td>Wildtype</td><td>Mutant</td><td>G6PD A</td></tr><tr><td>AS</td><td>12 (14%)</td><td>M-D<sup>e</sup></td><td>6 (7%)</td><td>Mutant</td><td>Mutant</td><td>G6PD A-</td></tr><tr><td>AC</td><td>0</td><td>VM-ND</td><td>10 (12%)</td><td>Single Mutant</td><td>Single Mutant</td><td>G6PD A</td></tr><tr><td>CC</td><td>0</td><td>VV-ND</td><td>8 (9%)</td><td>Wildtype</td><td>Single Mutant</td><td>G6PD A</td></tr><tr><td>SC</td><td>0</td><td>VM-DD</td><td>1 (1%)</td><td>Single Mutant</td><td>Mutant</td><td>G6PD A</td></tr><tr><td>No PCR-product</td><td>3</td><td>No PCR-product</td><td>6</td><td></td><td></td><td></td></tr></table> |
72c3d3f23844c468353ff726066aa1d0bf12c44d4f8d93ff22e69db51ac36de0.png | complex | <table><tr><td>Age</td><td colspan="2">65 – 74</td><td colspan="2">75 – 84</td><td colspan="2">≥ 85</td></tr><tr><td>Vaccinated</td><td>yes</td><td>no</td><td>yes</td><td>no</td><td>yes</td><td>no</td></tr><tr><td><i>2003 Influenza season</i></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Deaths/100 000</td><td>491</td><td>706</td><td>2235</td><td>2270</td><td>7224</td><td>7317</td></tr><tr><td> Reduction (95% CI) <i>p</i></td><td colspan="2">31% (0,44–1,07) < 0.1</td><td colspan="2">2% (0,79–1,22) < 0.9</td><td colspan="2">1% (0,81–1,20) < 0.9</td></tr><tr><td><i>Non-influenza season</i></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Deaths/100 000</td><td>610</td><td>767</td><td>2440</td><td>2332</td><td>6677</td><td>7580</td></tr><tr><td> Reduction (95% CI) <i>p</i></td><td colspan="2">21% (0,53–1,18) < 0.6</td><td colspan="2">- 5% (0,85–1,28) < 0.9</td><td colspan="2">12% (0,72–1,07) < 0.2</td></tr><tr><td><i>2004 Influenza season</i></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Deaths/100 000</td><td>973</td><td>837</td><td>2012</td><td>2566</td><td>8401</td><td>8974</td></tr><tr><td> Reduction (95% CI) <i>p</i></td><td colspan="2">- 16% (0,85–1,59) < 0.4</td><td colspan="2">22% (0,62–0,97) < 0.03</td><td colspan="2">7% (0,78–1,12) < 0.4</td></tr><tr><td><i>Non-influenza season</i></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Deaths/100 000</td><td>730</td><td>646</td><td>2028</td><td>2214</td><td>7667</td><td>8171</td></tr><tr><td> Reduction (95% CI) <i>p</i></td><td colspan="2">- 12% (0,79–1,65) < 0.5</td><td colspan="2">9% (0,72–1,15) < 0.5</td><td colspan="2">7% (0,77–1,13) < 0.5</td></tr><tr><td><i>2005 Influenza season</i></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Deaths/100 000</td><td>502</td><td>882</td><td>2144</td><td>2829</td><td>6979</td><td>8882</td></tr><tr><td> Reduction (95% CI) <i>p</i></td><td colspan="2">43% (0,40–0,82) < 0.002</td><td colspan="2">25% (0,62–0,92) < 0.01</td><td colspan="2">23% (0,64–0,92) < 0.01</td></tr><tr><td><i>Non-influenza season</i></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Deaths/100 000</td><td>698</td><td>813</td><td>1761</td><td>2188</td><td>6942</td><td>7676</td></tr><tr><td> Reduction (95% CI) <i>p</i></td><td colspan="2">14% (0,61–1,20) < 0.4</td><td colspan="2">20% (0,64–1,0) < 0.06</td><td colspan="2">11% (0,73–1,08) < 0.3</td></tr></table> |
cd332a328ebdac0e2197f1bd9776fbc57be1e0ef2f653bc89e87cde77cb4f3c9.png | simple | <table><tr><td>Variable</td><td>% increase (95% CI)</td></tr><tr><td>Age</td><td></td></tr><tr><td> 35-64 years</td><td>1.48 (0.28, 2.70)</td></tr><tr><td> 65-74 years</td><td>1.54 (0.34, 2.75)</td></tr><tr><td> 75-84 years</td><td>1.59 (0.42, 2.77)</td></tr><tr><td> ≥ 85 years</td><td>1.51 (0.34, 2.70)</td></tr><tr><td>Education</td><td></td></tr><tr><td> ≤ 8 years</td><td>1.53 (0.26, 2.83)</td></tr><tr><td> 9-12 years</td><td>1.54 (0.39, 2.70)</td></tr><tr><td> 13-16 year</td><td>1.56 (0.36, 2.77)</td></tr><tr><td> 17 years or more</td><td>1.46 (0.13, 2.80)</td></tr><tr><td>Marital status</td><td></td></tr><tr><td> Never Married</td><td>1.54 (0.32, 2.78)</td></tr><tr><td> Married or separated</td><td>1.51 (0.34, 2.69)</td></tr><tr><td> Widowed</td><td>1.57 (0.41, 2.74)</td></tr><tr><td> Divorced</td><td>1.49 (0.21, 2.79)</td></tr><tr><td>Race</td><td></td></tr><tr><td> White & non Hispanic</td><td>1.54 (0.39,2.70)</td></tr><tr><td> Black</td><td>1.47 (0.12,2.84)</td></tr><tr><td> Indian</td><td>1.26 (-7.46,10.81)</td></tr><tr><td> Hispanic</td><td>1.33 (-0.87,3.59)</td></tr><tr><td> Asian or Pacific</td><td>1.63 (-0.21,3.50)</td></tr><tr><td> Others</td><td>0.93 (-19.24,26.15)</td></tr><tr><td>Hispanic</td><td></td></tr><tr><td> Hispanic</td><td>1.54 (0.39,2.69)</td></tr><tr><td> Non Hispanic</td><td>1.53 (-0.43,3.52)</td></tr><tr><td>White</td><td></td></tr><tr><td> White</td><td>1.54 (0.39,2.69)</td></tr><tr><td> Non white</td><td>1.52 (0.23,2.83)</td></tr><tr><td>Gender</td><td></td></tr><tr><td> Male</td><td>1.55 (0.39,2.72)</td></tr><tr><td> Female</td><td>1.53 (0.37,2.69)</td></tr><tr><td>Population per km<sup>2 </sup>*</td><td></td></tr><tr><td> Low</td><td>1.5 (0.32,2.69)</td></tr><tr><td> Medium</td><td>1.54 (0.38,2.71)</td></tr><tr><td> High</td><td>1.57 (0.38,2.78)</td></tr><tr><td>Household income*</td><td></td></tr><tr><td> Low</td><td>1.58 (0.39,2.79)</td></tr><tr><td> Medium</td><td>1.51 (0.36,2.68)</td></tr><tr><td> High</td><td>1.56 (0.37,2.76)</td></tr><tr><td>Percent poverty*</td><td></td></tr><tr><td> Low</td><td>1.47 (0.3,2.66)</td></tr><tr><td> Medium</td><td>1.55 (0.4,2.72)</td></tr><tr><td> High</td><td>1.58 (0.37,2.8)</td></tr></table> |
ad5f8183b1ac32738703b578b8fff6741e6e9e9d4f5dc5967c4b9a6280d32705.png | complex | <table><tr><td></td><td colspan="2">Rape NOS</td><td colspan="2">Gang Rape</td><td colspan="2">Sexual Slavery</td><td colspan="2">Combined Gang Rape and Sexual Slavery</td></tr><tr><td></td><td>Number</td><td>Percent</td><td>Number</td><td>Percent</td><td>Number</td><td>Percent</td><td>Number</td><td>Percent</td></tr><tr><td>Physical:</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Pelvic pain</td><td>53</td><td>24.2</td><td>139</td><td>23.0</td><td>3</td><td>6.0</td><td>25</td><td>21.0</td></tr><tr><td> Lumbar pain</td><td>24</td><td>11.0</td><td>72</td><td>11.9</td><td>0</td><td>0</td><td>16</td><td>13.4</td></tr><tr><td> Abdominal pain</td><td>22</td><td>10.0</td><td>41</td><td>6.8</td><td>1</td><td>2.0</td><td>6</td><td>5.0</td></tr><tr><td> Pregnancy</td><td>12</td><td>5.5</td><td>13</td><td>2.1</td><td>20</td><td>40.0</td><td>17</td><td>14.3</td></tr><tr><td> Malaise</td><td>10</td><td>4.6</td><td>44</td><td>7.3</td><td>1</td><td>2.0</td><td>6</td><td>5.0</td></tr><tr><td> Vaginal discharge</td><td>10</td><td>4.6</td><td>36</td><td>6.0</td><td>1</td><td>2.0</td><td>8</td><td>6.7</td></tr><tr><td> Vaginal itching</td><td>9</td><td>4.1</td><td>25</td><td>4.1</td><td>1</td><td>2.0</td><td>8</td><td>6.7</td></tr><tr><td> Abnormal menses</td><td>10</td><td>4.6</td><td>26</td><td>4.3</td><td>1</td><td>2.0</td><td>6</td><td>5.0</td></tr><tr><td> Generally unwell</td><td>5</td><td>2.3</td><td>24</td><td>4.0</td><td>0</td><td>0</td><td>5</td><td>4.2</td></tr><tr><td>Social:</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Loss of possessions</td><td>55</td><td>25.1</td><td>147</td><td>24.3</td><td>10</td><td>20.0</td><td>19</td><td>16.0</td></tr><tr><td> Loss of child/spouse</td><td>13</td><td>5.9</td><td>75</td><td>12.4</td><td>2</td><td>4.0</td><td>21</td><td>17.6</td></tr><tr><td> Spousal abandonment</td><td>6</td><td>2.7</td><td>43</td><td>7.1</td><td>3</td><td>6.0</td><td>10</td><td>8.4</td></tr><tr><td> Loss of other family</td><td>2</td><td>0.91</td><td>15</td><td>2.5</td><td>0</td><td>0</td><td>9</td><td>7.6</td></tr><tr><td> Loss of home</td><td>1</td><td>0.46</td><td>9</td><td>1.5</td><td>0</td><td>0</td><td>1</td><td>0.84</td></tr><tr><td>Psychological:</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Anxiety about rape</td><td>53</td><td>24.2</td><td>154</td><td>25.5</td><td>18</td><td>36</td><td>31</td><td>26.1</td></tr><tr><td> Anxiety about spousal abandonment</td><td>6</td><td>2.7</td><td>38</td><td>6.3</td><td>4</td><td>8</td><td>9</td><td>7.6</td></tr><tr><td> Concern about STIs</td><td>25</td><td>11.4</td><td>76</td><td>12.6</td><td>4</td><td>8</td><td>19</td><td>16.0</td></tr><tr><td> Concern about HIV</td><td>14</td><td>6.4</td><td>56</td><td>9.3</td><td>4</td><td>8</td><td>13</td><td>10.9</td></tr><tr><td> General health concerns</td><td>16</td><td>7.3</td><td>66</td><td>10.9</td><td>7</td><td>14</td><td>9</td><td>7.6</td></tr><tr><td> Grief about loss of spouse</td><td>9</td><td>4.1</td><td>40</td><td>6.6</td><td>1</td><td>2</td><td>10</td><td>8.4</td></tr><tr><td> Grief about loss of child/children</td><td>8</td><td>3.7</td><td>25</td><td>4.1</td><td>0</td><td>0</td><td>3</td><td>2.5</td></tr></table> |
02389faf3f2800c41f920a8b3f5862a011931c0ea004bfa7f27d0e26a3bf7b64.png | complex | <table><tr><td></td><td>Key inclusion and exclusion criteria</td><td>Orchard et al. [7]</td><td>Meisser et al. [8]</td><td>Noehren et al. [11]</td><td>Ferber et al. [12]</td><td>Phinyonmark et al. [20]</td><td>Foch et al. [21]</td><td>Foch and Milner [22]</td><td>Foch and Milner [23]</td><td>Grau et al. [24]</td><td>Hein et al. [25]</td><td>Miller et al. [26]<sup>a</sup></td><td>Miller et al. [27]<sup>a</sup></td><td>Noehren et al. [28]</td></tr><tr><td>1</td><td>Clear definition of location of pain was reported</td><td>✓</td><td>✓</td><td>X</td><td>✓</td><td>✓</td><td>✓</td><td>X</td><td>X</td><td>✓</td><td>✓</td><td>X</td><td>X</td><td>✓</td></tr><tr><td>2</td><td>Reports a typical history of ITBS with symptoms consistent to the condition</td><td>✓</td><td>X</td><td>X</td><td>✓</td><td>✓</td><td>✓</td><td>X</td><td>X</td><td>✓</td><td>✓</td><td>X</td><td>✓</td><td>✓</td></tr><tr><td>4</td><td>Diagnosis was confirmed by a medical practitioner/physiotherapist/ trainer</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td></tr><tr><td>4</td><td>A positive clinical test (Obers/Nobles)/ palpation</td><td>✓</td><td>✓</td><td>X</td><td>X</td><td>✓</td><td>X</td><td>X</td><td>X</td><td>✓</td><td>✓</td><td>X</td><td>✓</td><td>✓</td></tr><tr><td>5</td><td>No previous knee surgery</td><td>✓</td><td>X</td><td>✓</td><td>✓</td><td>✓</td><td>X</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td><td>X</td><td>✓</td></tr><tr><td>6</td><td>No internal derangement or other sources of lateral knee pain present</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td><td>X</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td><td>X</td><td>✓</td></tr><tr><td>7</td><td>No previous spine or lower limb injury</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td><td>X</td><td>X</td><td>✓</td><td>✓</td><td>✓</td><td>✓</td><td>X</td><td>✓</td></tr><tr><td colspan="2">Criteria’s Met</td><td>7</td><td>5</td><td>4</td><td>6</td><td>7</td><td>3</td><td>3</td><td>4</td><td>7</td><td>7</td><td>4</td><td>3</td><td>7</td></tr></table> |
d1bacf47b5f53c2861d5a75d0a737c253c9ef6342a74f5875da7881161cd6d52.png | simple | <table><tr><td></td><td>Ordinary light</td><td>Infrared ray light</td></tr><tr><td>ICG-positive nodedetection</td><td>28/36(78 %)</td><td>36/36</td></tr><tr><td>The number ofICG-positive nodes</td><td>3.4 ± 3.7<sup>*</sup>(0 to 16)<sup>+</sup></td><td>9.2 ± 5.9<sup>*</sup>(2 to 25)<sup>+</sup></td></tr><tr><td>Lymph nodemetastasis sensitivity</td><td>1/5(20 %)</td><td>5/5(100 %)</td></tr></table> |
0112b07d4ec58c9cb0e008539ed6735f70516ecde9aa55cd8acb77a9d35a77ee.png | simple | <table><tr><td>Test </td><td>Day 0 (admission)</td><td>Day 13 (discharge)</td></tr><tr><td>Coxsackie A9 (NT)</td><td>8 Units</td><td>16 Units</td></tr><tr><td>Coxsackie B1 (NT)</td><td>16 Units</td><td>32 Units</td></tr><tr><td>Coxsackie B2 (NT)</td><td><4 Units</td><td><4 Units</td></tr><tr><td>Coxsackie B3 (NT)</td><td>32 Units</td><td>64 Units</td></tr><tr><td>Coxsackie B4 (NT)</td><td><4 Units</td><td><4 Units</td></tr><tr><td>Coxsackie B5 (NT)</td><td><4 Units</td><td><4 Units</td></tr><tr><td>Coxsackie B6 (NT)</td><td><4 Units</td><td><4 Units</td></tr></table> |
d68608421770de82f33270098e5b2cf565a929663bebf4f2380af90daf358489.png | simple | <table><tr><td>Characteristic</td><td>Female</td><td>Male</td><td>Total</td></tr><tr><td><i>n</i> of subjects</td><td>14</td><td>14</td><td>28</td></tr><tr><td>Gender (M/F) %</td><td></td><td></td><td>50/50</td></tr><tr><td>Age (years)</td><td>23 (23, 23)</td><td>20.5 (19, 21.25)</td><td>21.75 ± 1.92</td></tr><tr><td>Height (cm)</td><td>158 ± 7.34</td><td>170.3 ± 7.30</td><td>164.1 ± 9.53</td></tr><tr><td>Body weight (kg)</td><td>59.16 ± 8.79</td><td>72.61 ± 11.47</td><td>65.89 ± 12.14</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>23.67 ± 2.57</td><td>25.04 ± 3.28</td><td>24.36 ± 2.97</td></tr><tr><td>Waist circumference (cm)</td><td>76.57 ± 6.98</td><td>85.96 ± 8.20</td><td>81.27 ± 8.87</td></tr><tr><td>Waist-to-hip ratio</td><td>0.78 ± 0.05</td><td>0.85 ± 0.04</td><td>0.82 ± 0.06</td></tr><tr><td>Glycemia (mg/dL)</td><td>83.57 ± 5.87</td><td>82.64 ± 9.90</td><td>83.11 ± 8.00</td></tr><tr><td>Total cholesterol (mg/dL)</td><td>168.1 ± 33.76</td><td>172.6 ± 27.78</td><td>170.3 ± 30.43</td></tr><tr><td>Triglycerides (mg/dL)</td><td>89 (72.5, 161.5)</td><td>92.5 (65.75, 126.5)</td><td>92.50 (69.50, 153.8)</td></tr></table> |
65ff95bf8cbc342d2632aa3a4c3076067c22bccf0948906307399fd6db975fe7.png | simple | <table><tr><td>Who Would Use the App?</td><td>When Would They Use the App?</td><td>How Useful Is an App?</td><td>What Should Be in the App?</td><td>Who or How Should It Be Advertised to Users?</td></tr><tr><td>Parents of children ages 0–6First time momsParents about to switch their child to a new seatCaregiversFamilyBabysittersDads say they are less likely to use it but moms say dads would use it a lot</td><td>Before the baby is bornWhen buying a new seat (process) or about to switch seatsExternal caregiver installingFirst time installation with new seatWhen looking for car seat check pointsTroubleshootingIn need of non-installation factoids/frequently asked questions (expiration dates) </td><td>AdvantagesOn the go informationSimple to useAccessibleProvides direct infoEasier to readVisual assistanceDisadvantagesSome preferred websiteApps may be difficult to navigateUnfamiliarity with appsNot useful when installing—“keep checking your phone”</td><td>Car seat check locator and appointment schedulerWhat seat fit best in the carHow to install in different types of carsConsumer product reviewsCar seat laws and policiesTypes of car seats for height, weight, and ageFAQ’s, safety myths vs. factsExpiration datesTravelingOnline forum (social tools)Search functionMultiple languagesSpanishVideos and imagesTroubleshooting info and tools—inch and pinch test</td><td>Who:Not manufacturersDoctors in officeCHOPInsurance companiesSafekids WorldwideHow:No brochuresParent magazinesWebsite of CRS companiesPoster in waiting roomPrenatal and parenting classes</td></tr></table> |
3f49f2b60a45e61ddf45c95fdf54a680c4e63a5ae7d79a53ba290e027077453b.png | simple | <table><tr><td>Organizational</td><td>Socio-cultural</td><td>Intrinsic</td></tr><tr><td><i>Motivators</i></td><td></td><td></td></tr><tr><td>• Opportunities for higher qualifications</td><td>• Respect</td><td>• Serving people</td></tr><tr><td>• Good working and hygienic conditions</td><td>• Social rewards</td><td>• Work interest</td></tr><tr><td>• Personal safety</td><td></td><td>• Career growth</td></tr><tr><td>• Good professional experience</td><td></td><td>• Ability to support oneself and family</td></tr><tr><td>• Good pay</td><td></td><td>• Autonomy</td></tr><tr><td>• Financial incentives other than pay</td><td></td><td>• Empowerment</td></tr><tr><td><i>Demotivators</i></td><td></td><td></td></tr><tr><td>• Less pay</td><td>• Disrespect</td><td>• Less career growth</td></tr><tr><td>• Poor working and hygienic conditions</td><td>• Poor interpersonal relations</td><td>• Inability to support oneself and family</td></tr><tr><td>• Fewer opportunities for higher qualifications</td><td>• Less social rewards</td><td></td></tr><tr><td>• Less personal safety</td><td>• Less personal and social time</td><td></td></tr><tr><td>• Heavy work load</td><td></td><td></td></tr><tr><td>• Long duty hours</td><td></td><td></td></tr><tr><td>• Resource unavailability</td><td></td><td></td></tr><tr><td>• Fewer promotion opportunities</td><td></td><td></td></tr><tr><td>• Poor supervision</td><td></td><td></td></tr></table> |
481b4d7cf5ec36ca29c915ab69b0067b362a2fef5f5f25943a1deb99a25a2f7f.png | simple | <table><tr><td>Cost variable</td><td>Source</td><td>Unit cost in public system (Dollar)</td><td>Unit cost in private system (Dollar)</td></tr><tr><td>Medical visit</td><td></td><td></td><td></td></tr><tr><td>Public</td><td>Hospital accounts department/DMA</td><td>5*</td><td>125 (range 100-150)</td></tr><tr><td>Medication</td><td></td><td></td><td></td></tr><tr><td>Pain killer</td><td>Central Medical Store</td><td>0.05/500 mgx2×3=0.30**</td><td>2.00</td></tr><tr><td>ORS</td><td>Central Medical Store</td><td>0.75/packx3=2.25</td><td>4.5×3=13.5</td></tr><tr><td>Antibiotics</td><td>Central Medical Store</td><td>0.03/250 mgx3×3×5=1.35***</td><td>8.00</td></tr><tr><td>Gravol</td><td>Central Medical Store</td><td>0.05/50 mgx4×2=0.4****</td><td>2.00</td></tr><tr><td>Loperamide</td><td>Private dispensary</td><td>0.50/2 mgx2=1.0*****</td><td>2.00</td></tr><tr><td>IV fluid (0.9% sodium solution)</td><td>Central Medical Store</td><td>3.42/litre</td><td></td></tr><tr><td>Testing of stool specimens</td><td>Billing department, PMH</td><td>20.00</td><td></td></tr><tr><td>Loss of working days</td><td></td><td></td><td></td></tr><tr><td>Caregiver service</td><td>Labour standard order (Minimum wage)</td><td>28.75/day</td><td></td></tr><tr><td>Duration of illness</td><td>Population survey</td><td>2 days (Median value)</td><td></td></tr></table> |
2d87ae17623d10c7cf796815f212d7d84eadaae4494702aa671659eec1f0e0df.png | simple | <table><tr><td>Neuroprotectant</td><td>n (%*)</td></tr><tr><td>Edaravone</td><td>95 (8.4)</td></tr><tr><td>Ganglioside GM1</td><td>29 (2.6)</td></tr><tr><td>Cattle encephalon glycoside and ignotin</td><td>112 (9.9)</td></tr><tr><td>Cinepazide</td><td>56 (5.0)</td></tr><tr><td>Citicholine</td><td>334 (29.6)</td></tr><tr><td>Other<sup>†</sup></td><td>198 (17.5)</td></tr><tr><td>Unspecified</td><td>321 (28.4)</td></tr></table> |
9610eac5f7295e6cb655de4609a66430759e783d926ce33df6ff93fe1ffe876f.png | complex | <table><tr><td>Self-rated spiritual health</td><td>Ideators (%)</td><td>Non-ideators (%)</td><td><i>χ</i><sup>2</sup></td><td><i>p</i>-Value</td></tr><tr><td>Excellent OR good</td><td>117 (49.37)</td><td>2713 (85.10)</td><td rowspan="2">196.23</td><td rowspan="2"><.0001</td></tr><tr><td>Fair OR poor OR uncertain</td><td>120 (50.63)</td><td>475 (14.90)</td></tr></table> |
6ee9726e541f7bc7ba8471f9dcb965b61850fb5541170101bc129c29b8ff38a8.png | simple | <table><tr><td>Variable</td><td>Controls (n = 73)</td><td>Participants (n = 73)</td><td>p value<sup>a</sup></td></tr><tr><td>Lipoprotein subclass<sup>b</sup></td><td></td><td></td><td></td></tr><tr><td>VLDL and chylomicron particle concentrations (nmol/L)</td><td></td><td></td><td></td></tr><tr><td> Total VLDL and chylomicron particles</td><td>82.0 ± 45.3</td><td>87.5 ± 39.6</td><td>0.15</td></tr><tr><td> Large VLDL and chylomicron particles</td><td>4.6 ± 6.3</td><td>8.2 ± 6.8</td><td>< 0.01<sup>c</sup></td></tr><tr><td> Medium VLDL particles</td><td>38.1 ± 28.5</td><td>39.7 ± 25.7</td><td>0.50<sup>c</sup></td></tr><tr><td> Small VLDL particles</td><td>39.3 ± 19.9</td><td>39.7 ± 17.2</td><td>0.90</td></tr><tr><td>LDL particle concentrations (nmol/L)</td><td></td><td></td><td></td></tr><tr><td> Total LDL particles</td><td>1253 ± 367</td><td>1437 ± 477</td><td>0.01</td></tr><tr><td> Large LDL particles</td><td>337 ± 211</td><td>251 ± 218</td><td>< 0.01<sup>c</sup></td></tr><tr><td> Intermediate LDL particles</td><td>45.8 ± 38.5</td><td>72.6 ± 50.2</td><td>< 0.01<sup>c</sup></td></tr><tr><td> Small LDL particles</td><td>870 ± 434</td><td>1113 ± 478</td><td>< 0.01</td></tr><tr><td>HDL particle concentrations (μmol/L)</td><td></td><td></td><td></td></tr><tr><td> Total HDL particles</td><td>34.7 ± 6.7</td><td>32.1 ± 5.6</td><td>0.01</td></tr><tr><td> Large HDL particles</td><td>6.4 ± 3.5</td><td>4.6 ± 3.4</td><td>< 0.01</td></tr><tr><td> Medium HDL particles</td><td>5.2 ± 4.9</td><td>5.9 ± 4.8</td><td>0.25<sup>c</sup></td></tr><tr><td> Small HDL particles</td><td>23.1 ± 7.0</td><td>21.7 ± 5.8</td><td>0.17</td></tr><tr><td>Mean particle sizes (nm)</td><td></td><td></td><td></td></tr><tr><td> VLDL size</td><td>50.6 ± 9.0</td><td>55.6 ± 10.4</td><td>< 0.01</td></tr><tr><td> LDL size</td><td>20.7 ± 0.9</td><td>20.2 ± 0.8</td><td>< 0.01</td></tr><tr><td> HDL size</td><td>8.9 ± 0.4</td><td>8.6 ± 0.3</td><td>< 0.01</td></tr><tr><td>Physiological variables<sup>d</sup></td><td></td><td></td><td></td></tr><tr><td> Age</td><td>60.0 ± 7.8</td><td>60.3 ± 8.0</td><td>0.79</td></tr><tr><td> Body mass index (kg/m<sup>2</sup>)</td><td>28.2 ± 3.7</td><td>34.0 ± 7.0</td><td>< 0.01</td></tr><tr><td> Systolic blood pressure (mm Hg)</td><td>133 ± 17</td><td>136 ± 17</td><td>0.12<sup>c</sup></td></tr><tr><td> Diastolic blood pressure (mm Hg)</td><td>78.9 ± 9.2</td><td>80.8 ± 9.8</td><td>0.50<sup>c</sup></td></tr><tr><td> HDL-cholesterol (mg/dl)</td><td>50.5 ± 13.7</td><td>43.7 ± 13.1</td><td>< 0.01<sup>c</sup></td></tr><tr><td> LDL-cholesterol (mg/dl)</td><td>111 ± 33</td><td>111 ± 39</td><td>0.64<sup>c</sup></td></tr><tr><td> Total cholesterol (mg/dl)</td><td>191 ± 42</td><td>193 ± 47</td><td>0.82</td></tr><tr><td> Triglycerides (mg/dl)</td><td>148 ± 100</td><td>189 ± 99</td><td>< 0.01</td></tr><tr><td> Physical fitness (Bruce score)</td><td>10.4 ± 2.8</td><td>6.6 ± 2.2</td><td>< 0.01</td></tr><tr><td> Framingham risk (× 100)</td><td>7.4 ± 6.8</td><td>10.7 ± 8.5</td><td>0.02<sup>c</sup></td></tr></table> |
cd916fbd1c5f9a653b4efdb9bab51229818616c91466497e0a9a973d01defc4c.png | simple | <table><tr><td></td><td>Regular expression method</td><td></td><td>Term voting method</td><td></td></tr><tr><td>TOTAL terms</td><td>98435</td><td>100%</td><td>98435</td><td>100%</td></tr><tr><td>Selected set</td><td>13755</td><td>14%</td><td>13755</td><td>14%</td></tr><tr><td>Excluded set</td><td>84680</td><td>86%</td><td>84680</td><td>86%</td></tr><tr><td>Sample of excluded</td><td>3140</td><td>100%</td><td></td><td></td></tr><tr><td>Wrong (false negative)</td><td>49</td><td>1.6%</td><td></td><td></td></tr><tr><td>Correct (true negative)</td><td>3091</td><td>98.4%</td><td></td><td></td></tr><tr><td>Proportionate number of <i>bona fide </i>terms in excluded set</td><td>1321</td><td></td><td></td><td></td></tr><tr><td>Sample of included</td><td>2070</td><td>100%</td><td>2287</td><td>100%</td></tr><tr><td>Wrong (false positive)</td><td>1538</td><td>74.3%</td><td>1974</td><td>86.3%</td></tr><tr><td>Correct (true positive)</td><td>532</td><td>25.7%</td><td>313</td><td>13.7%</td></tr><tr><td>Probable number of <i>bona fide </i>terms in selected set</td><td>3535</td><td></td><td>1883</td><td></td></tr><tr><td>Recall</td><td>0.728</td><td></td><td></td><td></td></tr><tr><td>Precision</td><td>0.257</td><td></td><td>0.137</td><td></td></tr></table> |
3ef63dbfe1d3e88eca86c19b4ed4660f3a4007ae9c425f47256d7c84753f5e43.png | simple | <table><tr><td>N = 301</td><td>Total</td><td>Emotional</td><td>Physical</td><td>Active Coping</td><td>Passive Coping</td></tr><tr><td>Range</td><td>47.19</td><td>44.85</td><td>49.89</td><td>49.08</td><td>47.95</td></tr><tr><td>Minimum</td><td>26.63</td><td>31.07</td><td>20.44</td><td>25.04</td><td>24.91</td></tr><tr><td>Maximum</td><td>72.82</td><td>75.92</td><td>70.33</td><td>74.13</td><td>72.86</td></tr><tr><td>Percentile</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 25</td><td>42.53</td><td>42.04</td><td>43.52</td><td>42.51</td><td>42.98</td></tr><tr><td> 50</td><td>50</td><td>50</td><td>50</td><td>50</td><td>50</td></tr><tr><td> 75</td><td>56.70</td><td>56.80</td><td>56.92</td><td>57.48</td><td>56.88</td></tr></table> |
278856d667f0495455f35e2dceeb010a9ae168388d55ca97326dd638cb839ab6.png | simple | <table><tr><td>Target gene</td><td>Forward primer (5′ to 3′)</td><td>Reverse primer (5′ to 3′)</td><td>Source</td></tr><tr><td>Mad2</td><td>GAGTTCTTCTCATTCGGCATCA</td><td>CCAATCTTTCAGTTGTTCCACC</td><td>PrimerBank</td></tr><tr><td>Bub1</td><td>TGCTGCACAACTTGCGTCTAC</td><td>TCAACGCCCAACTCTGCCT</td><td>PrimerBank</td></tr><tr><td>APC</td><td>CCAACAAGGCTACGCTATGC</td><td>ATCTGCTCGCCAAGACAAAT</td><td>PrimerBank</td></tr><tr><td>β-actin</td><td>ATCATGTTTGAGACCTTCAACA</td><td>CATCTCTTGCTCGAAGTCCA</td><td>PrimerBank</td></tr></table> |
ae757a1c13a63ffa6422e9e17a07e19d453f204b7cb6718ec2a9ee3fa947c074.png | complex | <table><tr><td colspan="2">Comparison</td><td>BC1 <i>vs </i>BC2</td><td>BC1 <i>vs </i>BC3</td><td>BC2 <i>vs </i>BC3</td></tr><tr><td>Successful Calls for Both</td><td>SNPs</td><td>134128046</td><td>134063768</td><td>134107787</td></tr><tr><td></td><td>%</td><td>99.241</td><td>99.194</td><td>99.226</td></tr><tr><td>Concordant Calls (All)</td><td>SNPs</td><td>134109060</td><td>134036623</td><td>134095792</td></tr><tr><td></td><td>%</td><td>99.986</td><td>99.980</td><td>99.991</td></tr><tr><td>Concordant Calls (Hom)</td><td>SNPs</td><td>98050788</td><td>97992008</td><td>98016851</td></tr><tr><td></td><td>%</td><td>99.989</td><td>99.983</td><td>99.993</td></tr><tr><td>Concordant Calls (Het)</td><td>SNPs</td><td>36058272</td><td>36044165</td><td>36078941</td></tr><tr><td></td><td>%</td><td>99.977</td><td>99.970</td><td>99.985</td></tr></table> |
f1b650a0a6dd53fed3185b32d2986c72452bc0e90816eab7ac1bcdcf3427259b.png | simple | <table><tr><td>Inner cortical width of thoracic pedicles (mm)</td><td>No. of thoracic pedicles instrumented</td><td>No. of thoracic pedicles accurately instrumented</td><td>Accuracy (%)</td></tr><tr><td>0–1.0</td><td>194</td><td>68</td><td>35.05</td></tr><tr><td>1.1–2.0</td><td>176</td><td>115</td><td>65.34</td></tr><tr><td>2.1–3.0</td><td>352</td><td>304</td><td>86.36</td></tr><tr><td>≥3.1</td><td>376</td><td>339</td><td>90.16</td></tr><tr><td>Total</td><td>1098</td><td>826</td><td>75.23</td></tr></table> |
c138d794846e47a16f9e0ea365a72997c5b33c2f41b0f6a052584278b8cd2c5c.png | complex | <table><tr><td>EDA-Q items (18 items)</td><td>Corresponding DISCO items (17 items)</td><td>DISCO variables</td></tr><tr><td>Obsessively resists and avoids ordinary demands</td><td rowspan="2">Lack of co-operation</td><td rowspan="2">LACKCOP</td></tr><tr><td>Has difficulty complying unless carefully presented</td></tr><tr><td>Is driven by the need to be in charge</td><td rowspan="2">Using age peers as mechanical aids, bossy and domineering</td><td rowspan="2">CPEERAD*</td></tr><tr><td>Tells other children how to behave</td></tr><tr><td>Finds everyday pressures intolerably stressful</td><td>Anxiety</td><td>ANXIETY</td></tr><tr><td>Mimics adult mannerisms and styles</td><td>Repetitive acting out roles</td><td>CTROL*</td></tr><tr><td rowspan="2">Shows little shame or embarrassment</td><td>Behaviour in public places</td><td>BEHAPUB</td></tr><tr><td>Embarrassing remarks in public</td><td>REMARK</td></tr><tr><td>Good at getting around others</td><td>Apparently manipulative behaviour</td><td>MANBEH*</td></tr><tr><td>Unaware of differences between self and authority figures</td><td rowspan="2">Awareness of own identity</td><td rowspan="2">CIDENT*</td></tr><tr><td>Attempts to negotiate better terms with adults</td></tr><tr><td>If pressurised to do things, may have a ‘meltdown’</td><td>Temper tantrums</td><td>TEMPER</td></tr><tr><td>Mood changes rapidly</td><td>Changeable mood</td><td>MOODCH</td></tr><tr><td>Knows what to do or say to upset specific people</td><td>Difficulties with other people</td><td>DIFPEOP</td></tr><tr><td rowspan="2">Blames or targets a particular person</td><td>Harassment of others</td><td>HARAS*</td></tr><tr><td>Blaming other people</td><td>BLAME*</td></tr><tr><td>Denies behaviour, even when caught red-handed</td><td>Fantasising, lying, cheating, stealing</td><td>LYING*</td></tr><tr><td>Outrageous behaviour to get out of doing something</td><td>Socially shocking behaviour</td><td>SHOCK*</td></tr><tr><td>Extreme emotional responses to small events</td><td>Inappropriate sociability (rapid, inexplicable changes from loving to aggression)</td><td>CINAPP*</td></tr><tr><td>Social interaction has to be on his/her own terms</td><td>One-sided social approaches</td><td>CONESID</td></tr></table> |
ba22a43c753cba7e54a34236e8d015af726d8b12910198131acf09d22aecbf75.png | complex | <table><tr><td rowspan="2"> </td><td colspan="2">SA-test (reaction time (msec)</td></tr><tr><td>Active diet</td><td>Control diet</td></tr><tr><td>time 0</td><td>1320 ± 20</td><td>1320 ± 21</td></tr><tr><td>45 min</td><td>1219 ± 19</td><td>1230 ± 21</td></tr><tr><td>120 min</td><td>1182 ± 21</td><td>1202 ± 23</td></tr></table> |
f3820f2ee720fd52b362186851f2b1452b5798e5f69e15830fd1a44ab312bce5.png | simple | <table><tr><td></td><td>Treatment-naïve cancer patients (<i>n</i>= 555)</td></tr><tr><td>Age, years (IQR)</td><td>62 (52-71)</td></tr><tr><td>Male gender, n (%)</td><td>227 (41%)</td></tr><tr><td>BMI kg/m<sup>2</sup>, (IQR)</td><td>25.0 (22.6–28.4)</td></tr><tr><td>Comorbidities</td><td></td></tr><tr><td> Known CAD, <i>n</i> (%)</td><td>28 (5%)</td></tr><tr><td> Heart Failure, <i>n</i> (%)</td><td>38 (7%)</td></tr><tr><td> Diabetes mellitus, <i>n</i> (%)</td><td>43 (8%)</td></tr><tr><td> Arterial Hypertension, <i>n</i> (%)</td><td>250 (45%)</td></tr><tr><td> CKD, <i>n</i> (%)</td><td>31 (6%)</td></tr><tr><td> COPD, <i>n</i> (%)</td><td>113 (20%)</td></tr><tr><td>Cancer disease stage*</td><td></td></tr><tr><td> Stage 1, <i>n</i> (%)</td><td>96 (17%)</td></tr><tr><td> Stage 2, <i>n</i> (%)</td><td>50 (9%)</td></tr><tr><td> Stage 3, <i>n</i> (%)</td><td>108 (19%)</td></tr><tr><td> Stage 4, <i>n</i> (%)</td><td>183 (33%)</td></tr><tr><td>Hepatic involvement</td><td></td></tr><tr><td> Primary hepatic, biliary tract or pancreatic malignoma, <i>n</i> (%)</td><td>27 (5%)</td></tr><tr><td> Hepatic metastases, <i>n</i> (%)</td><td>51 (10%)</td></tr><tr><td>Laboratory parameters</td><td></td></tr><tr><td> GFR, mL/min/1.73 m<sup>2</sup> (IQR)</td><td>74.5 (63.7–86.0)</td></tr><tr><td> BUN, mg/dl (IQR)</td><td>15 (12-19)</td></tr><tr><td> BChE, kU/l (IQR)</td><td>7.31 (6.10–8.40)</td></tr><tr><td> AST (GOT), U/l (IQR)</td><td>24 (19–31)</td></tr><tr><td> ALT (GPT), U/l (IQR)</td><td>22 (16–32)</td></tr><tr><td> GGT, U/l (IQR)</td><td>32 (21–63)</td></tr><tr><td> Bilirubin, mg/dl (IQR)</td><td>0.58 (0.44-0.79)</td></tr><tr><td> Albumin, g/l (IQR)</td><td>43.0 (40.0–45.4)</td></tr><tr><td> CRP, mg/dl (IQR)</td><td>0 (0-1)</td></tr><tr><td> SAA, μg/ml (IQR)</td><td>8 (4-26)</td></tr><tr><td> IL-6, pg/ml (IQR)</td><td>2 (2–3)</td></tr></table> |
23b0492c3fd1436bde7529ebb613b31594f9670c786735d715d3392472908099.png | complex | <table><tr><td colspan="2">Time points of measurements</td><td>IOP</td><td>ONSD</td></tr><tr><td>T0</td><td>Patient awake in supine position before induction of anaesthesia</td><td>X</td><td>-</td></tr><tr><td>T1</td><td>20 min after induction of general anaesthesia in supine position</td><td>X</td><td>X</td></tr><tr><td>T2</td><td>After insufflation of the abdomen with CO<sub>2</sub> in supine position</td><td>X</td><td>X</td></tr><tr><td>T3</td><td>After 30 min in 45° Trendelenburg position with the abdomen still insufflated with CO<sub>2</sub></td><td>X</td><td>X</td></tr><tr><td>T4</td><td>Control of Santorini’s plexus in 45° Trendelenburg position with CO<sub>2</sub> still insufflated</td><td>X</td><td>X</td></tr><tr><td>T5</td><td>Anaesthetised before awakening in supine position</td><td>X</td><td>X</td></tr></table> |
715004b4f4b280be4b18c3c5261003354b1cfbe76d442cd180cc21cfe1a620fe.png | complex | <table><tr><td colspan="4"> </td></tr><tr><td colspan="4">Proteins present in all 8 <i>Mimiviridae </i>genomes</td></tr><tr><td>CLS10031</td><td>A1L transcription factor VLTF-2</td><td>CLS10052</td><td>Proliferating cell nuclear antigen</td></tr><tr><td>CLS10071</td><td>A2L transcription factor VLTF-3</td><td>CLS10035</td><td>protein disulfide Isomerase/thioredoxin family</td></tr><tr><td>CLS10199</td><td>asnB, asparagine synthetase B</td><td>CLS10216</td><td>putative DNA-directed RNA polymerase II subunit N</td></tr><tr><td>CLS10039</td><td>capsid protein</td><td>CLS10047</td><td>replication factor C small subunit</td></tr><tr><td>CLS10262</td><td>D5-like helicase-primase</td><td>CLS10049</td><td>replication factor C small subunit</td></tr><tr><td>CLS10015</td><td>DEAD/SNF2-like helicase or ATP-dependent RNA helicase</td><td>CLS10258</td><td>ribonuclease H</td></tr><tr><td>CLS10089</td><td>DNA directed RNA polymerase subunit L</td><td>CLS10041</td><td>ribonuclease III</td></tr><tr><td>CLS10259</td><td>DNA mismatch repair ATPase MutS</td><td>CLS10130</td><td>ribonucleosidediphosphatereductase large subunit</td></tr><tr><td>CLS10104</td><td>DNA polymerase elongation subunit family B</td><td>CLS10252</td><td>ribonucleosidediphosphatereductase small subunit</td></tr><tr><td>CLS10201</td><td>DNA topoisomerase IB</td><td>CLS10028</td><td>TATA-box-binding protein</td></tr><tr><td>CLS10230</td><td>DNA topoisomerase II</td><td>CLS10057</td><td>Transcription factor S-II (TFIIS)-domain-containing protein</td></tr><tr><td>CLS10090</td><td>DNA-dependent RNA polymerase subunit Rpb9/M</td><td>CLS10055</td><td>transcription initiation factor IIB</td></tr><tr><td>CLS10250</td><td>DNA-directed RNA polymerase subunit 5 (RPB5)</td><td>CLS10011</td><td>ubiquitin-conjugating enzyme E2</td></tr><tr><td>CLS10261</td><td>DNA-directed RNA polymerase subunit 6</td><td>CLS10214</td><td>Ulp1-like protease</td></tr><tr><td>CLS10076</td><td>DNA-directed RNA polymerase subunit alpha</td><td>CLS10066</td><td>VV A18-like helicase</td></tr><tr><td>CLS10053</td><td>DNA-directed RNA polymerase subunit beta</td><td>CLS10068</td><td>VV A32 virion packaging ATPase</td></tr><tr><td>CLS10249</td><td>DNA-directed RNA polymerase subunit E’ (RPB7)</td><td>CLS10218</td><td>YqaJ-like viral recombinase</td></tr><tr><td>CLS10024</td><td>Erv1 / Alr family oxidoreductase</td><td>CLS10212</td><td>hypothetical protein</td></tr><tr><td>CLS10221</td><td>eukaryotic translation initiation factor 4E-like protein</td><td>CLS10222</td><td>hypothetical protein</td></tr><tr><td>CLS10086</td><td>FtsJ-like methyltransferase</td><td>CLS10233</td><td>hypothetical protein</td></tr><tr><td>CLS10030</td><td>Holliday junction resolvase</td><td>CLS10236</td><td>hypothetical protein</td></tr><tr><td>CLS10056</td><td>metallopeptidase WLM</td><td>CLS10032</td><td>hypothetical protein</td></tr><tr><td>CLS10219</td><td>mRNA capping enzyme</td><td>CLS10043</td><td>hypothetical protein</td></tr><tr><td>CLS10088</td><td>NUDIX hydrolase</td><td>CLS10046</td><td>hypothetical protein</td></tr><tr><td>CLS10224</td><td>poxvirus poly(A) polymerase catalytic subunit-like protein</td><td>CLS10070</td><td>hypothetical protein</td></tr><tr><td>CLS10253</td><td>probable ubiquitin carboxyl-terminal hydrolase</td><td>CLS10081</td><td>hypothetical protein</td></tr><tr><td colspan="4">Genes missing in one or two OLPG genomes but present in all the other <i>Mimiviridae </i>genomes</td></tr><tr><td>CLS10059</td><td>AAA family ATPase</td><td>CLS10009</td><td>Lon domain protease</td></tr><tr><td>CLS10021</td><td>chaperone protein DnaJ</td><td>CLS10033</td><td>patatin-like phospholipase</td></tr><tr><td>CLS10022</td><td>chaperone protein DnaJ</td><td>CLS10072</td><td>Prolyl 4-hydroxylase</td></tr><tr><td>CLS10082</td><td>heat shock 70 kDa protein</td><td>CLS10091</td><td>thymidylate synthase</td></tr><tr><td>CLS10042</td><td>hypothetical protein</td><td>CLS10010</td><td>XRN 5'-3' exonuclease</td></tr></table> |
0d783210597fb784607f3e33aa4b07f3918ca778a84d4be9d7dd62635f840a3f.png | simple | <table><tr><td></td><td>MMSE Non-demented</td><td>MMSE Demented</td><td>EMSE Non-demented</td><td>EMSE Demented</td></tr><tr><td>Below 5<sup>th </sup>pcntle (MMSE cut-point = 21, EMSE cut-point = 41)</td><td>618 (3%)</td><td>622 (73%)</td><td>810 (5%)</td><td>474 (77%)</td></tr><tr><td>Below 10<sup>th </sup>pcntle (MMSE cut-point = 23, EMSE cut-point = 45)</td><td>1443 (8%)</td><td>707 (84%)</td><td>1676 (10%)</td><td>524 (88%)</td></tr><tr><td>Below -1 SD (MMSE cut-point = 23.1, EMSE cut-point = 44.5)</td><td>2075 (13%)</td><td>739 (90%)</td><td>1676 (10%)</td><td>524 (88%)</td></tr><tr><td>Below -2 SD (MMSE cut-point = 12.9, EMSE cut-point-24.5)</td><td>5 (0%)</td><td>229 (24%)</td><td>36 (0%)</td><td>125 (19%)</td></tr></table> |
64cc095c38eb90e89372d8ff13b52d596ad4698e1be7645e2c16690ae1e370bf.png | complex | <table><tr><td>Trial centre</td><td>Trial arm</td><td colspan="3">Questionnaire type</td><td></td><td></td></tr><tr><td></td><td></td><td>Standard</td><td>Mini</td><td>Mini-mini</td><td>Total by study arm</td><td>Total by site</td></tr><tr><td>Bristol</td><td>Control (%)</td><td>54 (31)</td><td>6 (30)</td><td>9 (50)</td><td>69 (33)</td><td></td></tr><tr><td></td><td>IPB+ (%)</td><td>56 (32)</td><td>6 (30)</td><td>6 (33)</td><td>68 (32)</td><td></td></tr><tr><td></td><td>IPB only (%)</td><td>63 (36)</td><td>8 (40)</td><td>3 (17)</td><td>74 (35)</td><td></td></tr><tr><td></td><td>Total (%)</td><td>173 (82)</td><td>20 (9)</td><td>18 (9)</td><td></td><td>211 (28)</td></tr><tr><td>Newcastle</td><td>Control (%)</td><td>38 (33)</td><td>9 (29)</td><td>5 (36)</td><td>52 (32)</td><td></td></tr><tr><td></td><td>IPB+ (%)</td><td>40 (35)</td><td>10 (32)</td><td>4(29)</td><td>54 (34)</td><td></td></tr><tr><td></td><td>IPB only (%)</td><td>38 (33)</td><td>12 (39)</td><td>5 (36)</td><td>55 (34)</td><td></td></tr><tr><td></td><td>Total (%)</td><td>116 (72)</td><td>31(19)</td><td>14 (9)</td><td></td><td>161 (21)</td></tr><tr><td>Norwich</td><td>Control (%)</td><td>65 (38)</td><td>9 (43)</td><td>4 (44)</td><td>78 (39)</td><td></td></tr><tr><td></td><td>IPB+ (%)</td><td>48 (28)</td><td>7 (33)</td><td>3 (33)</td><td>58 (29)</td><td></td></tr><tr><td></td><td>IPB only (%)</td><td>57 (34)</td><td>5 (24)</td><td>2 (22)</td><td>64 (32)</td><td></td></tr><tr><td></td><td>Total (%)</td><td>170 (85)</td><td>21 (10)</td><td>9 (5)</td><td></td><td>200 (27)</td></tr><tr><td>Nottingham</td><td>Control (%)</td><td>51 (36)</td><td>1 (8)</td><td>9 (39)</td><td>61 (34)</td><td></td></tr><tr><td></td><td>IPB+ (%)</td><td>47 (33)</td><td>7 (54)</td><td>5 (22)</td><td>59 (33)</td><td></td></tr><tr><td></td><td>IPB only (%)</td><td>45 (32)</td><td>5 (39)</td><td>9 (39)</td><td>59 (33)</td><td></td></tr><tr><td></td><td>Total (%)</td><td>143 (80)</td><td>13 (7)</td><td>23 (13)</td><td></td><td>179 (24)</td></tr><tr><td>Total by questionnaire type (%)</td><td></td><td>602 (80)</td><td>85 (11)</td><td>64 (9)</td><td></td><td>751 (100)</td></tr></table> |
1327cc5fd22984b1a156d27d172e7471703552904423bca3d8dc64370345a871.png | complex | <table><tr><td rowspan="3">Variable</td><td colspan="4">WAI</td></tr><tr><td>Status</td><td>Mean</td><td>S.D</td><td>P-value</td></tr><tr><td rowspan="2">Body mass index (kg/m<sup>2</sup>)</td><td>≥ 25 (n= 393)</td><td>41.65</td><td>6.72</td><td rowspan="2">0.031</td></tr><tr><td>< 25 (n= 283)</td><td>42.66</td><td>4.88</td></tr><tr><td rowspan="2">Smoking</td><td>Yes (n= 153)</td><td>40.27</td><td>6.80</td><td rowspan="2">< 0.001</td></tr><tr><td>No (n= 523)</td><td>42.60</td><td>5.71</td></tr><tr><td rowspan="3">Physical activity (MET.min/week)</td><td>Low (≤ 600) (n= 261)</td><td>40.63</td><td>6.71</td><td rowspan="3">< 0.001</td></tr><tr><td>Moderate(600-3000)(n= 206)</td><td>42.53</td><td>5.47</td></tr><tr><td>High (> 3000) (n= 209)</td><td>43.42</td><td>5.28</td></tr></table> |
b1c749df95d37b99bd8ac9d9e25f9bdba1395582edf24d50d17ab6c1213f1d70.png | complex | <table><tr><td> </td><td colspan="2">Subchondral bone volume</td><td colspan="2">Subchondral bone migration area</td></tr><tr><td> </td><td>Pearson's <i>r</i></td><td><i>P</i> value</td><td>Pearson's <i>r</i></td><td><i>P</i> value</td></tr><tr><td>Weeks</td><td>0.799</td><td><0.001</td><td>0.799</td><td><0.001</td></tr><tr><td>Gross appearance</td><td>0.865</td><td>0.001</td><td>0.923</td><td><0.001</td></tr><tr><td>Histology</td><td>0.649</td><td>0.059</td><td>0.520</td><td>0.152</td></tr></table> |
6dee634dd6e2a5006003855d935bd593cdc62f6857388534966677225868c690.png | complex | <table><tr><td>Country</td><td>Study type</td><td>Phase</td><td>n</td><td>Primary objective</td><td>Major findings</td></tr><tr><td rowspan="4">Thailand</td><td>HNV, PK and tolerability</td><td>1</td><td>24</td><td>PK and bio-availability of AS and MQ; administered separately and as a coformulation to healthy volunteers and patients</td><td>No difference was seen in the bio-equivalence of MQ in the two formulations; although a difference was seen for AS/DHA, this was not concluded to be clinically relevant[20]</td></tr><tr><td>PK, efficacy and safety</td><td>2</td><td>50</td><td>Population PK model of new dosage regime of MQ with AS in loose combination over three days</td><td>Splitting the 25 mg/kg dose of MQ into three doses of 8 mg/kg improved oral bio-availability compared to the conventional split-dose regimen results. New regimen was well tolerated and with an equivalent therapeutic response[21]</td></tr><tr><td>PK, efficacy and safety</td><td>2b</td><td>50</td><td>Safety and PK of ASMQ FDC vs non-fixed AS+MQ against multi-drug resistant falciparum malaria in adults</td><td>FDC well-tolerated with broadly similar PK profiles to non-fixed AS plus MQ[22]. The observed slowing of heart rate was best explained by malaria resolution[23]</td></tr><tr><td>Efficacy and safety</td><td>3</td><td>500</td><td>ASMQ FDC with separate tablets in adults and children with uncomplicated multidrug-resistant falciparum malaria</td><td>Cure rates were 91.9% for the FDC after 63 days, with a lower incidence of vomiting compared to those in the loose tablets group[24]</td></tr><tr><td>Myanmar</td><td>Competitive Effectiveness</td><td>4</td><td>808</td><td>Effectiveness of five artemisinin combination regimens with or without PQ in uncomplicated falciparum malaria</td><td>ASMQ provided the greatest post-treatment suppression of malaria after 63 days, with the addition of PQ substantially reducing transmission potential of malaria[25]</td></tr><tr><td>India</td><td>Efficacy and safety</td><td>3</td><td>77</td><td>PCR corrected cure rate of ASMQ FDC in adult patients with uncomplicated falciparum malaria</td><td>Mean parasite clearance time of 48 hours</td></tr><tr><td>Brazil</td><td>Intervention study: PK Efficacy and safety</td><td>3b/4</td><td>23,845</td><td>Effectiveness of ASMQ FDC in reducing malaria transmission in the Juruá valley</td><td>Early detection of malaria and treatment with ASMQ FDC was feasible and efficacious, significantly reduced the incidence and morbidity of falciparum malaria[26]</td></tr></table> |
4ce424d1896e7d94e80d7c326a6e50ddc8864a1f0064b508ee2670b0d599c9f1.png | simple | <table><tr><td>Outcome and complication</td><td>No. (%)</td></tr><tr><td>Mortality</td><td>6 (14.2%)</td></tr><tr><td>30 day</td><td>2 (4.8%)</td></tr><tr><td>1 year</td><td>1 (2.4%)</td></tr><tr><td>5 years</td><td>2 (4.8%)</td></tr><tr><td>Complications</td><td></td></tr><tr><td> Grade I</td><td>14 (33.3%)</td></tr><tr><td> Grade II</td><td>2 (4.8%)</td></tr><tr><td> Grade IIIa</td><td>4 (9.5%)</td></tr><tr><td> Grade IIIb</td><td>2 (4.8%)</td></tr><tr><td> Grade IV</td><td>3 (7.1%)</td></tr><tr><td>Massive intraoperative bleeding and edema.</td><td>2 (4.8%)</td></tr><tr><td>Wound infection</td><td>4 (9.5%)</td></tr><tr><td>New hemiparesis, sensory changes</td><td>4 (9.5%)</td></tr><tr><td>New cranial nerve palsy</td><td>7 (16.7%)</td></tr><tr><td>Deep vein thrombosis.</td><td>1 (2.4%)</td></tr><tr><td>Discharge location</td><td>42 (100%)</td></tr><tr><td>Home ± rehabilitation</td><td>24 (57.1%)</td></tr><tr><td>Rehabilitation center</td><td>14 (33.3%)</td></tr><tr><td>Convalescence hospital</td><td>2 (4.8%)</td></tr><tr><td>Hospital persist</td><td>2 (4.8%)</td></tr><tr><td>Karnofsky score at 1 year</td><td>(<i>n</i> = 38)</td></tr><tr><td> > 70</td><td>23 (60.5%)</td></tr><tr><td> < 70</td><td>15 (39.5%)</td></tr><tr><td>Karnofsky score at 5 years</td><td>(<i>n</i> = 34)</td></tr><tr><td> > 70</td><td>20 (58.8%)</td></tr><tr><td> < 70</td><td>14 (41.2%)</td></tr></table> |
74103fb49a6d7410c186459613c54c6d4e0178829a5c8939a7aae738037b7303.png | complex | <table><tr><td rowspan="2">Ordered by socioeconomic variable<sup>b</sup></td><td colspan="2">Male</td><td colspan="2">Female</td></tr><tr><td>Prevalence<sup>c</sup></td><td>Times/day<sup>d</sup></td><td>Prevalence<sup>c</sup></td><td>Times/day<sup>d</sup></td></tr><tr><td colspan="5">Based on ranges. <i>n</i> = 24<sup>e</sup></td></tr><tr><td> Reason for extreme rates</td><td>1.06</td><td>1.26</td><td>1.26</td><td>6.00</td></tr><tr><td> Difference of extreme rates</td><td>4.53</td><td>0.11</td><td>17.16</td><td>0.45</td></tr><tr><td> Prevalence attributable to population</td><td>−3.44</td><td>−0.13</td><td>1.69</td><td>−0.07</td></tr><tr><td> Prevalence attributable to population (%)</td><td>−4.39</td><td>−44.00</td><td>2.49</td><td>45.28</td></tr><tr><td colspan="5">Based on disparity or dispersion. <i>n</i> = 33</td></tr><tr><td> Pearcy-Keppel</td><td>0.57</td><td>2.29</td><td>0.66</td><td>1.23</td></tr><tr><td> Pearcy-Keppel (Adjusted <sub>A</sub>)</td><td>28.02</td><td>0.21</td><td>25.34</td><td>0.08</td></tr><tr><td> Variance between groups (VEG)</td><td>60.14</td><td>0.02</td><td>105.35</td><td>0.01</td></tr><tr><td> Variance between groups (VEG<sub>A</sub>)</td><td>0.77</td><td>0.05</td><td>1.55</td><td>0.05</td></tr><tr><td colspan="5">Based on disproportionality and concentration. <i>n</i> = 24</td></tr><tr><td> Gini</td><td>0.05</td><td>0.22</td><td>0.08</td><td>0.25</td></tr><tr><td> Concentration</td><td>0.01</td><td>0.12</td><td>−0.01</td><td>−0.05</td></tr><tr><td colspan="5">Based on regression models. <i>n</i> = 24</td></tr><tr><td> Coefficient β</td><td>0.12</td><td>−0.00</td><td>0.24</td><td>0.00</td></tr><tr><td> Coefficient of determination</td><td>0.00</td><td>0.00</td><td>0.02</td><td>0.11</td></tr><tr><td> Inequality of slope</td><td>3.23</td><td>0.22</td><td>−3.16</td><td>−0.05</td></tr><tr><td> Inequality of Pamuk or relative</td><td>0.04</td><td>0.73</td><td>0.05</td><td>0.28</td></tr><tr><td> Inequality of Kunst and Mackenbach</td><td>1.04</td><td>1.53</td><td>1.05</td><td>1.33</td></tr><tr><td> Dimensional inequality</td><td>3.23</td><td>0.49</td><td>1.04</td><td>1.29</td></tr><tr><td colspan="5">Based on the concept of entropy. <i>n</i> = 33</td></tr><tr><td> Kullback-Liebler (Z)</td><td>0.01</td><td>0.09</td><td>0.01</td><td>0.11</td></tr><tr><td> Hoover or dissimilitudes (Z)</td><td>0.04</td><td>0.15</td><td>0.06</td><td>0.17</td></tr><tr><td> Theil (Z)</td><td>0.01</td><td>0.08</td><td>0.01</td><td>0.11</td></tr></table> |
0c41e4fa7794a7506e5f8c9e70e9edd35ba73275411de0127291684d77ea6989.png | simple | <table><tr><td><i>Pollutant</i></td><td><i>Concentration</i></td><td><i>Averaging period</i></td><td><i>Permitted exceedences each year</i></td></tr><tr><td>Cuprum [μ/m<sup>3</sup>]</td><td>0,6 μg/m3</td><td>1 year</td><td>n/a</td></tr><tr><td>PM10</td><td>40 μg/m3</td><td>1 year</td><td>n/a</td></tr><tr><td>Lead (Pb)</td><td>0,35 μg/m3</td><td>1 year</td><td>n/a</td></tr></table> |
ccf5652e5b43fe461a3d0b198e55951bedaeda44440af9e0c72f95197d9b32fb.png | complex | <table><tr><td rowspan="2">Publication</td><td colspan="3">Zona pellucida breach</td><td rowspan="2">Embryonic stage</td><td rowspan="2">No of ET</td><td rowspan="2">Pregnancies conceived</td><td rowspan="2">Intervention</td><td rowspan="2">Outcome</td></tr><tr><td>ICSI</td><td>Assisted hatching</td><td>Embryo biopsy</td></tr><tr><td rowspan="2">Salat-Baroux et al., 1994</td><td rowspan="2">No</td><td rowspan="2">No</td><td rowspan="2">No</td><td rowspan="2">Cleavage</td><td rowspan="2">4</td><td>MCTA triplets</td><td rowspan="2">Reduction</td><td rowspan="2">DCDA miscarriage</td></tr><tr><td>DCDA twins</td></tr><tr><td>Belaisch-Allart et al., 1995</td><td>No</td><td>No</td><td>No</td><td>Cleavage</td><td>3</td><td>MCTA triplets</td><td>Nil</td><td>Delivery ?weeks</td></tr><tr><td rowspan="2">Yakin et al., 2001</td><td rowspan="2">Yes</td><td rowspan="2">No</td><td rowspan="2">No</td><td rowspan="2">Blastocyst</td><td rowspan="2">3</td><td>MCTA triplets</td><td rowspan="2">Reduction</td><td rowspan="2">DCDA delivery 36 weeks</td></tr><tr><td>DCDA twins</td></tr><tr><td>Ghulmiyyah et al., 2003</td><td>Yes</td><td>Yes</td><td>No</td><td>Blastocyst</td><td>2</td><td>MCTA triplets</td><td>Nil</td><td>CS at week 31</td></tr><tr><td rowspan="3">Ulug et al., 2004</td><td rowspan="2">Yes</td><td rowspan="2">Yes</td><td rowspan="2">No</td><td rowspan="2">Cleavage</td><td rowspan="2">3</td><td>MCTA triplets</td><td rowspan="2">Reduction</td><td rowspan="2">Singleton CS at week 38</td></tr><tr><td>Singleton</td></tr><tr><td>Yes</td><td>Yes</td><td>No</td><td>Cleavage</td><td>3</td><td>MCTA triplets</td><td>Nil</td><td>CS at week 34</td></tr><tr><td rowspan="2">Unger et al., 2004</td><td rowspan="2">Yes</td><td rowspan="2">No</td><td rowspan="2">No</td><td rowspan="2">Blastocyst</td><td rowspan="2">2</td><td>MCTA triplets</td><td rowspan="2">Reduction</td><td rowspan="2">Ongoing MCDA pregnancy 22 weeks</td></tr><tr><td>MCDA twins</td></tr><tr><td rowspan="2">Zikopoulos et al., 2004</td><td rowspan="2">Yes</td><td rowspan="2">No</td><td rowspan="2">No</td><td rowspan="2">Blastocyst</td><td rowspan="2">2</td><td>MCTA triplets</td><td rowspan="2">Reduction</td><td rowspan="2">Ongoing MCDA pregnancy 20 weeks</td></tr><tr><td>MCDA twins</td></tr><tr><td rowspan="2">Risquez et al., 2004</td><td rowspan="2">Yes</td><td rowspan="2">Yes</td><td rowspan="2">No</td><td rowspan="2">Cleavage</td><td rowspan="2">1</td><td rowspan="2">MCTA triplets</td><td rowspan="2">Nil</td><td>Ongoing pregnancy</td></tr><tr><td>16 weeks</td></tr><tr><td>Jain et al., 2004</td><td>No</td><td>No</td><td>No</td><td>Blastocyst</td><td>2</td><td>MCTA triplets</td><td>Nil</td><td>Ongoing pregnancy 7 weeks</td></tr><tr><td>Henne et al., 2005</td><td>No</td><td>No</td><td>No</td><td>Blastocyst</td><td>2</td><td>MCTA triplets</td><td>Termination</td><td></td></tr><tr><td>Yanaihara et al., 2007</td><td>No</td><td>No</td><td>No</td><td>Blastocyst</td><td>1</td><td>MCTA triplets</td><td>Termination</td><td></td></tr><tr><td>Lee et al., 2008</td><td>Yes</td><td>No</td><td>No</td><td>Blastocyst</td><td>1</td><td>MCTA triplets</td><td>Nil</td><td>CS at 33 weeks</td></tr><tr><td>Faraj et al., 2008</td><td>No</td><td>No</td><td>No</td><td>Blastocyst</td><td>1</td><td>MCTA triplets</td><td>Nil</td><td>CS at 32 weeks</td></tr><tr><td rowspan="2">Pantos et al., 2004</td><td rowspan="2">Yes</td><td rowspan="2">Yes</td><td rowspan="2">No</td><td rowspan="2">Day 4</td><td rowspan="2">3</td><td>MCTA triplets</td><td rowspan="2">Reduction</td><td rowspan="2">Singleton CS at 38 weeks</td></tr><tr><td>singleton</td></tr><tr><td rowspan="2">Haimov-Kochman et al., 2009</td><td rowspan="2">Yes</td><td rowspan="2">No</td><td rowspan="2">Yes</td><td rowspan="2">Day 4</td><td rowspan="2">3</td><td>MCTA triplets</td><td rowspan="2">Reduction</td><td rowspan="2">Singleton delivery at 38 weeks</td></tr><tr><td>singleton</td></tr><tr><td>Liu et al., 2010</td><td>No</td><td>No</td><td>No</td><td>Cleavage</td><td>2</td><td>MCQA</td><td>Nil</td><td>Miscarriage</td></tr><tr><td>Gurunath et al., 2015</td><td>No</td><td>No</td><td>No</td><td>Blastocyst</td><td>2</td><td>MCTA</td><td>Termination</td><td></td></tr><tr><td rowspan="2">Saravelos et al., 2015</td><td>Yes</td><td>No</td><td>Yes</td><td>Day 4</td><td>1</td><td>MCQA</td><td>Reduction</td><td>MCDA CS at 35 + 6 weeks</td></tr><tr><td>No</td><td>No</td><td>No</td><td>Blastocyst</td><td>1</td><td>MCTA</td><td>Reduction</td><td>Ongoing MCDA pregnancy</td></tr></table> |
88bb5404cd6393fbc0bea4641ff296f7091384ad940a59cb1830d01cf23f5260.png | simple | <table><tr><td>Location and day</td><td>Central station</td><td>Adjacent to patient</td></tr><tr><td>John Radcliffe Hospital Adult ICU weekday</td><td>58.4 dB</td><td>59.7 dB</td></tr><tr><td>John Radcliffe Hospital Adult ICU weekend</td><td>59.1 dB</td><td>59.5 dB</td></tr><tr><td>Royal Berkshire Hospital ICU weekday</td><td>58.7 dB</td><td>59.9 dB</td></tr><tr><td>Royal Berkshire Hospital ICU weekend</td><td>57.7 dB</td><td>58.5 dB</td></tr><tr><td>Wycombe General Hospital ICU weekday</td><td>52.4 dB</td><td>55.4 dB</td></tr><tr><td>Wycombe General Hospital ICU weekend</td><td>51.3 dB</td><td>54.1 dB</td></tr><tr><td>John Radcliffe Neurosciences ICU weekday</td><td>58.0 dB</td><td>58.8 dB</td></tr><tr><td>Churchill Hospital Adult ICU weekend</td><td>55.7 dB</td><td>55.4 dB</td></tr></table> |
7560d24b9499d1de6bbd5073753013ebac55492024eb9162afd80a2b83f71156.png | complex | <table><tr><td>Gene ID</td><td>Description</td><td>Lineage<sup>a</sup></td><td colspan="5"><i>dN/dS</i></td></tr><tr><td></td><td></td><td></td><td><i>A</i></td><td><i>B</i></td><td><i>C</i></td><td><i>D</i></td><td><i>E</i></td></tr><tr><td>YDR197W</td><td>Mitochondrial translational activator of the COB mRNA</td><td><i>B</i></td><td>0.078</td><td>1.472</td><td>0.092</td><td>0.088</td><td>0.131</td></tr><tr><td>YER174C</td><td>Hydroperoxide and superoxide- radical responsive glutathione- dependent oxidoreductase</td><td><i>B</i></td><td>0.086</td><td>1.243</td><td>0.033</td><td>0.102</td><td>0.044</td></tr><tr><td>YFR041C</td><td>telomere maintenance</td><td><i>B</i></td><td>0.132</td><td>1.138</td><td>0.054</td><td>0.111</td><td>0.071</td></tr><tr><td>YGL119W</td><td>Protein required for ubiquinone (coenzyme Q) biosynthesis and for respiratory growth</td><td><i>B</i></td><td>0.045</td><td>4.607</td><td>0.044</td><td>0.073</td><td>0.078</td></tr><tr><td>YMR006C</td><td>glycerophospholipid metabolism</td><td><i>C</i></td><td>0.060</td><td>0.036</td><td>2.788</td><td>0.060</td><td>0.052</td></tr><tr><td>YPL248C</td><td>galactose metabolism; DNA- dependent regulation of transcription</td><td><i>C</i></td><td>0.175</td><td>0.240</td><td>1.078</td><td>0.145</td><td>0.170</td></tr></table> |
5fb8b154085fd44387ae5c8cf149d7dcbfeb8649032b91badb8cece30d739ab9.png | simple | <table><tr><td>Code</td><td>Before wetting</td><td>After wetting</td><td>Increased by</td></tr><tr><td>CH</td><td>220 μm</td><td>410 μm</td><td>46.34%</td></tr><tr><td>MCG</td><td>225 μm</td><td>310 μm</td><td>27.42%</td></tr><tr><td>F</td><td>240 μm</td><td>440 μm</td><td>45.45%</td></tr><tr><td>MF</td><td>300 μm</td><td>380 μm</td><td>21.05%</td></tr></table> |
b1c3e28b1e044b59f0d88b1a7cb4d1b16a444f1a6a3043e88f69fcde2e1d5a55.png | complex | <table><tr><td>Vol.</td><td>Class</td><td>Macrogametocyte</td><td><i>k-1</i></td><td>Round stage</td><td><i>k-2</i></td><td>Ookinete</td><td><i>k-3</i></td><td>Oocyst</td><td><i>K</i></td></tr><tr><td></td><td colspan="9"><i>Anopheles dirus</i></td></tr><tr><td>11</td><td>HIGH</td><td>2978.0</td><td>*</td><td>3.23</td><td>1.96</td><td>32.69</td><td>1.40</td><td>1.30</td><td>3.36</td></tr><tr><td>15</td><td></td><td>1242.0</td><td>1.63</td><td>29.27</td><td>0.00</td><td>31.37</td><td>0.00</td><td>59.50</td><td>1.63</td></tr><tr><td>2</td><td></td><td>812.9</td><td>1.12</td><td>61.05</td><td>0.21</td><td>37.69</td><td>0.35</td><td>17.00</td><td>1.68</td></tr><tr><td>5</td><td></td><td>416.3</td><td>*</td><td>42.39</td><td>0.33</td><td>192.58</td><td>0.65</td><td>42.70</td><td>0.98</td></tr><tr><td>6</td><td></td><td>358.6</td><td>1.38</td><td>15.08</td><td>0.17</td><td>10.15</td><td>0.63</td><td>2.40</td><td>2.18</td></tr><tr><td>1</td><td></td><td>332.8</td><td>1.44</td><td>12.20</td><td>0.00</td><td>13.43</td><td>0.00</td><td>25.10</td><td>1.44</td></tr><tr><td>13</td><td></td><td>277.7</td><td>0.85</td><td>39.33</td><td>0.52</td><td>11.88</td><td>0.77</td><td>2.00</td><td>2.14</td></tr><tr><td>3</td><td></td><td>233.3</td><td>1.37</td><td>10.02</td><td>0.00</td><td>14.03</td><td>0.00</td><td>85.80</td><td>1.37</td></tr><tr><td>14</td><td></td><td>96.1</td><td>*</td><td>6.71</td><td>0.77</td><td>16.20</td><td>0.00</td><td>61.70</td><td>0.77</td></tr><tr><td>12</td><td></td><td>56.6</td><td>1.20</td><td>3.54</td><td>0.08</td><td>2.96</td><td>0.00</td><td>10.60</td><td>1.28</td></tr><tr><td>8</td><td>LOW</td><td>804.4</td><td>2.15</td><td>5.70</td><td>0.77</td><td>0.15</td><td>0.06</td><td>0.00</td><td>2.98</td></tr><tr><td>7</td><td></td><td>165.5</td><td>0.93</td><td>19.63</td><td>1.17</td><td>1.32</td><td>0.25</td><td>0.30</td><td>2.35</td></tr><tr><td>10</td><td></td><td>138.8</td><td>2.06</td><td>0.23</td><td>0.09</td><td>0.00</td><td>0.00</td><td>0.10</td><td>2.15</td></tr><tr><td>4</td><td></td><td>101.8</td><td>1.58</td><td>2.70</td><td>0.34</td><td>1.23</td><td>0.14</td><td>0.60</td><td>2.06</td></tr><tr><td>9</td><td></td><td>34.7</td><td>1.54</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.00</td><td>1.54</td></tr><tr><td colspan="2">Average Losses</td><td colspan="2">1.44 (27-fold)</td><td colspan="2">0.43 (3-fold)</td><td colspan="2">0.28 (2-fold)</td><td colspan="2">1.86 (72-fold)</td></tr><tr><td></td><td colspan="9"><i>Anopheles minimus</i></td></tr><tr><td>15</td><td>HIGH</td><td>485.9</td><td>1.57</td><td>12.96</td><td>0.18</td><td>8.57</td><td>0.00</td><td>10.7</td><td>1.75</td></tr><tr><td>2</td><td></td><td>318.0</td><td>0.97</td><td>33.91</td><td>0.34</td><td>15.48</td><td>ND</td><td>ND†</td><td>ND</td></tr><tr><td>13</td><td></td><td>108.6</td><td>0.43</td><td>40.54</td><td>0.67</td><td>8.66</td><td>1.34</td><td>0.4</td><td>2.44</td></tr><tr><td>14</td><td></td><td>37.6</td><td>0.67</td><td>8.06</td><td>0.00</td><td>11.17</td><td>0.40</td><td>4.4</td><td>1.07</td></tr><tr><td>12</td><td></td><td>22.2</td><td>0.83</td><td>3.32</td><td>0.52</td><td>1.00</td><td>0.19</td><td>0.3</td><td>1.54</td></tr><tr><td>8</td><td>LOW</td><td>314.7</td><td>1.60</td><td>7.89</td><td>0.70</td><td>0.76</td><td>0.25</td><td>0</td><td>2.55</td></tr><tr><td>7</td><td></td><td>64.8</td><td>0.35</td><td>29.18</td><td>0.83</td><td>4.32</td><td>0.64</td><td>0</td><td>1.82</td></tr><tr><td>10</td><td></td><td>54.3</td><td>1.73</td><td>0.00</td><td>0.00</td><td>0.00</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>9</td><td></td><td>13.6</td><td>1.03</td><td>0.37</td><td>0.14</td><td>0.00</td><td>0.00</td><td>0</td><td>1.17</td></tr><tr><td colspan="2">Average Losses</td><td colspan="2">1.02 (10 -fold)</td><td colspan="2">0.33 (2-fold)</td><td colspan="2">0.40 (2-fold)</td><td colspan="2">1.76 (58-fold)</td></tr><tr><td></td><td colspan="9"><i>Anopheles sawadwongporni</i></td></tr><tr><td>15</td><td>HIGH</td><td>518.3</td><td>1.51</td><td>15.92</td><td>0.34</td><td>7.26</td><td>0.58</td><td>1.9</td><td>2.43</td></tr><tr><td>2</td><td></td><td>339.2</td><td>1.00</td><td>34.23</td><td>0.54</td><td>9.98</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>13</td><td></td><td>115.9</td><td>1.35</td><td>5.13</td><td>0.56</td><td>1.42</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>3</td><td></td><td>97.4</td><td>1.08</td><td>8.08</td><td>0.24</td><td>4.67</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>14</td><td></td><td>40.1</td><td>0.67</td><td>8.61</td><td>0.04</td><td>7.82</td><td>1.05</td><td>0.7</td><td>1.76</td></tr><tr><td>12</td><td></td><td>23.6</td><td>1.15</td><td>0.76</td><td>0.18</td><td>0.15</td><td>0.06</td><td>0</td><td>1.39</td></tr><tr><td>8</td><td>LOW</td><td>335.7</td><td>2.48</td><td>0.12</td><td>0.05</td><td>0.00</td><td>ND -</td><td>ND</td><td>ND</td></tr><tr><td colspan="2">Average Losses</td><td colspan="2">1.27 (19-fold)</td><td colspan="2">0.38 (2-fold)</td><td colspan="2">0.35 (2-fold)</td><td colspan="2">1.83 (68-fold)</td></tr></table> |
116220d2a69d768809cf40fc28e0a9760ba84905678c39ab39d5fd0ebedd91a4.png | complex | <table><tr><td></td><td colspan="3">Simulated Ontario Illness Attack Rates by the Percentage of Adults 53+ Years Old with Pre-existing Immunity<sup>1</sup></td><td></td><td colspan="2">Calibrated Attack Rates (AR)</td></tr><tr><td>Age</td><td>30%</td><td>50%</td><td>70%</td><td></td><td>Age</td><td>AR</td></tr><tr><td>0–4</td><td>30.6%</td><td>31.0%</td><td>30.8%</td><td></td><td>0–4</td><td>29.5%</td></tr><tr><td>5–13</td><td>53.8%</td><td>55.0%</td><td>55.2%</td><td></td><td rowspan="2">5–18</td><td rowspan="2">55.9%</td></tr><tr><td>14–17</td><td>56.0%</td><td>57.1%</td><td>57.3%</td><td></td><td></td><td></td></tr><tr><td>18–22</td><td>48.9%</td><td>49.7%</td><td>49.7%</td><td></td><td rowspan="2">19–52</td><td rowspan="2">40.8%</td></tr><tr><td>23–52</td><td>39.6%</td><td>39.8%</td><td>39.3%</td><td></td><td></td><td></td></tr><tr><td>53–64</td><td>21.7%</td><td>15.3%</td><td>8.8%</td><td></td><td>53–59</td><td>14.3%</td></tr><tr><td>65+</td><td>19.1%</td><td>13.2%</td><td>7.5%</td><td></td><td>60+</td><td>11.0%</td></tr><tr><td>Overall</td><td>36.8%</td><td>35.4%</td><td>33.5%</td><td></td><td>Overall</td><td>34.1%</td></tr></table> |
9bb2d30a5cbd35003d7c7d305a17dee2ad743daf665659f06d923842dc506d44.png | complex | <table><tr><td rowspan="2">Author</td><td rowspan="2" colspan="2">Sample size</td><td colspan="6">+936C/T</td><td colspan="6">−1154G/A</td></tr><tr><td>C</td><td>T</td><td>CC</td><td>CT</td><td>TT</td><td>HWE</td><td>G</td><td>A</td><td>GG</td><td>GA</td><td>AA</td><td>HWE</td></tr><tr><td rowspan="2">Rueda et al. (2005)</td><td>Case</td><td>53</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td></td><td>77</td><td>29</td><td>26</td><td>25</td><td>2</td><td></td></tr><tr><td>Control</td><td>226</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td></td><td>320</td><td>132</td><td>118</td><td>84</td><td>24</td><td>0.13</td></tr><tr><td rowspan="2">Liu et al. (2007)</td><td>Case</td><td>155</td><td></td><td></td><td>90</td><td></td><td></td><td></td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td></td></tr><tr><td>Control</td><td>195</td><td></td><td></td><td>150</td><td></td><td></td><td></td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td></td></tr><tr><td rowspan="2">Zhang et al. (2007)</td><td>Case</td><td>1849</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td></td><td>2018</td><td>1680</td><td>539</td><td>940</td><td>370</td><td></td></tr><tr><td>Control</td><td>1798</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td></td><td>1937</td><td>1659</td><td>515</td><td>907</td><td>376</td><td>0.00</td></tr><tr><td rowspan="2">Li et al. (2007)</td><td>Case</td><td>200</td><td>285</td><td>115</td><td>125</td><td>35</td><td>40</td><td></td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td></td></tr><tr><td>Control</td><td>100</td><td>154</td><td>46</td><td>70</td><td>14</td><td>16</td><td>0.00</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td></td></tr><tr><td rowspan="2">Li et al. (2009)</td><td>Case</td><td>150</td><td>190</td><td>110</td><td>51</td><td>88</td><td>11</td><td></td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td></td></tr><tr><td>Control</td><td>120</td><td>180</td><td>60</td><td>67</td><td>46</td><td>7</td><td>0.80</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td></td></tr><tr><td rowspan="2">Kim et al. (2011)</td><td>Case</td><td>991</td><td>1604</td><td>378</td><td>642</td><td>320</td><td>29</td><td></td><td>1619</td><td>363</td><td>674</td><td>271</td><td>46</td><td></td></tr><tr><td>Control</td><td>494</td><td>824</td><td>164</td><td>344</td><td>136</td><td>14</td><td>0.89</td><td>815</td><td>173</td><td>339</td><td>137</td><td>18</td><td>0.37</td></tr><tr><td rowspan="2">Fu et al. (2011)</td><td>Case</td><td>147</td><td>249</td><td>45</td><td>106</td><td>37</td><td>4</td><td></td><td>227</td><td>67</td><td>86</td><td>55</td><td>6</td><td></td></tr><tr><td>Control</td><td>131</td><td>218</td><td>44</td><td>90</td><td>38</td><td>3</td><td>0.66</td><td>194</td><td>68</td><td>69</td><td>56</td><td>6</td><td>0.20</td></tr><tr><td rowspan="2">Yu et al. (2012)</td><td>Case</td><td>420</td><td>573</td><td>267</td><td>172</td><td>229</td><td>19</td><td></td><td>–</td><td>‐</td><td>–</td><td>–</td><td>–</td><td></td></tr><tr><td>Control</td><td>456</td><td>706</td><td>206</td><td>267</td><td>172</td><td>17</td><td>0.09</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td></td></tr><tr><td rowspan="2">Fontanella et al. (2013)</td><td>Case</td><td>200</td><td>350</td><td>50</td><td>153</td><td>44</td><td>3</td><td></td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td></td></tr><tr><td>Control</td><td>200</td><td>348</td><td>52</td><td>151</td><td>46</td><td>3</td><td>0.81</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td></td></tr><tr><td rowspan="2">Zhang et al. (2014)</td><td>Case</td><td>68</td><td>114</td><td>22</td><td>48</td><td>18</td><td>2</td><td></td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td></td></tr><tr><td>Control</td><td>118</td><td>196</td><td>40</td><td>81</td><td>34</td><td>3</td><td>0.80</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td></td></tr></table> |
bc7b9adde466f639cda77fb9a6d13c7d654ba98ad479dfa98438dd0d1e7afbaf.png | complex | <table><tr><td></td><td colspan="2">Child demographics</td><td colspan="2">Maternal psychopathology</td></tr><tr><td>Maternal Abuse Group</td><td>Age, M ± SD</td><td>Sex, % female</td><td>PTSD, M ± SD</td><td>Depression, M ± SD</td></tr><tr><td colspan="5">Physical Childhood Abuse</td></tr><tr><td> Low (<i>n</i> = 22)</td><td>8.9 ± 2.0</td><td>54.5</td><td>11.5 ± 11.0</td><td>17.3 ± 10.0</td></tr><tr><td> High (<i>n</i> = 11)</td><td>10.7 ± 2.0*</td><td>45.5</td><td>22.3 ± 13.9*</td><td>28.5 ± 14.7*</td></tr><tr><td colspan="5">Emotional Childhood Abuse</td></tr><tr><td> Low (<i>n</i> = 24)</td><td>8.9 ± 2.1</td><td>54.2</td><td>11.9 ± 10.7</td><td>16.7 ± 9.7</td></tr><tr><td> High (<i>n</i> = 9)</td><td>11.1 ± 1.4*</td><td>44.4</td><td>23.7 ± 15.0*</td><td>32.2 ± 13.6**</td></tr><tr><td colspan="5">Sexual Childhood Abuse</td></tr><tr><td> Low (<i>n</i> = 17)</td><td>8.6 ± 2.2</td><td>52.9</td><td>7.7 ± 7.9</td><td>14.8 ± 8.5</td></tr><tr><td> High (<i>n</i> = 16)</td><td>10.4 ± 1.8*</td><td>50.0</td><td>22.7 ± 12.8**</td><td>27.7 ± 13.3**</td></tr></table> |
768bfd48789a6b686b203a90ff4d3ad1d5a61ec0293809ec3d5f841d2519881c.png | simple | <table><tr><td> </td><td>Enthalpy of desolvation, Δ<sub>desolv</sub>H (kJ mol<sup>−1</sup>) from DSC</td><td>Enthalpy of desolvation, Δ<sub>desolv</sub>H (kJ mol<sup>−1</sup>) calculated from equation 4</td></tr><tr><td>Atorvastatin (ATC)</td><td>-</td><td> </td></tr><tr><td>Solvate- I (ATC + 0.5 Isopropyl alcohol)</td><td>24.20</td><td>25.93</td></tr><tr><td>Solvate- II (ATC + THF)</td><td>51.47</td><td>57.17</td></tr><tr><td>Solvate- III (ATC + Ethanol)</td><td>44.69</td><td>34.39</td></tr><tr><td>Solvate- IV (ATC + 0.5 t-butanol)</td><td>78.85</td><td>78.31</td></tr><tr><td>Solvate- V (ATC + methanol)</td><td>26.27</td><td>26.70</td></tr><tr><td>Solvate-VI (ATC + 1 Acetone +0.5 Ethanol)</td><td>56.74</td><td>52.01</td></tr><tr><td>Solvate-VII (ATC + 0.5 Ethanol + Water)</td><td>104.64</td><td>103.96</td></tr><tr><td>Solvate- VIII (ATC + 1- butanol)</td><td>28.56</td><td>31.81</td></tr></table> |
8a6842e0111ec4b676778aea6cb2dd348bd9f22a7095ca1f3b1232328656e088.png | simple | <table><tr><td>Behavioral trait</td><td></td></tr><tr><td>Time spent in predator channel (proportion)</td><td>0.44 ± 0.01<i>n </i>=<i> </i>11</td></tr><tr><td>Direct approaches toward predator (proportion)</td><td>0.32 ± 0.03<i>n </i>=<i> </i>11</td></tr><tr><td>Startle responses</td><td>0.52 ± 0.06<i>n </i>=<i> </i>11</td></tr><tr><td>Number of freezes</td><td>0.99 ± 0.15<i>n </i>=<i> </i>11</td></tr><tr><td>Relative swimming activity</td><td>0.17 ± 0.01<i>n </i>=<i> </i>11</td></tr></table> |
6272f06cdacd946d4d2b1aba64498b5aed6ade0feceaca65b91a2138c8eca229.png | complex | <table><tr><td rowspan="3">Analyte</td><td colspan="3">FN<sup><i>a</i></sup></td><td colspan="3">FP</td></tr><tr><td rowspan="2">Original result (total)</td><td colspan="2">Discrepant investigation outcome<sup><i>b</i></sup></td><td rowspan="2">Original result (total)</td><td colspan="2">Discrepant investigation outcome</td></tr><tr><td>RP2 confirmed (TN)</td><td>RP2 unconfirmed (FN)</td><td>RP2 confirmed (TP)</td><td>RP2 unconfirmed (FP)</td></tr><tr><td>Viruses</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Adenovirus</td><td>4</td><td>1</td><td>3</td><td>48</td><td>40</td><td>8</td></tr><tr><td>Coronavirus 229E</td><td>1</td><td>1</td><td>0</td><td>5</td><td>0</td><td>5</td></tr><tr><td>Coronavirus HKU1</td><td>0</td><td></td><td></td><td>12</td><td>3</td><td>9</td></tr><tr><td>Coronavirus NL63</td><td>0</td><td></td><td></td><td>10</td><td>3</td><td>7</td></tr><tr><td>Coronavirus OC43</td><td>8</td><td>2</td><td>6<sup><i>c</i></sup></td><td>5</td><td>2</td><td>3</td></tr><tr><td>Human metapneumovirus</td><td>2</td><td>2</td><td>0</td><td>8</td><td>6</td><td>2</td></tr><tr><td>Human rhinovirus/enterovirus</td><td>11</td><td>6</td><td>5</td><td>77</td><td>33</td><td>44</td></tr><tr><td>Influenza virus A</td><td>0</td><td></td><td></td><td>0</td><td></td><td></td></tr><tr><td>H1</td><td>0</td><td></td><td></td><td>0</td><td></td><td></td></tr><tr><td>H1-2009</td><td>0</td><td></td><td></td><td>0</td><td></td><td></td></tr><tr><td>H3</td><td>0</td><td></td><td></td><td>0</td><td></td><td></td></tr><tr><td>Influenza virus B</td><td>0</td><td></td><td></td><td>2</td><td>2</td><td>0</td></tr><tr><td>Middle East respiratory syndrome coronavirus (MERS-CoV)</td><td>0</td><td></td><td></td><td>0</td><td></td><td></td></tr><tr><td>Parainfluenza virus 1</td><td>0</td><td></td><td></td><td>1</td><td>0</td><td>1</td></tr><tr><td>Parainfluenza virus 2</td><td>1</td><td>1</td><td>0</td><td>8</td><td>5</td><td>3</td></tr><tr><td>Parainfluenza virus 3</td><td>2</td><td>0</td><td>2</td><td>10</td><td>4</td><td>6</td></tr><tr><td>Parainfluenza virus 4</td><td>0</td><td></td><td></td><td>7</td><td>1</td><td>6</td></tr><tr><td>Respiratory syncytial virus</td><td>1</td><td>1</td><td>0</td><td>24</td><td>8</td><td>16</td></tr><tr><td>Bacteria</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Bordetella parapertussis (IS<i>1001</i>)</td><td>1</td><td>0</td><td>1</td><td>0</td><td></td><td></td></tr><tr><td>Bordetella pertussis (<i>ptxP</i>)</td><td>1</td><td>0</td><td>1</td><td>1</td><td>1</td><td>0</td></tr><tr><td>Chlamydia pneumoniae</td><td>0</td><td></td><td></td><td>1</td><td>1</td><td>0</td></tr><tr><td>Mycoplasma pneumoniae</td><td>1</td><td>0</td><td>1</td><td>5</td><td>5</td><td>0</td></tr><tr><td>Total</td><td>33</td><td>14</td><td>19</td><td>224</td><td>114</td><td>110</td></tr></table> |
716065bf1be92c936546bdf9f77c9c70c1c9f99ba87363d83cea5fd9ec1041c2.png | simple | <table><tr><td>Clinical profile</td><td>Asthmatics (all subject)</td><td>AIA</td><td>ATA</td></tr><tr><td>N</td><td>592</td><td>163</td><td>429</td></tr><tr><td>Age of first medical examination (mean (range))</td><td>46.15 (15.40-77.88)</td><td>43.13 (17.22-72.73)</td><td>47.30 (15.40-77.88)</td></tr><tr><td>Height (cm)</td><td>160.78 ± 8.63</td><td>161.72 ± 8.69</td><td>160.42 ± 8.39</td></tr><tr><td>Weight (kg)</td><td>62.81 ± 10.84</td><td>61.25 ± 10.38</td><td>63.40 ± 10.97</td></tr><tr><td>Fall rate (%)</td><td>9.27 ± 13.24</td><td>24.63 ± 16.11</td><td>3.54 ± 4.85</td></tr><tr><td>Blood eosinophil (%)</td><td>6.01 ± 5.73</td><td>5.96 ± 5.21</td><td>6.03 ± 5.92</td></tr><tr><td>FVC %, predicted</td><td>88.54 ± 14.08</td><td>90.35 ± 14.04</td><td>87.85 ± 14.05</td></tr><tr><td>FEV<sub>1 </sub>%, predicted</td><td>90.54 ± 16.97</td><td>87.58 ± 16.94</td><td>91.66 ± 16.87</td></tr><tr><td>PC20, methacholine (mg/ml)</td><td>6.43 ± 8.67</td><td>5.02 ± 7.83</td><td>6.91 ± 8.90</td></tr><tr><td>Total IgE (IU/ml)*</td><td>156 (62, 394)</td><td>164 (78, 357)</td><td>154 (53, 416)</td></tr><tr><td>Sex (male/female)</td><td>206/386</td><td>59/104</td><td>147/282</td></tr><tr><td>Current Smoker (%)</td><td>27.70</td><td>21.47</td><td>30.07</td></tr><tr><td>Positive rate of skin test (%)</td><td>56.42</td><td>52.76</td><td>57.81</td></tr></table> |
34d48a5eb44137023cb2ef858d29f0fb210fa9dd2b9f1b59269a2d0b7949d002.png | simple | <table><tr><td></td><td>Survivors(<i>n </i>= 45)</td><td>Nonsurvivors(<i>n </i>= 43)</td></tr><tr><td>Age (mean ± SD)</td><td>42 (35-50)</td><td>38 (29-46)</td></tr><tr><td>Male gender (%)</td><td>36 (80%)</td><td>31 (72%)</td></tr><tr><td>Location before ICU (ward, %)</td><td>24 (53%)</td><td>29 (67%)</td></tr><tr><td>Performance status 3 or 4</td><td>1 (0-2)</td><td>2 (1-3)</td></tr><tr><td>CD4 count <50 mm<sup>3 </sup>(%)</td><td>20 (44%)</td><td>21 (49%)</td></tr><tr><td>Length of time from AIDS diagnosis</td><td>39 (2-92)</td><td>50 (2-85)</td></tr><tr><td>Recent (<3 months) AIDS diagnosis</td><td>13 (29%)</td><td>13 (30%)</td></tr><tr><td>HAART use</td><td>20 (44%)</td><td>20 (46%)</td></tr><tr><td>SAPS II expanded (points)</td><td>44 (37-54)</td><td>54 (46-67)<sup>b</sup></td></tr><tr><td>SOFA D1 (points)</td><td>4 (1-7)</td><td>7 (4-10)<sup>b</sup></td></tr><tr><td>Mechanical ventilation</td><td>17 (38%)</td><td>36 (84%)<sup>b</sup></td></tr><tr><td>Use of vasopressors on day 1</td><td>6 (13%)</td><td>15 (30%)<sup>a</sup></td></tr><tr><td>Renal support</td><td>3 (7%)</td><td>13 (30%)<sup>b</sup></td></tr><tr><td>Severe sepsis/septic shock (%)</td><td>15 (33%)</td><td>29 (67%)<sup>b</sup></td></tr><tr><td>ICU length of stay (days)</td><td>9 (5-17)</td><td>10 (4-14)</td></tr><tr><td>Hospital length of stay (days)</td><td>24 (12-58)</td><td>15 (10-24)<sup>a</sup></td></tr></table> |
060e05d1801f9da92c0ef614657d4c88ea3c924a030495e7164ee86ede746aea.png | complex | <table><tr><td rowspan="2">Characteristics</td><td colspan="2">Correlation coefficient (<i>r</i>)</td><td colspan="2"><i>P</i> value</td></tr><tr><td>AA</td><td>SS</td><td>AA</td><td>SS </td></tr><tr><td>Age </td><td>−0.752</td><td>−0.744</td><td>0.000</td><td>0.000 </td></tr><tr><td>BMI</td><td>0.120</td><td>0.386</td><td>0.241</td><td>0.000 </td></tr><tr><td>Subischial leg length</td><td>−0.922</td><td>−0.919</td><td>0.000</td><td> 0.000 </td></tr><tr><td>Sitting height</td><td>−0.728</td><td>−0.670</td><td>0.000</td><td>0.000 </td></tr><tr><td>Weight</td><td>−0.565</td><td>−0.700</td><td>0.000</td><td>0.000 </td></tr></table> |
5b09e71ab1b3acdbeb88b8fba4ab61f55b58615306ff86a8a712e4fc5ba9a662.png | complex | <table><tr><td rowspan="2">Variable</td><td rowspan="2">β</td><td rowspan="2">SE</td><td colspan="2">Ventricular septal defects (yes vs. no)</td><td rowspan="2"><i>P </i>value</td></tr><tr><td>Odds ratio</td><td>95% confidence interval</td></tr><tr><td>NBL</td><td>−0.37</td><td>0.12</td><td>0.69</td><td>0.55 to 0.87</td><td>0.001</td></tr><tr><td>UA PI</td><td> 2.09</td><td>0.32</td><td>8.10</td><td>4.31 to 15.21</td><td><0.0001</td></tr><tr><td>MCA PI</td><td>−1.37</td><td>0.38</td><td>0.25</td><td>0.12 to 0.54</td><td><0.0001</td></tr></table> |
3246ab3bb41b1292beae95eff5ef2b00d2bb99c5adb54d10d2077f7177d4130e.png | simple | <table><tr><td> </td><td>RSV group A</td><td> </td><td>RSV group B</td><td> </td></tr><tr><td> </td><td>Global</td><td>Dadaab</td><td>Global</td><td>Dadaab</td></tr><tr><td>Period (years)</td><td>2006-11</td><td>2007-11</td><td>2006-11</td><td>2007-11</td></tr><tr><td>Total Sequences<sup>@</sup></td><td>649</td><td>182</td><td>504</td><td>108</td></tr><tr><td>Overall % Genetic distance</td><td>6.9</td><td>1.4</td><td>4.7</td><td>2.4</td></tr><tr><td>Sequences Unique (%)*</td><td>338 (52.1)</td><td>39 (21.4)</td><td>361(71.6)</td><td>24 (22.2)</td></tr><tr><td>Number of genotypes identified</td><td>2</td><td>2</td><td>4</td><td>1</td></tr></table> |
2ed38b8d0a2c210238fac69baa0706fa4d6eb3c88b676e86e6169931ae73a69a.png | simple | <table><tr><td>Technique</td><td>N</td><td>TP</td><td>TN</td><td>FN</td><td>k</td><td>Sensitivity</td><td>Specify%</td><td>Specify%</td><td>PPV%</td><td>NPV%</td><td>Accuracy%</td></tr><tr><td>4D-TRAK</td><td>52</td><td>42</td><td>6</td><td>1</td><td>3</td><td>0.91</td><td>93.33</td><td>85.71</td><td>96.67</td><td>66.67</td><td>92.31</td></tr><tr><td>3D-TOF-MRA</td><td>52</td><td>45</td><td>6</td><td>1</td><td>0</td><td>0.95</td><td>100.00</td><td>85.71</td><td>97.83</td><td>100</td><td>98.08</td></tr></table> |
12e23151922c4536c672b61988940ec19010526d9ce7330be3bac99b81227d63.png | simple | <table><tr><td>Pupil size (mm)</td><td><i>n</i></td><td>Nurses’ estimations<sup>a</sup> (mm)</td><td>Pupillometer measurements<sup>a</sup> (mm)</td><td><i>P</i> value</td><td>Spearman's coefficient (95 % CI)</td><td><i>P</i> value</td></tr><tr><td><2</td><td>61</td><td>2 (2–2)</td><td>1.8 (1.6–1.8)</td><td>0.057</td><td>0.39 (0.15–0.59)</td><td>0.002</td></tr><tr><td>2–4</td><td>232</td><td>3 (2–3)</td><td>2.8 (2.5–3.3)</td><td>0.005</td><td>0.44 (0.33–0.54)</td><td><0.001</td></tr><tr><td>>4</td><td>113</td><td>4 (3–5)</td><td>4.9 (4.4–5.6)</td><td><0.001</td><td>0.37 (0.19–0.51)</td><td>0.001</td></tr><tr><td>All</td><td>406</td><td>3 (2–4)</td><td>3.0 (2.3–4.3)</td><td><0.001</td><td>0.75 (0.71–0.79)</td><td><0.001</td></tr></table> |
c052757abd67e1c2b4e4760b5c60f7c22cd1060c1a8c2dd8643b020c19e5155e.png | complex | <table><tr><td> </td><td> </td><td colspan="2">Full cohort</td><td colspan="2">Matched cohort</td></tr><tr><td> </td><td>Total<sup>a</sup></td><td>AKI<sup>a</sup></td><td>non-AKI<sup>a</sup></td><td>AKI<sup>a</sup></td><td>non-AKI<sup>a</sup></td></tr><tr><td>Clinical features</td><td>n = 1,030</td><td>n = 287</td><td>n = 743</td><td>n = 257</td><td>n = 257</td></tr><tr><td>Pre-operative characteristics</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Male gender</td><td>750 (72.8)</td><td>209 (72.8)</td><td>541 (72.8)</td><td>190 (73.9)</td><td>189 (73.5)</td></tr><tr><td>Age (years), mean (IQR)</td><td>65.8 (59 to 75)</td><td>70.0 (64 to 78)</td><td>64.1 (58 to 73)</td><td>69.4 (63 to 77)</td><td>69.3 (65 to 76)</td></tr><tr><td>Smoker</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Present</td><td>487 (47.3)</td><td>147 (51.2)</td><td>340 (45.8)</td><td>130 (50.6)</td><td>129 (50.2)</td></tr><tr><td>Never</td><td>357 (34.7)</td><td>88 (30.7)</td><td>269 (36.2)</td><td>82 (31.9)</td><td>83 (32.3)</td></tr><tr><td>Previous</td><td>186 (18.1)</td><td>52 (18.1)</td><td>134 (18.0)</td><td>45 (17.5)</td><td>45 (17.5)</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><25</td><td>287 (27.9)</td><td>85 (29.6)</td><td>202 (27.2)</td><td>72 (28.0)</td><td>63 (24.5)</td></tr><tr><td>25 to 30</td><td>425 (41.3)</td><td>110 (38.3)</td><td>315 (42.4)</td><td>103 (40.0)</td><td>100 (38.9)</td></tr><tr><td>>30</td><td>318 (30.9)</td><td>92 (32.1)</td><td>226 (30.4)</td><td>82 (31.9)</td><td>94 (36.6)</td></tr><tr><td>Previous ischemic peripheral disease</td><td>57 (5.5)</td><td>19 (6.6)</td><td>38 (5.1)</td><td>17 (6.6)</td><td>13 (5.1)</td></tr><tr><td>Previous stroke</td><td>104 (10.1)</td><td>37 (12.9)</td><td>67 (9.0)</td><td>32 (12.5)</td><td>29 (11.3)</td></tr><tr><td>Previous myocardial infarction</td><td>256 (24.9)</td><td>66 (23.0)</td><td>190 (25.6)</td><td>63 (24.5)</td><td>65 (25.3)</td></tr><tr><td>History of arrhythmias</td><td>154 (15.0)</td><td>60 (20.9)</td><td>94 (12.7)</td><td>49 (19.1)</td><td>51 (19.8)</td></tr><tr><td>Diabetes mellitus</td><td>166 (16.1)</td><td>58 (20.2)</td><td>108 (14.5)</td><td>50 (19.5)</td><td>55 (21.4)</td></tr><tr><td>Dyslipidemia</td><td>570 (55.3)</td><td>156 (54.3)</td><td>414 (55.7)</td><td>141 (54.9)</td><td>147 (57.2)</td></tr><tr><td>Hypertension</td><td>585 (56.8)</td><td>166 (57.8)</td><td>419 (56.4)</td><td>146 (56.8)</td><td>153 (59.5)</td></tr><tr><td>Normal <140 and <90<sup>b</sup></td><td>455 (44.2)</td><td>121 (42.2)</td><td>324 (43.6)</td><td>111 (43.2)</td><td>104 (40.5)</td></tr><tr><td>Grade I 140 to 159 or 90 to 99<sup>b</sup></td><td>306 (29.7)</td><td>80 (27.9)</td><td>226 (31.4)</td><td>70 (27.2)</td><td>91 (23.7)</td></tr><tr><td>Grade II 160 to 179 or 100 to 109<sup>b</sup></td><td>189 (18.4)</td><td>61 (21.3)</td><td>128 (17.2)</td><td>56 (21.8)</td><td>42 (16.3)</td></tr><tr><td>Grade III > =180 or > =110<sup>b</sup></td><td>90 (8.7)</td><td>25 (8.7)</td><td>65 (8.8)</td><td>20 (7.8)</td><td>20 (7.8)</td></tr><tr><td>Charlson comorbidity index</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Low (score 0)</td><td>396 (38.5)</td><td>91 (31.7)</td><td>305 (41.5)</td><td>86 (33.5)</td><td>91 (35.0)</td></tr><tr><td>Medium (score 1 to 2)</td><td>456 (44.3)</td><td>135 (47.0)</td><td>321 (43.2)</td><td>119 (46.3)</td><td>112 (43.6)</td></tr><tr><td>High (score >3)</td><td>178 (17.3)</td><td>61 (21.3)</td><td>117 (15.7)</td><td>52 (20.2)</td><td>54 (21.0)</td></tr><tr><td>Baseline creatinine (μmol/L), mean (IQR)</td><td>85.0 (68 to 98)</td><td>94.2 (73 to 109)</td><td>81.4 (66 to 92)</td><td>90.9 (72 to 107)</td><td>91.3 (73 to 105)</td></tr><tr><td>euroSCORE, mean (IQR)<sup>c</sup></td><td>5.2 (3 to 7)</td><td>6.4 (4 to 8)</td><td>4.7 (3 to 7)</td><td>6.1 (4 to 8)</td><td>6.1 (4 to 8)</td></tr><tr><td>Low risk (score 0 to 2)</td><td>199 (19.3)</td><td>30 (10.5)</td><td>169 (22.8)</td><td>30 (11.7)</td><td>28 (10.9)</td></tr><tr><td>Medium risk (score >2 to 5)</td><td>369 (35.8)</td><td>82 (28.6)</td><td>287 (38.6)</td><td>78 (30.4)</td><td>81 (31.5)</td></tr><tr><td>High risk (score >5)</td><td>462 (44.9)</td><td>175 (70.0)</td><td>287 (38.6)</td><td>149 (58.0)</td><td>148 (57.6)</td></tr><tr><td>Surgical procedure characteristics</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Type of surgery</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Valve<sup>d</sup></td><td>313 (30.4)</td><td>84 (29.3)</td><td>229 (30.8)</td><td>77 (30.0)</td><td>78 (30.4)</td></tr><tr><td>CABG</td><td>372 (36.1)</td><td>85 (29.6)</td><td>287 (38.6)</td><td>80 (31.1)</td><td>71 (27.6)</td></tr><tr><td>Valve and CABG</td><td>158 (15.3)</td><td>59 (20.6)</td><td>99 (13.3)</td><td>51 (19.8)</td><td>54 (17.1)</td></tr><tr><td>Other<sup>e</sup></td><td>187 (18.2)</td><td>59 (20.6)</td><td>128 (17.2)</td><td>49 (19.1)</td><td>54 (17.1)</td></tr><tr><td>Extra corporal circulation</td><td>910 (88.4)</td><td>255 (88.9)</td><td>655 (88.2)</td><td>227 (88.3)</td><td>223 (86.8)</td></tr></table> |
bf583cbcca7e8ed677f3e7735f5c27da41741cebd7df3112698a38e2cd4a955e.png | simple | <table><tr><td> </td><td>n</td><td>Mean</td><td>Std. Deviation</td></tr><tr><td>FRACTURE STRENGTH</td><td>80</td><td>1016.6670</td><td>171.58485</td></tr></table> |
a70633dc191752fe6fac558181e10384ede42e4d6a0289429519d5931dff2006.png | simple | <table><tr><td></td><td>1997</td><td>2012</td></tr><tr><td>Subconjunctival hemorrhage</td><td>92 (28.75%)</td><td>133 (27.42%)</td></tr><tr><td>Conjunctivitis</td><td>108 (33.75%)</td><td>153 (31.75%)</td></tr><tr><td>Keratitis</td><td>20 (6.25%)</td><td>32 (6.60%)</td></tr><tr><td>Eyelid-related disorders</td><td>61 (19.06%)</td><td>79 (16.29%)</td></tr><tr><td>Contact lens-related disorders</td><td>39 (12.19%)</td><td>87 (17.94%)</td></tr><tr><td>Total</td><td>320 (100%)</td><td>485 (100%)</td></tr></table> |
bf87c87cb054abf461f48851b791e5816abade45bae3be9ba4ffd00b2ca4d010.png | complex | <table><tr><td>Season</td><td>Entry<sup>∗</sup></td><td>Grain yield (t ha<sup>−1</sup>) (±SEM)</td><td>Number holes/plant (±SEM)</td><td>% Stem height tunnelled (±SEM)</td></tr><tr><td rowspan="3">1</td><td>Bt</td><td>6.4 ± 0.4ab</td><td>0.4 ± 0.3a</td><td>0.7 ± 0.3a</td></tr><tr><td>Non-Bt</td><td>5.7 ± 0.4ab</td><td>2.7 ± 0.3c</td><td>3.8 ± 0.3c</td></tr><tr><td>Checks</td><td>5.0 ± 0.5a</td><td>2.8 ± 0.5c</td><td>5.0 ± 0.4d</td></tr><tr><td rowspan="3">2</td><td>Bt</td><td>11.7 ± 0.4d</td><td>1.7 ± 0.3b</td><td>0.1 ± 0.3a</td></tr><tr><td>Non-Bt</td><td>7.2 ± 0.4bc</td><td>4.0 ± 0.3d</td><td>3.9 ± 0.3c</td></tr><tr><td>Checks</td><td>5.9 ± 0.5ab</td><td>4.9 ± 0.5d</td><td>4.8 ± 0.4d</td></tr><tr><td rowspan="3">3</td><td>Bt</td><td>11.0 ± 0.4d</td><td>0.03 ± 0.3a</td><td>0.07 ± 0.3a</td></tr><tr><td>Non-Bt</td><td>6.9 ± 0.4ab</td><td>1.5 ± 0.3b</td><td>2.1 ± 0.3b</td></tr><tr><td>Checks</td><td>7.0 ± 0.5bc</td><td>2.1 ± 0.5b</td><td>3.4 ± 0.4c</td></tr><tr><td rowspan="3">Mean entry</td><td>Bt</td><td>9.7 ± 0.2c</td><td>0.7 ± 0.2a</td><td>0.3 ± 0.1a</td></tr><tr><td>Non-Bt</td><td>6.9 ± 0.2b</td><td>2.8 ± 0.2b</td><td>3.7 ± 0.1b</td></tr><tr><td>Checks</td><td>6.0 ± 0.3a</td><td>3.3 ± 0.2c</td><td>4.7 ± 0.2c</td></tr><tr><td rowspan="3">Mean season</td><td>1</td><td>5.8 ± 0.2a</td><td>2.0 ± 0.2b</td><td>3.3 ± 0.2b</td></tr><tr><td>2</td><td>8.3 ± 0.2b</td><td>3.6 ± 0.2c</td><td>3.1 ± 0.2b</td></tr><tr><td>3</td><td>8.4 ± 0.2b</td><td>1.2 ± 0.2a</td><td>2.3 ± 0.2a</td></tr></table> |
b224b6964e7c80743b2a44c608f03629fa026d01487651b0b9731137c32acbef.png | simple | <table><tr><td>Spot no.</td><td>Identity</td><td>MW (Da)</td><td>GenBank acc. no.</td><td>FC</td></tr><tr><td>1</td><td>Ser/Thr-specific protein phosphatase 2A A regulatory subunit β isoform (<i>Medicago sativa</i> subsp.×varia)</td><td>65161.6</td><td>AAG29594</td><td>0.647</td></tr><tr><td>2</td><td>Pyruvate kinase (<i>Lactuca sativa</i>)</td><td>56174.9</td><td>ABS87384</td><td>0.481</td></tr><tr><td>3</td><td>Branched-chain amino acid aminotransferase, putative (<i>Ricinus communis</i>)</td><td>45159.9</td><td>XP_002530599</td><td>0.541</td></tr><tr><td>4</td><td>Glucose-6-phosphate isomerase (<i>Zea mays</i>)</td><td>68403.5</td><td>NP_001147983</td><td>1.837</td></tr><tr><td>5</td><td>Actin (<i>Phaseolus acutifolius</i>)</td><td>33121.3</td><td>AAZ95077</td><td>2.277</td></tr><tr><td>6</td><td>Dehydrin (<i>Phaseolus vulgaris</i>)</td><td>22955.6</td><td>AAB00554</td><td>2.048</td></tr><tr><td>7</td><td>Dehydrin (<i>Phaseolus vulgaris</i>)</td><td>22955.6</td><td>AAB00554</td><td>1.846</td></tr><tr><td>8</td><td>Lactoylglutathione lyase, putative/glyoxalase I, putative (<i>Arabidopsis thaliana</i>)</td><td>20830.4</td><td>NP_001030996</td><td>2.414</td></tr><tr><td>9</td><td>Dehydrin (<i>Phaseolus vulgaris</i>)</td><td>22955.6</td><td>AAB00554</td><td>2.438</td></tr><tr><td>10</td><td>Dehydrin (<i>Phaseolus vulgaris</i>)</td><td>22955.6</td><td>AAB00554</td><td>1.625</td></tr></table> |
ab5712d4b3eac0ca0ff95682ab186855f5ffaeb6a49de17df8e54a32ff0c5d68.png | complex | <table><tr><td rowspan="3"></td><td colspan="10">Dorsal</td><td colspan="6">Ventral</td></tr><tr><td colspan="2">1 (pSN)</td><td colspan="2">2 (pSN)</td><td colspan="2">3 (aSN)</td><td colspan="2">4 (aSN)</td><td colspan="2">5 (aSN)</td><td colspan="2">A (pSN)</td><td colspan="2">B (pSN)</td><td colspan="2">C (aSN)</td></tr><tr><td>L</td><td>R</td><td>L</td><td>R</td><td>L</td><td>R</td><td>L</td><td>R</td><td>L</td><td>R</td><td>L</td><td>R</td><td>L</td><td>R</td><td>L</td><td>R</td></tr><tr><td>pHipp</td><td>−0.05</td><td>−0.06</td><td>−0.06</td><td>−0.06</td><td>0.02</td><td>−0.01</td><td>0.08</td><td>0.06</td><td>0.13</td><td>0.12</td><td>0</td><td>0.01</td><td>0.08</td><td>0.06</td><td>0.08</td><td>0.11</td></tr><tr><td>aHipp</td><td>−0.03</td><td>−0.03</td><td>−0.08</td><td>−0.07</td><td>0.06</td><td>0.02</td><td>0.13</td><td>0.11</td><td>0.22</td><td>0.20</td><td>0.03</td><td>0.07</td><td>0.11</td><td>0.09</td><td>0.12</td><td>0.15</td></tr></table> |
071fda764443bb874670d389db87d23ef3cd8731a6a51345d8ed9fca87f662ea.png | complex | <table><tr><td>Day</td><td colspan="3">Haematocrit</td><td colspan="3">Haemoglobin</td></tr><tr><td></td><td>Control</td><td>Group A</td><td>Group B</td><td>Control</td><td>Group A</td><td>Group B</td></tr><tr><td>0</td><td>28.3 ± 3.7</td><td>28.2 ± 3.7</td><td>28.4 ± 2.8</td><td>9.2 ± 1.3</td><td>9.3 ± 1.2</td><td>9.2 ± 0.9</td></tr><tr><td>3</td><td>27.9 ± 3.7</td><td>26.7 ± 5.0</td><td>28.2 ± 3.7</td><td>9.1 ± 1.3</td><td>9.0 ± 1.1</td><td>9.1 ± 1.2</td></tr><tr><td>7</td><td>28.4 ± 4.1</td><td>28.4 ± 3.7</td><td>29.5 ± 4.0</td><td>9.1 ± 1.4</td><td>9.2 ± 1.2</td><td>9.5 ± 1.3</td></tr><tr><td>10</td><td>28.8 ± 4.5</td><td>29.4 ± 4.1</td><td>30.3 ± 4.2*</td><td>9.4 ± 1.6</td><td>9.6 ± 1.2</td><td>9.7 ± 1.4</td></tr><tr><td>14</td><td>28.8 ± 4.5</td><td>30.8 ± 4.5</td><td>32.3 ± 5.4*</td><td>9.4 ± 1.4</td><td>10.0 ± 1.5</td><td>10.3 ± 1.9*</td></tr><tr><td>21</td><td>29.4 ± 6.2</td><td>31.9 ± 5.0</td><td>36.5 ± 6.3* <sup>†</sup></td><td>9.7 ± 2.0</td><td>10.3 ± 1.7</td><td>11.3 ± 2.1*</td></tr><tr><td>28</td><td>30.4 ± 4.5</td><td>33.3 ± 5.3</td><td>37.5 ± 5.8* <sup>†</sup></td><td>9.9 ± 1.5</td><td>10.6 ± 1.9</td><td>11.6 ± 1.9*</td></tr></table> |
f31df8bf2108472641ec086695c51635d48d540021874bf0f9c07fd91f9e674f.png | simple | <table><tr><td>Index</td><td>Segment</td><td><i>L</i></td><td><i>N</i><sub>opt</sub><sup>1</sup></td><td>Index</td><td>Segment</td><td><i>L</i></td><td><i>N</i><sub>opt</sub><sup>1</sup></td><td>Index</td><td>Segment</td><td><i>L</i></td><td><i>N</i><sub>opt</sub><sup>1</sup></td></tr><tr><td>1</td><td>B1 ↔ B2</td><td>8.1</td><td>10</td><td>31</td><td>T8 ↔ T9</td><td>18.8</td><td>27</td><td>61</td><td>H9 ↔ H10</td><td>50.8</td><td>75</td></tr><tr><td>2</td><td>B1 ↔ B6</td><td>73.5</td><td>91</td><td>32</td><td>T8 ↔ T18</td><td>12.9</td><td>18</td><td>62</td><td>H9 ↔ H14</td><td>70.4</td><td>104</td></tr><tr><td>3</td><td>B1 ↔ H1</td><td>56.9</td><td>87</td><td>33</td><td>T9 ↔ T10</td><td>10.6</td><td>15</td><td>63</td><td>H10 ↔ H11</td><td>24.3</td><td>35</td></tr><tr><td>4</td><td>B2 ↔ B3</td><td>19.5</td><td>24</td><td>34</td><td>T9 ↔ T17</td><td>22.5</td><td>33</td><td>64</td><td>H10 ↔ H13</td><td>32</td><td>47</td></tr><tr><td>5</td><td>B2 ↔ H4</td><td>36.8</td><td>56</td><td>35</td><td>T10 ↔ T11</td><td>13.9</td><td>20</td><td>65</td><td>H11 ↔ H12</td><td>45.8</td><td>67</td></tr><tr><td>6</td><td>B3 ↔ B4</td><td>10.5</td><td>13</td><td>36</td><td>T10 ↔ T16</td><td>18.9</td><td>27</td><td>66</td><td>H12 ↔ H13</td><td>42.6</td><td>62</td></tr><tr><td>7</td><td>B3 ↔ H5</td><td>36.3</td><td>55</td><td>37</td><td>T11 ↔ T12</td><td>14.8</td><td>21</td><td>67</td><td>H12 ↔ H20</td><td>96.5</td><td>143</td></tr><tr><td>8</td><td>B4 ↔ B5</td><td>11.3</td><td>14</td><td>38</td><td>T11 ↔ T15</td><td>34.6</td><td>51</td><td>68</td><td>H13 ↔ H14</td><td>37.5</td><td>55</td></tr><tr><td>9</td><td>B4 ↔ H6</td><td>23.5</td><td>36</td><td>39</td><td>T12 ↔ T13</td><td>38.6</td><td>57</td><td>69</td><td>H13 ↔ H21</td><td>85.2</td><td>126</td></tr><tr><td>10</td><td>B5 ↔ B6</td><td>7.8</td><td>9</td><td>40</td><td>T13 ↔ T14</td><td>9.8</td><td>14</td><td>70</td><td>H14 ↔ H15</td><td>65.8</td><td>97</td></tr><tr><td>11</td><td>B5 ↔ B7</td><td>12.6</td><td>19</td><td>41</td><td>T13 ↔ T15</td><td>6</td><td>8</td><td>71</td><td>H14 ↔ H28</td><td>71.9</td><td>106</td></tr><tr><td>12</td><td>B6 ↔ B8</td><td>12</td><td>18</td><td>42</td><td>T14 ↔ T15</td><td>12.6</td><td>18</td><td>72</td><td>H15 ↔ H17</td><td>21.1</td><td>30</td></tr><tr><td>13</td><td>B7 ↔ B8</td><td>6.7</td><td>10</td><td>43</td><td>T14 ↔ H16</td><td>33.1</td><td>47</td><td>73</td><td>H15 ↔ H28</td><td>82</td><td>121</td></tr><tr><td>14</td><td>B7 ↔ T2</td><td>29.2</td><td>45</td><td>44</td><td>T15 ↔ T16</td><td>21.3</td><td>31</td><td>74</td><td>H16 ↔ H17</td><td>17.9</td><td>26</td></tr><tr><td>15</td><td>B7 ↔ H6</td><td>13.7</td><td>21</td><td>45</td><td>T16 ↔ T17</td><td>37.6</td><td>56</td><td>75</td><td>H16 ↔ H18</td><td>29.8</td><td>43</td></tr><tr><td>16</td><td>B8 ↔ T1</td><td>24.4</td><td>37</td><td>46</td><td>T16 ↔ H19</td><td>62.1</td><td>89</td><td>76</td><td>H17 ↔ H18</td><td>23.6</td><td>34</td></tr><tr><td>17</td><td>T1 ↔ T2</td><td>7.3</td><td>10</td><td>47</td><td>T17 ↔ T18</td><td>12.5</td><td>18</td><td>77</td><td>H18 ↔ H19</td><td>35.5</td><td>52</td></tr><tr><td>18</td><td>T1 ↔ T6</td><td>39.2</td><td>58</td><td>48</td><td>H1 ↔ H2</td><td>16.7</td><td>24</td><td>78</td><td>H20 ↔ H22</td><td>15.8</td><td>23</td></tr><tr><td>19</td><td>T2 ↔ T4</td><td>23.8</td><td>35</td><td>49</td><td>H1 ↔ H3</td><td>13.1</td><td>19</td><td>79</td><td>H20 ↔ H23</td><td>14</td><td>20</td></tr><tr><td>20</td><td>T2 ↔ T5</td><td>27.9</td><td>41</td><td>50</td><td>H2 ↔ H3</td><td>20.1</td><td>29</td><td>80</td><td>H21 ↔ H22</td><td>20.9</td><td>30</td></tr><tr><td>21</td><td>T3 ↔ T4</td><td>11.2</td><td>16</td><td>51</td><td>H2 ↔ H11</td><td>35.2</td><td>51</td><td>81</td><td>H21 ↔ H25</td><td>36.1</td><td>53</td></tr><tr><td>22</td><td>T3 ↔ T12</td><td>7.2</td><td>10</td><td>52</td><td>H3 ↔ H4</td><td>13.7</td><td>19</td><td>82</td><td>H22 ↔ H24</td><td>14</td><td>20</td></tr><tr><td>23</td><td>T3 ↔ H8</td><td>31.8</td><td>45</td><td>53</td><td>H4 ↔ H5</td><td>25.1</td><td>36</td><td>83</td><td>H23 ↔ H24</td><td>19.4</td><td>28</td></tr><tr><td>24</td><td>T4 ↔ T5</td><td>19</td><td>28</td><td>54</td><td>H4 ↔ H10</td><td>48.7</td><td>71</td><td>84</td><td>H23 ↔ H26</td><td>40.8</td><td>60</td></tr><tr><td>25</td><td>T4 ↔ H7</td><td>29.5</td><td>42</td><td>55</td><td>H5 ↔ H6</td><td>26.7</td><td>39</td><td>85</td><td>H24 ↔ H25</td><td>18.7</td><td>27</td></tr><tr><td>26</td><td>T5 ↔ T6</td><td>12.6</td><td>18</td><td>56</td><td>H5 ↔ H9</td><td>32.8</td><td>48</td><td>86</td><td>H24 ↔ H26</td><td>25.2</td><td>37</td></tr><tr><td>27</td><td>T5 ↔ T8</td><td>36.7</td><td>54</td><td>57</td><td>H6 ↔ H7</td><td>26.3</td><td>38</td><td>87</td><td>H25 ↔ H27</td><td>25.7</td><td>37</td></tr><tr><td>28</td><td>T6 ↔ T7</td><td>19.4</td><td>28</td><td>58</td><td>H7 ↔ H8</td><td>25.1</td><td>36</td><td>88</td><td>H25 ↔ H28</td><td>81.4</td><td>120</td></tr><tr><td>29</td><td>T7 ↔ T8</td><td>17.6</td><td>25</td><td>59</td><td>H8 ↔ H9</td><td>26.6</td><td>39</td><td>89</td><td>H26 ↔ H27</td><td>13.4</td><td>19</td></tr><tr><td>30</td><td>T7 ↔ T18</td><td>22.6</td><td>33</td><td>60</td><td>H8 ↔ H16</td><td>85.5</td><td>126</td><td></td><td></td><td></td><td></td></tr></table> |
101a34820961aab10677d06c00828f09a4d91595cc8575ec30ffd5728755f896.png | complex | <table><tr><td></td><td>CS-cineCMR</td><td>3D-HR-CMR(ref)</td><td>Diff</td><td rowspan="2">Diff [%]</td></tr><tr><td></td><td>Volume [ml]</td><td>Volume [ml]</td><td>Volume [ml]</td></tr><tr><td>Patient 1</td><td>62.5</td><td>59.0</td><td>3.5</td><td>5.7 %</td></tr><tr><td>Patient 2</td><td>61.5</td><td>71.0</td><td>−9.5</td><td>−14.3 %</td></tr><tr><td>Patient 3</td><td>395.0</td><td>397.0</td><td>−2.0</td><td>−0.5 %</td></tr></table> |
365f8c64ed6eb2fcd7acc21e68410c25a340ad17e6c630bba58e61d74b34dcf9.png | complex | <table><tr><td>Variable</td><td>Overall</td><td>0–5 years (<i>n</i> = 145)</td><td>6–10 years (<i>n</i> = 36)</td><td>11–15 years (<i>n</i> = 13)</td></tr><tr><td colspan="5">Weight-for-Height z-score</td></tr><tr><td>< −2 (%)</td><td>45 (31.5)</td><td>45 (31.5)</td><td>N/A</td><td>N/A</td></tr><tr><td>≥ 2 (%)</td><td>98 (68.5)</td><td>98 (68.5)</td><td>N/A</td><td>N/A</td></tr><tr><td> Median WHZ (IQR)</td><td><i>n</i> = 143; −0.89 (−2.46,0.10)</td><td><i>n</i> = 143; −0.89 (−2.46,0.10)</td><td>N/A</td><td>N/A</td></tr><tr><td colspan="5">Weight-for-age z-score</td></tr><tr><td>< −2 (%)</td><td>77 (42.5)</td><td>65 (44.8)</td><td>12 (33.3)</td><td>N/A</td></tr><tr><td>≥ 2 (%)</td><td>104 (57.5)</td><td>80 (55.2)</td><td>24 (66.7)</td><td>N/A</td></tr><tr><td> Median WAZ (IQR)</td><td><i>n</i> = 181; −1.69 (−3.07,-0.69)</td><td><i>n</i> = 145; −1.83 (−3.36,-0.62)</td><td><i>n</i> = 36; −1.54 (−2.17,-0.77)</td><td>N/A</td></tr><tr><td colspan="5">Height-for-age z-score</td></tr><tr><td>< −2 (%)</td><td>88 (45.4)</td><td>70 (48.3)</td><td>14 (38.9)</td><td>4 (30.8)</td></tr><tr><td>≥ 2 (%)</td><td>106 (54.6)</td><td>75 (51.7)</td><td>22 (61.1)</td><td>9 (69.2)</td></tr><tr><td> Median HAZ (IQR)</td><td><i>n</i> = 194; −1.67 (−3.21,-0.51)</td><td><i>n</i> = 145; −1.91 (−3.34,-0.58)</td><td><i>n</i> = 36; −1.62 (−2.47,-0.52)</td><td><i>n</i> = 13; −0.93 (−2.57,-0.47)</td></tr><tr><td colspan="5">BMI for age z-score</td></tr><tr><td>< −2 (%)</td><td>53 (27.3)</td><td>46 (31.7)</td><td>4 (11.1)</td><td>3 (23.1)</td></tr><tr><td>≥ 2 (%)</td><td>141 (72.7)</td><td>99 (68.3)</td><td>32 (88.9)</td><td>10 (76.9)</td></tr><tr><td> Median BMIZ (IQR)</td><td><i>n</i> = 194; −0.72 (−2.21,0.17)</td><td><i>n</i> = 145; −0.74 (−2.41,0.33)</td><td><i>n</i> = 36; −0.61 (−1.53,-0.15)</td><td><i>n</i> = 13; −0.81 (−1.89,0.29)</td></tr></table> |
92b8c850627b5762ab190972fb9f31f5b8783f3fb16802af6c5d91bd9d773b2f.png | complex | <table><tr><td>Study sites</td><td>Sampling units (classes of listed educational institutions below, wards of Village Development Committee (VDC<sup>a</sup> ))</td><td>Sampling unit population</td><td>Sample size (i.e. number of respondents)</td><td>Sample size (%)</td></tr><tr><td rowspan="2">Bachhayauli</td><td>Class 12, Jhuwani Higher Secondary School, Bachhayauli 09, Chitwan</td><td>33 (10 students, 23 teachers)<sup>b</sup></td><td>25 (10 students, 15 teachers)</td><td>76</td></tr><tr><td>Ward number 3, Bachhayauli VDC<sup>a</sup>, Chitwan</td><td>148 household heads<sup>c</sup></td><td>25 (household heads)</td><td>17</td></tr><tr><td rowspan="2">Baghauda</td><td>Bachelor’s degree of Business Studies, 1st year, Madi Multiple Campus, Tribhuvan University, Baghauda 03, Chitwan</td><td>44 (24 students, 20 teachers)<sup>b</sup></td><td>25 (10 students, 15 teachers)</td><td>57</td></tr><tr><td>Ward number 5, Baghauda VDC<sup>a</sup>, Chitwan</td><td>87 household heads<sup>c</sup></td><td>25 (household heads)</td><td>29</td></tr><tr><td rowspan="2">Meghauli</td><td>Class 11 and 12, Janaki Higher Secondary School, Telauli, Meghauli 05, Chitwan</td><td>60 (28 students, 32 teachers)<sup>b</sup></td><td>25 (10 students, 15 teachers)</td><td>42</td></tr><tr><td>Ward number 6, Meghauli VDC<sup>a</sup>, Chitwan</td><td>43 household heads<sup>c</sup></td><td>25 (household heads)</td><td>58</td></tr><tr><td></td><td>Total</td><td>415</td><td>150 (30 students, 45 teachers, 75 villagers)</td><td>36</td></tr></table> |
24ea1dee716ac99039a0c863237a7493156d3b0a4fd8eb076692f60227a1493f.png | complex | <table><tr><td></td><td>Women (<i>n</i> = 203)</td><td>Men (<i>n</i> = 161)</td><td>Overall (<i>N</i> = 364)</td></tr><tr><td colspan="4">Number (%) by age (years)</td></tr><tr><td> 25–44</td><td>90 (46.0)</td><td>76 (49.1)</td><td>16 (47.8)</td></tr><tr><td> 45–64</td><td>113 (54.0)</td><td>85 (50.9)</td><td>198 (52.2)</td></tr><tr><td colspan="4">Number (%) by education</td></tr><tr><td>< Tertiary<sup>a</sup></td><td>127 (77.9)</td><td>99 (76.3)</td><td>226 (77.2)</td></tr><tr><td> Tertiary<sup>a</sup></td><td>76 (22.1)</td><td>62 (23.7)</td><td>138 (22.8)</td></tr><tr><td colspan="4">Anthropometry</td></tr><tr><td> Mean BMI (Kg/m<sup>2</sup>)</td><td>30.3 (29.0, 31.6)</td><td>27.1 (26.0, 28.2)</td><td>28.7 (27.9, 29.6)</td></tr><tr><td> Mean waist circ (cm)</td><td>94.7 (91.9, 97.4)</td><td>92.4 (89.7, 95.1)</td><td>93.6 (91.9, 95.2)</td></tr><tr><td> % overweight (BMI ≥ 25)</td><td>73.9 (64.1, 81.8)</td><td>57.9 (47.2, 67.9)</td><td>66.0 (58.4, 72.9)</td></tr><tr><td> % obese (BMI ≥ 30)</td><td>46.4 (38.4, 54.6)</td><td>25.3 (19.0, 32.8)</td><td>36.0 (30.8, 41.5)</td></tr><tr><td colspan="4">Blood pressure</td></tr><tr><td> Systolic BP (mm Hg)</td><td>124.4 (121.6, 127.2)</td><td>130.5 (127.4, 133.7)</td><td>127.3 (125.3, 129.4)</td></tr><tr><td> Diastolic BP (mm Hg)</td><td>78.1 (76.1, 80.0)</td><td>79.5 (77.1, 81.8)</td><td>78.7 (77.3, 80.2)</td></tr><tr><td> % reported hypertension</td><td>25.8 (17.8, 36.0)</td><td>14.4 (9.6, 21.0)</td><td>20.4 (15.5, 26.3)</td></tr><tr><td> % total hypertension</td><td>35.5 (27.5, 44.4)</td><td>32.7 (23.2, 43.8)</td><td>34.1 (27.7, 41.2)</td></tr><tr><td colspan="4">Glucose</td></tr><tr><td> Fasting (mmol/l)</td><td>5.5 (5.2, 5.8)</td><td>5.4 (5.2, 5.6)</td><td>5.4 (5.3, 5.6)</td></tr><tr><td> % reported diabetes</td><td>9.9 (5.7, 16.5)</td><td>9.0 (5.0, 15.6)</td><td>9.4 (6.6, 13.3)</td></tr><tr><td> % all diabetes</td><td>15.1 (9.8, 22.5)</td><td>10.9 (6.1, 18.7)</td><td>13.1 (9.6, 17.6)</td></tr></table> |
81a3753d6c7acbf135b80f22467901f5a276f5ab53950f45441c6d5e290d5b74.png | complex | <table><tr><td></td><td>Referral hospitals</td><td>District hospitals</td><td>Health centers</td><td>Private clinics</td><td>Kigali</td><td>Other regions</td><td>All facilities/all regions</td></tr><tr><td>Average number of PAC cases per year per facility</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>From incidence study (2009)<sup>a</sup></td><td>484</td><td>200</td><td>37</td><td>75</td><td>100</td><td>44</td><td>57</td></tr><tr><td colspan="2">Percent of PAC cases with specific complications</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Incomplete abortion</td><td>73.2%</td><td>70.8%</td><td>78.1%</td><td>78.9%</td><td>70.3%</td><td>79.1%</td><td>76.0%</td></tr><tr><td>Sepsis</td><td>6.1%</td><td>12.5%</td><td>12.8%</td><td>18.0%</td><td>17.6%</td><td>10.4%</td><td>13.0%</td></tr><tr><td>Shock</td><td>5.2%</td><td>14.9%</td><td>8.1%</td><td>2.5%</td><td>7.2%</td><td>9.7%</td><td>8.8%</td></tr><tr><td>Lacerations</td><td>4.9%</td><td>1.5%</td><td>0.0%</td><td>0.0%</td><td>1.7%</td><td>0.2%</td><td>0.8%</td></tr><tr><td>Perforations</td><td>10.7%</td><td>0.3%</td><td>1.0%</td><td>0.6%</td><td>3.2%</td><td>0.6%</td><td>1.5%</td></tr><tr><td>Total</td><td>100.0%</td><td>100.0%</td><td>100.0%</td><td>100.0%</td><td>100.0%</td><td>100.0%</td><td>100.0%</td></tr><tr><td colspan="2">Number of PAC cases with rare complications<sup>b</sup></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Number per 1000</td><td>9.3</td><td>2.5</td><td>0.1</td><td>0.0</td><td>3.0</td><td>3.0</td><td>1.4</td></tr><tr><td colspan="2">Percent of PAC patients treated as inpatients</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Incomplete abortion</td><td>76.7%</td><td>90.0%</td><td>95.2%</td><td>21.7%</td><td>51.7%</td><td>97.6%</td><td>81.1%</td></tr><tr><td>Sepsis</td><td>100.0%</td><td>97.8%</td><td>98.1%</td><td>55.0%</td><td>80.6%</td><td>97.6%</td><td>91.5%</td></tr><tr><td>Shock</td><td>100.0%</td><td>100.0%</td><td>84.0%</td><td>99.5%</td><td>92.6%</td><td>91.2%</td><td>91.7%</td></tr><tr><td>Lacerations</td><td>73.3%</td><td>100.0%</td><td>100.0%</td><td>83.3%</td><td>87.1%</td><td>100.0%</td><td>95.4%</td></tr><tr><td>Perforations</td><td>100.0%</td><td>100.0%</td><td>100.0%</td><td>83.3%</td><td>92.9%</td><td>100.0%</td><td>97.4%</td></tr><tr><td>All Complications</td><td>81.6%</td><td>92.6%</td><td>94.7%</td><td>30.0%</td><td>63.5%</td><td>97.1%</td><td>83.8%</td></tr><tr><td colspan="2">Percent of all admissions that are PAC cases<sup>c</sup></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Percent of all cases</td><td>1.24%</td><td>2.76%</td><td>0.87%</td><td>0.77%</td><td>0.88%</td><td>1.32%</td><td>1.17%</td></tr><tr><td colspan="3">Estimated number of PAC cases annually (2012) due to induced abortion</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Incomplete abortion</td><td>700</td><td>4000</td><td>7700</td><td>1500</td><td>3000</td><td>11 000</td><td>13 900</td></tr><tr><td>Sepsis</td><td>100</td><td>700</td><td>1200</td><td>300</td><td>900</td><td>1400</td><td>2300</td></tr><tr><td>Shock</td><td>100</td><td>800</td><td>800</td><td>0</td><td>500</td><td>1200</td><td>1700</td></tr><tr><td>Lacerations</td><td>0</td><td>100</td><td>0</td><td>0</td><td>100</td><td>0</td><td>100</td></tr><tr><td>Perforations</td><td>100</td><td>0</td><td>100</td><td>0</td><td>100</td><td>100</td><td>200</td></tr><tr><td>All complications</td><td>1000</td><td>5600</td><td>9800</td><td>1900</td><td>4600</td><td>13 700</td><td>18 300</td></tr></table> |
824f1ee999ce19d9e1b95683291fe1279cabde317ddfc1173db6190b9d4dfc95.png | complex | <table><tr><td>parameter</td><td>apo-Spr1654</td><td>Spr1654/PLP</td><td>Spr1654/PMP</td></tr><tr><td colspan="4">data collection statistics</td></tr><tr><td> resolution (Å) (range)</td><td>30.0–1.9 (2.0–1.9)</td><td>29.7–2.2 (2.3–2.2)</td><td>29.8–2.4 (2.5–2.4)</td></tr><tr><td> space group</td><td><i>P</i>1211</td><td><i>P</i>1211</td><td><i>P</i>1211</td></tr><tr><td> cell dimensions for <i>a</i>, <i>b</i>, <i>c</i> (Å)</td><td>79.3, 100.0, 110.4</td><td>79.0, 99.3, 107.6</td><td>78.9, 99.6, 108.1</td></tr><tr><td> <i>α</i>, <i>β</i>, <i>γ</i> (°)</td><td>90.0, 97.7, 90.0</td><td>90.0, 97.7, 90.0</td><td>90.0, 97.5, 90.0</td></tr><tr><td colspan="4">no. reflections<sup>a</sup></td></tr><tr><td> observed</td><td>348 605 (35 719)</td><td>169 716 (16 002)</td><td>213 232 (19 470)</td></tr><tr><td> unique</td><td>130 980 (13 145)</td><td>79 389 (7743)</td><td>64 471 (6344)</td></tr><tr><td>mean <i>I</i>/<i>σ</i>(<i>I</i>)</td><td>10.9 (2.3)</td><td>6.4 (2.0)</td><td>7.4 (2.0)</td></tr><tr><td>completeness (%)</td><td>97</td><td>95</td><td>99</td></tr><tr><td><i>R</i><sub>merge</sub> (%)</td><td>6.3 (44.4)</td><td>9.8 (50.1)</td><td>15.1 (61.6)</td></tr><tr><td><i>B</i>-factor from Wilson plot (Å<sup>2</sup>)</td><td>23.5</td><td>21.8</td><td>21.3</td></tr><tr><td colspan="4">refinement statistics<sup>b</sup></td></tr><tr><td> <i>R</i><sub>cryst</sub> (%)</td><td>23.6 (33.4)</td><td>23.8 (32.6)</td><td>24.2 (31.4)</td></tr><tr><td> <i>R</i><sub>free</sub> (%)</td><td>26.5 (37.1)</td><td>28.8 (35.9)</td><td>28.5 (34.1)</td></tr><tr><td colspan="4">no. non-hydrogen atoms</td></tr><tr><td> total</td><td>13 277</td><td>13 383</td><td>12 804</td></tr><tr><td> protein</td><td>12 564</td><td>12 506</td><td>12 533</td></tr><tr><td> ligands</td><td>None</td><td>60</td><td>64</td></tr><tr><td> water</td><td>713</td><td>817</td><td>207</td></tr><tr><td colspan="4">average <i>B</i>-factor values</td></tr><tr><td> total</td><td>28.3</td><td>23.6</td><td>25.4</td></tr><tr><td> protein (Å<sup>2</sup>)</td><td>28.2</td><td>23.7</td><td>25.6</td></tr><tr><td> ligands (Å<sup>2</sup>)</td><td>None</td><td>24.9</td><td>25.3</td></tr><tr><td> solvent (A<sup>°2</sup>)</td><td>29.8</td><td>18.9</td><td>15.6</td></tr><tr><td colspan="4">RMSD from ideal geometry</td></tr><tr><td> bond length (Å)</td><td>0.014</td><td>0.012</td><td>0.011</td></tr><tr><td> bond angle (°)</td><td>1.6</td><td>1.53</td><td>1.52</td></tr><tr><td colspan="4">Ramachandran plot</td></tr><tr><td> % of residues in preferred regions</td><td>100</td><td>100</td><td>100</td></tr><tr><td> % of residues in disallowed regions</td><td>0</td><td>0</td><td>0</td></tr></table> |
300cfd0333293461996b3d13432631ba644044a464b4237ef748cd3714ef42db.png | simple | <table><tr><td>First examiner</td><td>Hand</td><td>Thyroid </td><td>Eye lens</td><td>Chest</td><td>No. of Film</td><td>Exposure time (min)</td><td>X-ray tube location</td></tr><tr><td>Present study</td><td>27.0</td><td>5.0</td><td>3.0</td><td>6.0</td><td>2.5</td><td>2.4</td><td>Overcouch</td></tr><tr><td>Buls et al [14]</td><td>0.64</td><td>0.45</td><td>0.55</td><td>nd</td><td>4</td><td>6.0</td><td>Overcouch</td></tr><tr><td>Naidu et al. [9]*</td><td>NR</td><td>0.2</td><td>0.04</td><td>NR</td><td>4.6</td><td>5.9</td><td>Overcouch</td></tr><tr><td>Sulieman et al. [3] </td><td>27.2</td><td>5.4</td><td>3.8</td><td>6.2</td><td>2.6</td><td>2.9</td><td>Overcouch</td></tr><tr><td>Oztas et al. [10]</td><td>20.0</td><td>2.0</td><td>82.0</td><td>NR</td><td>1.7</td><td>5.7</td><td>undercouch</td></tr></table> |
6de3ed5fcd985b739042f36bf7bb4addfb7d8321aa33b6930f48cb12dd507516.png | simple | <table><tr><td>Population <i>n</i></td><td>Age (years)/avg ± SD range</td><td>Mass (kg)/Avg ± SD range</td><td>Stature (m)/Avg ± SDr ange</td><td>BMI/Avg ± SD range</td></tr><tr><td>10(<i>f</i> = 3, <i>m</i> = 7)</td><td>35.8 ± 8.822–53</td><td>53.6 ± 10.444–73</td><td>1.60 ± 0.091.45–1.75</td><td>20.7 ± 3.116.4–25.9</td></tr></table> |
8997e7e41e1ce4c027f23cc9fd14c040aded4969e784c8f9e649cb638d164873.png | complex | <table><tr><td>Parameter</td><td>Pre-control</td><td>Post-control</td><td>Pre-transport</td><td>Post-transport</td></tr><tr><td colspan="5">Vital signs</td></tr><tr><td> Temperature (°C)</td><td>26.86 ± 0.06</td><td>26.35 ± 0.07</td><td>27.77 ± 0.06</td><td>25.63 ± 0.33</td></tr><tr><td> Heart rate (beats/min)</td><td>52.80 ± 1.25</td><td>51.60 ± 1.05</td><td>55.00 ± 1.74</td><td>48.00 ± 1.35</td></tr><tr><td> Respirations (breaths/min)</td><td>4.85 ± 0.59</td><td>3.93 ± 0.34</td><td>3.03 ± 0.38</td><td>4.40 ± 0.41</td></tr><tr><td colspan="5">Timing parameters (min; measured from time of first disturbance)</td></tr><tr><td> Bleeding time</td><td>1.94 ± 0.08</td><td>3.05 ± 0.35</td><td>2.33 ± 0.36</td><td>1.36 ± 0.18</td></tr><tr><td> Handling time</td><td>11.98 ± 0.72</td><td>9.63 ± 0.53</td><td>Not recorded</td><td>Not recorded</td></tr><tr><td> CG4 lag time</td><td>2.54 ± 0.50</td><td>1.52 ± 0.14</td><td>2.19 ± 0.26</td><td>2.52 ± 0.39</td></tr><tr><td> CG8 lag time</td><td>7.01 ± 0.81</td><td>5.24 ± 0.14</td><td>5.69 ± 0.22</td><td>6.07 ± 0.39</td></tr><tr><td colspan="5">Haematological data</td></tr><tr><td> Heterophils (%)</td><td>64.87 ± 1.97</td><td>68.93 ± 2.49</td><td>63.87 ± 2.69</td><td>71.80 ± 3.69</td></tr><tr><td> Lymphocytes (%)</td><td>32.47 ± 1.73</td><td>29.00 ± 2.41</td><td>34.60 ± 2.68</td><td>26.27 ± 3.52</td></tr><tr><td> Monocytes (%)</td><td>1.93 ± 0.32</td><td>1.33 ± 0.21</td><td>1.27 ± 0.25</td><td>1.53 ± 0.27</td></tr><tr><td> Eosinophils (%)</td><td>0.73 ± 0.18</td><td>0.67 ± 0.23</td><td>0.27 ± 0.12</td><td>0.40 ± 0.21</td></tr><tr><td> Heterophils (cells/μl)</td><td>2877 ± 202.6</td><td>3789 ± 570.4</td><td>3784 ± 458.0</td><td>5045 ± 1109.9</td></tr><tr><td> Lymphocytes (cells/μl)</td><td>1412 ± 87.9</td><td>1466 ± 152.2</td><td>1873 ± 141.8</td><td>1386 ± 125.9</td></tr><tr><td> Monocytes (cells/μl)</td><td>85 ± 15.8</td><td>63 ± 10.6</td><td>75 ± 18.0</td><td>92 ± 17.2</td></tr><tr><td> Eosinophils (cells/μl)</td><td>33 ± 8.4</td><td>26 ± 8.2</td><td>14 ± 6.5</td><td>17 ± 9.8</td></tr></table> |
76b71378bd995d486836fa5eb471a34c00f519bad2613277b4913a3a96f75de9.png | simple | <table><tr><td>Funcats</td><td>Number of genes assigned an InterAct class</td><td>Number of InterAct class 0000 genes</td><td><i>p</i>-value</td></tr><tr><td>All funcats</td><td>3,447</td><td>1,089</td><td>-</td></tr><tr><td>Metabolism</td><td>496</td><td>120</td><td>6.0 × 10<sup>-4</sup></td></tr><tr><td>Protein synthesis</td><td>218</td><td>55</td><td>2.6 × 10<sup>-2</sup></td></tr><tr><td>Energy</td><td>125</td><td>21</td><td>1.34 × 10<sup>-4</sup></td></tr></table> |
0cfcdcb5c398dc0448dcbffad50b0324964828dc0f244c6de50e6fa7368eac5e.png | simple | <table><tr><td>Factor</td><td>Coefficients</td><td>Standard error</td><td><i>t</i>-value</td><td><i>P</i> value</td></tr><tr><td>Intercept</td><td>−249.9</td><td>80.11</td><td>−3.120</td><td>0.02059</td></tr><tr><td>Yeast extract (L<sup>a</sup>)</td><td>41.53</td><td>12.19</td><td>3.405</td><td>0.01440</td></tr><tr><td>Yeast extract (Q<sup>b</sup>)</td><td>−3.236</td><td>0.7220</td><td>−4.482</td><td>0.004182</td></tr><tr><td>Cu2<sup>+</sup> (L)</td><td>2.071</td><td>0.4551</td><td>4.550</td><td>0.003890</td></tr><tr><td>Cu2<sup>+</sup> (Q)</td><td>−0.0060</td><td>0.00116</td><td>−5.483</td><td>0.001539</td></tr><tr><td>Ferulic acid (L)</td><td>106.7</td><td>34.13</td><td>3.127</td><td>0.02040</td></tr><tr><td>Ferulic acid (Q)</td><td>−28.68</td><td>6.498</td><td>−4.414</td><td>0.004501</td></tr></table> |
4d936d699f2aba0c7da500af493b4ebcabeac968e77b8ee09ea4cb3d1db2d607.png | simple | <table><tr><td>Characteristics</td><td>No. of errors</td><td>%</td></tr><tr><td>Gender</td><td></td><td></td></tr><tr><td>Male</td><td>860</td><td>64.5</td></tr><tr><td>Female</td><td>473</td><td>35.5</td></tr><tr><td>Total</td><td>1333</td><td>100</td></tr><tr><td>Age group</td><td></td><td></td></tr><tr><td>Less than 1 year</td><td>593</td><td>44.5</td></tr><tr><td>1-3 years</td><td>249</td><td>18.7</td></tr><tr><td>4-6 years</td><td>167</td><td>12.5</td></tr><tr><td>7-9 years</td><td>43</td><td>3.2</td></tr><tr><td>10-12 years</td><td>281</td><td>21.1</td></tr><tr><td>Total</td><td>1333</td><td>100</td></tr><tr><td>Administration route</td><td></td><td></td></tr><tr><td>Intravenous</td><td>669</td><td>50.2</td></tr><tr><td>Oral</td><td>342</td><td>25.7</td></tr><tr><td>Inhalation</td><td>222</td><td>16.6</td></tr><tr><td>Topical</td><td>60</td><td>4.5</td></tr><tr><td>Subcutaneous</td><td>24</td><td>1.8</td></tr><tr><td>Intramuscular</td><td>16</td><td>1.2</td></tr><tr><td>Total</td><td>1333</td><td>100</td></tr><tr><td>Location</td><td></td><td></td></tr><tr><td>PICU</td><td>452</td><td>33.9</td></tr><tr><td>Pediatric wards</td><td>881</td><td>66.1</td></tr><tr><td>Total</td><td>1333</td><td>100</td></tr></table> |
36022f86fb284ef6368d595e94780b9d55b3902550ddbc91b65fa27d3d336a21.png | simple | <table><tr><td>Drugs:</td><td>n</td><td>%</td></tr><tr><td>Adefovir</td><td>1</td><td>1.9</td></tr><tr><td>Boceprevir</td><td>1</td><td>1.9</td></tr><tr><td>Entecavir</td><td>9</td><td>17.3</td></tr><tr><td>Interferon</td><td>4</td><td>7.7</td></tr><tr><td>Pegylated interferon</td><td>9</td><td>17.3</td></tr><tr><td>Lamivudine</td><td>4</td><td>7.7</td></tr><tr><td>Ribavirin</td><td>13</td><td>25.0</td></tr><tr><td>Telapravir</td><td>1</td><td>1.9</td></tr><tr><td>Tenofovir</td><td>10</td><td>19.2</td></tr><tr><td>Total</td><td>52</td><td>100</td></tr></table> |
2243e48084e8111ab5a1b03eabf9fe7ba4c4950aa3d3f6df4a0655d8d74fa9b9.png | simple | <table><tr><td>Liver</td><td>Total Modules</td><td>Counter-Intuitive Modules</td><td>% Total</td></tr><tr><td>1</td><td>88</td><td>20</td><td>22.73</td></tr><tr><td>2</td><td>143</td><td>52</td><td>36.36</td></tr><tr><td>3</td><td>147</td><td>67</td><td>45.58</td></tr><tr><td>4</td><td>117</td><td>41</td><td>35.04</td></tr><tr><td>5</td><td>191</td><td>57</td><td>29.84</td></tr><tr><td>6</td><td>102</td><td>30</td><td>29.41</td></tr><tr><td>7</td><td>170</td><td>91</td><td>53.53</td></tr><tr><td>8</td><td>143</td><td>90</td><td>62.94</td></tr><tr><td>9</td><td>141</td><td>68</td><td>48.23</td></tr><tr><td></td><td></td><td>Average</td><td>40.41</td></tr><tr><td></td><td></td><td>Stdev</td><td>13.03</td></tr></table> |
f5c5daeba7ba8e76ccf1efbe1669c23e01ff93a1fc46cbaced974c8ae0d48975.png | complex | <table><tr><td>Variables</td><td>Entire sample (100%)</td><td>Multiple sclerosis<sup>§ </sup>(46%)</td><td>Depressive disorders (32%)</td><td>Psychotic and other disorders (22%)*</td><td>Statistics (Pearson’s χ<sup>2 </sup>or ANOVA)</td></tr><tr><td>Gender, %</td><td> </td><td> </td><td> </td><td> </td><td rowspan="3">p < .0001</td></tr><tr><td>Women</td><td>68</td><td>78</td><td>66</td><td>56</td></tr><tr><td>Men</td><td>32</td><td>22</td><td>34</td><td>44</td></tr><tr><td>Age, years (Mean, standard deviation)</td><td>41 ± 13</td><td>43 ± 11</td><td>41 ± 14</td><td>38 ± 13</td><td>F = 5.2; p = .006</td></tr><tr><td>Family status, %</td><td> </td><td> </td><td> </td><td> </td><td rowspan="5">p < .0001</td></tr><tr><td>Married</td><td>58</td><td>56</td><td>50</td><td>67</td></tr><tr><td>With partner, not married</td><td>22</td><td>17</td><td>34</td><td>21</td></tr><tr><td>Divorced</td><td>11</td><td>19</td><td>0</td><td>0</td></tr><tr><td>Single</td><td>10</td><td>8</td><td>16</td><td>12</td></tr><tr><td>Educational level, %</td><td> </td><td> </td><td> </td><td> </td><td rowspan="5">p = .007</td></tr><tr><td>Through Grade 9</td><td>24</td><td>22</td><td>26</td><td>26</td></tr><tr><td>Through Grade 10</td><td>33</td><td>33</td><td>37</td><td>31</td></tr><tr><td>High school diploma</td><td>38</td><td>36</td><td>37</td><td>41</td></tr><tr><td>Other</td><td>5</td><td>9</td><td>0</td><td>1</td></tr><tr><td>Spiritual/religious self-categorization, %</td><td> </td><td> </td><td> </td><td> </td><td>n.s.</td></tr><tr><td>R + S + (religious and spiritual)</td><td>15</td><td>12</td><td>16</td><td>18</td><td> </td></tr><tr><td>R + S- (religious, not spiritual)</td><td>21</td><td>19</td><td>24</td><td>21</td><td> </td></tr><tr><td>R-S + (not religious but spiritual)</td><td>15</td><td>16</td><td>14</td><td>14</td><td> </td></tr><tr><td>R-S- (neither religious nor spiritual)</td><td>50</td><td>54</td><td>47</td><td>46</td><td> </td></tr><tr><td>Engagement in spiritual activities (0–100)**</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Existential practices</td><td>54 ± 25</td><td>43 ± 11</td><td>60 ± 23</td><td>62 ± 22</td><td>F = 23.2; p < .0001</td></tr><tr><td>Humanistic practices</td><td>65 ± 19</td><td>65 ± 19</td><td>66 ± 16</td><td>65 ± 20</td><td>F = 0.1; n.s.</td></tr><tr><td>Religious practices</td><td>26 ± 24</td><td>22 ± 24</td><td>31 ± 25</td><td>27 ± 23</td><td>F = 5.1; p = .007</td></tr><tr><td>Spiritual (MB) practices</td><td>19 ± 22</td><td>21 ± 24</td><td>15 ± 17</td><td>19 ± 21</td><td>F = 2.6; n.s.</td></tr><tr><td>Gratitude/Awe</td><td>42 ± 24</td><td>44 ± 22</td><td>38 ± 25</td><td>43 ± 25</td><td>F = 2.2; n.s.</td></tr><tr><td>Life satisfaction Sum Score (BMLSS-10) (0-100)</td><td>54.6 ± 22.3</td><td>69.1 ± 17.1</td><td>42.5 ± 15.6</td><td>42.5 ± 20.7</td><td>F = 123.1; p < .0001</td></tr><tr><td>Life Satisfaction Subdimensions (0–6)</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Family life</td><td>3.62 ± 1.83</td><td>4.60 ± 1.45</td><td>2.83 ± 1.55</td><td>2.84 ± 1.84</td><td>F = 66.0; p < .0001</td></tr><tr><td>Friendships</td><td>3.70 ± 1.73</td><td>4.49 ± 1.43</td><td>3.03 ± 1.64</td><td>3.06 ± 1.73</td><td>F = 46.7; p < .0001</td></tr><tr><td>Work situation</td><td>2.82 ± 1.96</td><td>3.69 ± 1.72</td><td>2.30 ± 1.75</td><td>2.18 ± 1.98</td><td>F = 28.2; p < .0001</td></tr><tr><td>Myself</td><td>2.81 ± 1.80</td><td>4.00 ± 1.40</td><td>1.82 ± 1.44</td><td>1.88 ± 1.53</td><td>F = 121.5; p < .0001</td></tr><tr><td>Where I live</td><td>4.01 ± 1.64</td><td>4.55 ± 1.42</td><td>3.50 ± 1.61</td><td>3.62 ± 1.71</td><td>F = 22.1; p < .0001</td></tr><tr><td>Life in general</td><td>3.32 ± 1.69</td><td>4.39 ± 1.20</td><td>2.21 ± 1.37</td><td>2.32 ± 1.66</td><td>F = 142.6; p < .0001</td></tr><tr><td>Financial situation</td><td>3.24 ± 1.83</td><td>3.93 ± 1.55</td><td>2.82 ± 1.76</td><td>2.59 ± 1.92</td><td>F = 29.6 ; p < .0001</td></tr><tr><td>Future prospects</td><td>2.92 ± 1.60</td><td>3.64 ± 1.29</td><td>2.22 ± 1.49</td><td>2.43 ± 1.66</td><td>F = 43.5; p < .0001</td></tr><tr><td>Health situation</td><td>2.45 ± 1.62</td><td>3.20 ± 1.49</td><td>1.89 ± 1.39</td><td>1.77 ± 1.47</td><td>F = 50.3; p < .0001</td></tr><tr><td>Abilities to deal withDaily life activities</td><td>3.07 ± 1.62</td><td>4.03 ± 1.33</td><td>2.29 ± 1.26</td><td>2.24 ± 1.47</td><td>F = 94.8; p < .0001</td></tr></table> |
c9755cfd3cec28b45c8d1df943f474f213b674c31e807ffabd3b30544a627c7f.png | complex | <table><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td colspan="2">IOP</td><td colspan="2">Visual acuity</td><td> </td></tr><tr><td>Patient code</td><td>Gender</td><td>Age Dx</td><td>Diagnosis</td><td>Gly326Ser</td><td>RE</td><td>LE</td><td>RE</td><td>LE</td><td>Surgical procedure</td></tr><tr><td>G62</td><td>Male</td><td>59/65</td><td>OHT/POAG</td><td>yes</td><td>30</td><td>30</td><td>20/40</td><td>20/40</td><td>Trabeculectomy LE</td></tr><tr><td>01A</td><td>Female</td><td>65</td><td>Blind by POAG</td><td>yes</td><td>ptosis</td><td>20</td><td>HM</td><td>HM</td><td>-</td></tr><tr><td>03A</td><td>Female</td><td>63</td><td>OHT with tendency to angle closure</td><td>yes</td><td>26</td><td>20</td><td>20/30</td><td>20/30</td><td>Iridotomy</td></tr><tr><td>24A</td><td>Male</td><td>72</td><td>Advanced POAG</td><td>yes</td><td>26</td><td>26</td><td>HM</td><td>20/40</td><td>-</td></tr><tr><td>05A</td><td>Male</td><td>75</td><td>Pseudo exfoliation Glaucoma</td><td>no</td><td>25</td><td>17</td><td>-</td><td>20/40</td><td>Trabeculectomy, cataract surgery</td></tr><tr><td>08A</td><td>Male</td><td>76</td><td>POAG</td><td>no</td><td>22</td><td>23</td><td>20/50</td><td>20/40</td><td>Trabaculoplasty</td></tr></table> |
76a44d87cf1f5b1b889f45595aee0fbe3ed034b53135109163ca02212251f0a6.png | simple | <table><tr><td></td><td></td><td>Single-Task</td><td>Dual-Task</td></tr><tr><td>200ms before and after HS<sup>a</sup></td><td>Frontal plane</td><td>0.9529±0.029</td><td>0.9270±0.044 *</td></tr><tr><td></td><td>Sagittal plane</td><td>0.9505±0.042</td><td>0.9373±0.046</td></tr><tr><td></td><td>Transverse plane</td><td>0.8530±0.150</td><td>0.8539±0.140</td></tr><tr><td>HS-TO<sup>b</sup></td><td>Frontal plane</td><td>0.9396±0.042</td><td>0.91150.092</td></tr><tr><td></td><td>Sagittal plane</td><td>0.9842±0.019</td><td>0.9825±0.022</td></tr><tr><td></td><td>Transverse plane</td><td>0.9228±0.092</td><td>0.9274±0.072</td></tr></table> |
de2319cafd9c7aafcf95ffa2e7814f72b84582e7b649e42d0c1be7f85486cbf3.png | simple | <table><tr><td>Test type</td><td>Dataset</td><td>Threshold</td><td><i>P</i>-value</td></tr><tr><td>Unpaired two sample</td><td>Aging—old vs. young</td><td>0.0537</td><td>0.0363</td></tr><tr><td></td><td></td><td>0.1074</td><td>0.0023</td></tr><tr><td></td><td></td><td>0.1609</td><td>8.45 × 10<sup>−4</sup></td></tr><tr><td></td><td></td><td>0.2144</td><td>4.15 × 10<sup>−4</sup></td></tr><tr><td></td><td></td><td>0.3208</td><td>1.40 × 10<sup>−4</sup></td></tr><tr><td></td><td></td><td>0.4264</td><td>3.00 × 10<sup>−5</sup></td></tr><tr><td></td><td></td><td>0.6349</td><td>0</td></tr><tr><td></td><td></td><td>0.8476</td><td>0</td></tr><tr><td></td><td></td><td>1</td><td>1</td></tr><tr><td></td><td>Connectome Leipzig</td><td>0.0535</td><td>0.4387</td></tr><tr><td></td><td></td><td>0.1069</td><td>0.3073</td></tr><tr><td></td><td></td><td>0.1604</td><td>0.2436</td></tr><tr><td></td><td></td><td>0.2138</td><td>0.1864</td></tr><tr><td></td><td></td><td>0.3206</td><td>0.1765</td></tr><tr><td></td><td></td><td>0.4277</td><td>0.1066</td></tr><tr><td></td><td></td><td>0.6395</td><td>0.4672</td></tr><tr><td></td><td></td><td>0.8505</td><td>0.0828</td></tr><tr><td></td><td></td><td>1</td><td>1</td></tr><tr><td>Paired two sample</td><td>Aging—rest vs. MS</td><td>0.0533</td><td>2.00 × 10<sup>−5</sup></td></tr><tr><td></td><td></td><td>0.1067</td><td>1.50 × 10<sup>−5</sup></td></tr><tr><td></td><td></td><td>0.1599</td><td>3.00 × 10<sup>−5</sup></td></tr><tr><td></td><td></td><td>0.2131</td><td>3.50 × 10<sup>−5</sup></td></tr><tr><td></td><td></td><td>0.3193</td><td>2.50 × 10<sup>−5</sup></td></tr><tr><td></td><td></td><td>0.4243</td><td>5.50 × 10<sup>−5</sup></td></tr><tr><td></td><td></td><td>0.6321</td><td>3.10 × 10<sup>−4</sup></td></tr><tr><td></td><td></td><td>0.8411</td><td>2.50 × 10<sup>−4</sup></td></tr><tr><td></td><td></td><td>1</td><td>1</td></tr><tr><td></td><td>Aging—rest vs. visual</td><td>0.0535</td><td>9.80 × 10<sup>−5</sup></td></tr><tr><td></td><td></td><td>0.107</td><td>2.00 × 10<sup>−5</sup></td></tr><tr><td></td><td></td><td>0.1604</td><td>5.00 × 10<sup>−6</sup></td></tr><tr><td></td><td></td><td>0.2138</td><td>5.00 × 10<sup>−6</sup></td></tr><tr><td></td><td></td><td>0.3202</td><td>0</td></tr><tr><td></td><td></td><td>0.4251</td><td>5.00 × 10<sup>−6</sup></td></tr><tr><td></td><td></td><td>0.633</td><td>2.50 × 10<sup>−6</sup></td></tr><tr><td></td><td></td><td>0.8415</td><td>2.00 × 10<sup>−6</sup></td></tr><tr><td></td><td></td><td>1</td><td>1</td></tr></table> |
62aba6bc56f411e715af9ba2c96307ec907d68e5d5507936a7bfc83fd79cc069.png | simple | <table><tr><td></td><td>cis-acting</td><td>trans-acting</td></tr><tr><td>KS p-value 10<sup>-6 </sup>- 10<sup>-15</sup></td><td>4,484</td><td>646</td></tr><tr><td>KS p-value 10<sup>-15 </sup>- 10<sup>-30</sup></td><td>5,311</td><td>500</td></tr></table> |
c3a5ae77f3ba11350a0a0dba63c857ff3d0d6329eb18df43f3d4b735d4c446e7.png | complex | <table><tr><td></td><td></td><td></td><td></td><td colspan="2">Correlation with BMI z-score<sup>1)</sup></td></tr><tr><td></td><td>Without MS</td><td>With MS</td><td><i>P</i><sup>2)</sup></td><td>WHO</td><td>CDC</td></tr><tr><td>Number of participants (%)</td><td>185 (75.2)</td><td>61 (24.8)</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Females, n (%)</td><td>97 (52.4)</td><td>25 (41.0)</td><td>0.141</td><td>-</td><td>-</td></tr><tr><td>Pubertal Stage (pre-pub (%))<sup>3)</sup></td><td>30 (16.2)</td><td>8 (13.1)</td><td>0.684</td><td>-</td><td>-</td></tr><tr><td>Age (years)</td><td>12.7 ± 1.8</td><td>13.4 ± 2.1</td><td>0.017</td><td>0.057</td><td>0.122</td></tr><tr><td>Height (cm)</td><td>158.5 ± 8.9</td><td>162.8 ± 9.9</td><td>0.002</td><td>0.189**</td><td>0.277**</td></tr><tr><td>Weight (kg)</td><td>78.0 (68.0-89.0)</td><td>90.2 (76.0-113.5)</td><td><0.001</td><td>0.673**</td><td>0.726**</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>30.55 (28.15-34.08)</td><td>34.52 (30.20-39.14)</td><td><0.001</td><td>0.848**</td><td>0.865**</td></tr><tr><td>BMI z-score (CDC)</td><td>2.20 ± 0.29</td><td>2.43 ± 0.31</td><td><0.001</td><td>0.933**</td><td>-</td></tr><tr><td>BMI z-score (WHO)</td><td>3.00 ± 0.62</td><td>3.51 ± 0.86</td><td><0.001</td><td>-</td><td>0.933**</td></tr><tr><td>Waist circumference (cm)</td><td>99.0 (91.8-106.5)</td><td>105.0 (96.5-118.0)</td><td><0.001</td><td>0.736**</td><td>0.778**</td></tr><tr><td>Waist / Height</td><td>0.630 ± 0.066</td><td>0.668 ± 0.081</td><td>0.002</td><td>0.794**</td><td>0.783**</td></tr><tr><td>Blood pressure</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Systolic (mmHg)<sup>4)</sup></td><td>116 ± 12</td><td>135 ± 13</td><td><0.001</td><td>0.323**</td><td>0.360**</td></tr><tr><td>Diastolic (mmHg)<sup>4)</sup></td><td>63 ± 8</td><td>70 ± 12</td><td>0.001</td><td>0.267**</td><td>0.218**</td></tr><tr><td>Lipid profile</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TG (mg/dl)</td><td>71.0 (53.1-100.6)</td><td>126.7 (81.5-181.5)</td><td><0.001</td><td>0.186**</td><td>0.185**</td></tr><tr><td>HDLc (mg/dl)</td><td>43.0 (38.3-49.0)</td><td>35.0 (32.0-38.4)</td><td><0.001</td><td>−0.215**</td><td>−0.223**</td></tr><tr><td>TC (mg/dl)</td><td>150.8 (134.5-174.0)</td><td>164.0 (142.0-189.2)</td><td>0.038</td><td>0.105</td><td>0.084</td></tr><tr><td>LDLc (mg/dl)</td><td>92.0 (76.0-109.8)</td><td>101.0 (83.5-119.4)</td><td>0.055</td><td>0.145*</td><td>0.126*</td></tr><tr><td>Glucose metabolism</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Glucose (mg/dl)</td><td>83.0 (77.0-89.6)</td><td>88.0 (80.0-93.8)</td><td>0.005</td><td>0.043</td><td>0.046</td></tr><tr><td>Insulin (μU/ml)</td><td>15.9 (12.2-22.1)</td><td>23.3 (14.6-33.3)</td><td><0.001</td><td>0.421**</td><td>0.440**</td></tr><tr><td>HOMA-IR</td><td>3.18 (2.43-4.52)</td><td>4.94 (3.34-7.06)</td><td><0.001</td><td>0.410**</td><td>0.429**</td></tr><tr><td>Inflammatory mediator</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>CRP (mg/l)<sup>5)</sup></td><td>1.61 (0.84-4.05)</td><td>2.30 (1.00-4.59)</td><td>0.072</td><td>0.326**</td><td>0.302**</td></tr></table> |
c8002461e107f08033f835e58fb34dbc5dec3dd9423a17aa64f2c480a1485b8c.png | complex | <table><tr><td rowspan="2">Parameter</td><td colspan="3">Correct</td></tr><tr><td>Study 1, No. (%)</td><td>Study, No. (%)</td><td>p</td></tr><tr><td>Registration of insertion date</td><td>337 (42.3)</td><td>339 (50.1)</td><td>0.003</td></tr><tr><td>Registration of daily surveillance</td><td>779 (97.7)</td><td>660 (98.2)</td><td>0.52</td></tr><tr><td>Registration of dressing change date</td><td>322 (41.2)</td><td>328 (49.1)</td><td>0.003</td></tr><tr><td>Registration of set replacement date</td><td>74 (45.4)</td><td>65 (43.3)</td><td>0.71</td></tr><tr><td>Use of connectors (split-septum) in all hubs</td><td>660 (83.7)</td><td>615 (92.2)</td><td><0.001</td></tr></table> |
0c2836b0e7327e9c84736e217cc592725d40536f9bb35234b36286451a9bcd61.png | simple | <table><tr><td>Characteristics</td><td>LGSOCNo. of patients (%)</td><td>HGSOCNo. of patients (%)</td><td><i>p</i> values</td></tr><tr><td>All cases</td><td>25</td><td>55</td><td></td></tr><tr><td>Mean Age, years (± SEM)</td><td>49.8 ± 3.0</td><td>56.8 ± 1.5</td><td>0.03</td></tr><tr><td>Type of primary surgery</td><td></td><td></td><td></td></tr><tr><td> Cytoreduction</td><td>25</td><td>55</td><td>–</td></tr><tr><td>Residual tumor after primary surgery (cm)</td><td></td><td></td><td></td></tr><tr><td> 0</td><td>22</td><td>36</td><td>0.06#</td></tr><tr><td> < 1</td><td>3</td><td>14</td><td></td></tr><tr><td> > 1</td><td>0</td><td>5</td><td></td></tr><tr><td>FIGO Stage</td><td></td><td></td><td></td></tr><tr><td> I/II</td><td>10 (40)</td><td>8 (15)</td><td>0.01</td></tr><tr><td> III/IV</td><td>15 (60)</td><td>47 (85)</td><td></td></tr><tr><td>Primary chemotherapy</td><td></td><td></td><td></td></tr><tr><td> None</td><td>3 (12)</td><td>1 (1.8)</td><td>0.08§</td></tr><tr><td> Platinum/paclitaxel</td><td>17 (68.0)</td><td>48 (87.3)</td><td></td></tr><tr><td> Platinum-based</td><td>4 (16.0)</td><td>5 (9.1)</td><td></td></tr><tr><td> Other</td><td>1 (4)</td><td>1 (1.8)</td><td></td></tr></table> |
5aff254d9ecb07b4e5332975c4cca3878ee7f9f25c1821f289fb9889fb1c17ac.png | simple | <table><tr><td></td><td>p-Nephrin</td><td>Nck (with p-Nephrin)</td><td>Nck (with p-TIR)</td><td>N-WASP</td></tr><tr><td>Null hypothesis</td><td>Single Exp.</td><td>Single Exp.</td><td>Single Exp.</td><td>Single Exp.</td></tr><tr><td>Alternate hypothesis</td><td>Double Exp.</td><td>Double Exp.</td><td>Double Exp.</td><td>Double Exp.</td></tr><tr><td>p value</td><td><0.0001</td><td><0.0001</td><td><0.0001</td><td><0.0001</td></tr><tr><td>Conclusion (alpha = 0.05)</td><td>Reject null hypo.</td><td>Reject null hypo.</td><td>Reject null hypo.</td><td>Reject null hypo.</td></tr><tr><td>Preferred model</td><td>Double Exp.</td><td>Double Exp.</td><td>Double Exp.</td><td>Double Exp.</td></tr><tr><td>F (DFn, DFd)</td><td>64.16 (2282)</td><td>47.33 (2635)</td><td>46.72 (2379)</td><td>48.64 (2379)</td></tr></table> |
a8777745e47e5deec535bc654e88708b0c372e324bb84e2e8148aeba68c551d3.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">2014</td><td colspan="2">2014+>2 HR</td><td colspan="2">2015</td><td colspan="2">2015+>2 HR</td></tr><tr><td>HR</td><td>VHR</td><td>HR</td><td>VHR</td><td>HR</td><td>VHR</td><td>HR</td><td>VHR</td></tr><tr><td>N</td><td>166</td><td>37</td><td>131</td><td>72</td><td>100</td><td>103</td><td>65</td><td>138</td></tr><tr><td>%</td><td>82%</td><td>18%</td><td>64.5%</td><td>35.5%</td><td>49%</td><td>51%</td><td>32%</td><td>68%</td></tr><tr><td>4y bDFS % (95% CI)</td><td>89 (82–93)</td><td>83 (66–92)</td><td>89 (82–93)</td><td>84 (73–91)</td><td>90 (82–95)</td><td>85 (75–91)</td><td>92 (80–97)</td><td>85 (78–90)</td></tr><tr><td>4y MFS % (95% CI)</td><td>90 (84–94)</td><td>83 (63–93)</td><td>92 (84–96)</td><td>85 (72–92)</td><td>93 (85–97)</td><td>85 (75–92)</td><td>93 (78–98)</td><td>87 (80–92)</td></tr><tr><td>4y CSS % (95% CI)</td><td>100</td><td>92 (70–98)</td><td>100</td><td>95 (82–99)</td><td>100</td><td>97 (88–99)</td><td>100</td><td>98 (91–99)</td></tr><tr><td>4y OS % (95% CI)</td><td>96 (92–99)</td><td>85 (64–94)</td><td>98 (93–100)</td><td>87 (74–94)</td><td>96 (89–99)</td><td>92 (83–96)</td><td>100</td><td>91 (84–96)</td></tr></table> |
f02a214f578e5fabe60e1e8cc824e16be02ae72c117e046a41f164119117b95b.png | complex | <table><tr><td>Day</td><td>Parameter</td><td>Reference<sup>§</sup></td><td>HFE mean</td><td>LFE mean</td><td><i>P</i>-value</td></tr><tr><td rowspan="9">0</td><td>Cholesterol (mg/dL) <sup>♦</sup></td><td>80–120</td><td>112.33 ± 20.6</td><td>122.22 ± 25.9</td><td>0.1904</td></tr><tr><td>Triglycerides (mg/dL)<sup>○</sup></td><td>0–14</td><td>14.51 ± 5.6</td><td>12.62 ± 5.2</td><td>0.1675</td></tr><tr><td>Globulin (g/dL)<sup>○</sup></td><td>3.00–3.48</td><td>3.71 ± 0.5</td><td>3.51 ± 0.4</td><td>0.1045</td></tr><tr><td>AST (U/L)<sup>○</sup></td><td>78–132</td><td>82.25 ± 16.9</td><td>78.50 ± 42.8</td><td>0.5606</td></tr><tr><td>ALT (U/L)<sup>○</sup></td><td>11–40</td><td>20.25 ± 6.8</td><td>21.20 ± 5.0</td><td>0.6058</td></tr><tr><td>GGT (U/L)<sup>♦</sup></td><td>6.1–17.4</td><td>17.35 ± 5.1</td><td>18.15 ± 4.7</td><td>0.6084</td></tr><tr><td>ALP (U/L)<sup>○</sup></td><td>0–488</td><td>308.25 ± 89.4</td><td>322.35 ± 115.7</td><td>0.4818</td></tr><tr><td>Albumin (g/dL)<sup>♦</sup></td><td>3.03–3.55</td><td>2.78 ± 0.2</td><td>2.82 ± 0.2</td><td>0.4793</td></tr><tr><td>Protein (g/dL)<sup>○</sup></td><td>6.74–7.46</td><td>6.49 ± 0.5</td><td>6.33 ± 0.4</td><td>0.1894</td></tr><tr><td rowspan="9">70</td><td>Cholesterol (mg/dL)<sup>♦</sup></td><td><i>80–120</i></td><td><i>123.15 ± 26.5</i></td><td><i>147.45 ± 17.7</i></td><td><i>0.0017*</i></td></tr><tr><td>Triglycerides (mg/dL)<sup>○</sup></td><td>0–14</td><td>11.61 ± 4.6</td><td>12.63 ± 3.4</td><td>0.6455</td></tr><tr><td>Globulins (g/dL)<sup>○</sup></td><td>3.00–3.48</td><td>3.41 ± 0.4</td><td>3.41 ± 0.3</td><td>0.5074</td></tr><tr><td>AST (U/L)<sup>○</sup></td><td>78–132</td><td>86.50 ± 12.6</td><td>82.30 ± 13.7</td><td>0.2179</td></tr><tr><td>ALT (U/L)<sup>○</sup></td><td>11–40</td><td>29.05 ± 5.2</td><td>28.45 ± 3.5</td><td>0.3149</td></tr><tr><td>GGT (U/L)<sup>○</sup></td><td><i>6.1–17.4</i></td><td><i>15.25 ± 5.2</i></td><td><i>18.95 ± 3.3</i></td><td><i>0.0150*</i></td></tr><tr><td>ALP (U/L)<sup>♦</sup></td><td>0–488</td><td>443.30 ± 96.8</td><td>382.30 ± 143.2</td><td>0.6560</td></tr><tr><td>Albumin (g/dL)<sup>○</sup></td><td>3.03–3.55</td><td>3.03 ± 0.2</td><td>3.07 ± 0.1</td><td>0.2284</td></tr><tr><td>Protein (g/dL)<sup>○</sup></td><td>6.74–7.46</td><td>6.44 ± 0.4</td><td>6.48 ± 0.3</td><td>0.9892</td></tr></table> |
82a9dcf04c99efa68998838d3ea4764086043d96d94e5abffb4470daf51de26b.png | complex | <table><tr><td></td><td colspan="7">Talairach coordinates</td></tr><tr><td></td><td>Hemisphere</td><td>BA</td><td><i>x</i></td><td><i>y</i></td><td><i>z</i></td><td>Volume (mm<sup>3</sup>)</td><td>Mean <i>t</i></td></tr><tr><td colspan="8">REGION OF ACTIVATION</td></tr><tr><td>Medial frontal gyrus</td><td>Left/Right</td><td>6/8</td><td>5</td><td>18</td><td>43</td><td>2590</td><td>5.40</td></tr><tr><td>Anterior insula</td><td>Right</td><td>13</td><td>41</td><td>18</td><td>5</td><td>4015</td><td>5.67</td></tr><tr><td>Anterior insula</td><td>Left</td><td>13</td><td>−30</td><td>18</td><td>5</td><td>1153</td><td>5.13</td></tr><tr><td>Dorsolateral prefrontal gyrus</td><td>Right</td><td>9/10</td><td>38</td><td>42</td><td>27</td><td>888</td><td>4.94</td></tr><tr><td>Precentral gyurs</td><td>Right</td><td>9</td><td>43</td><td>26</td><td>34</td><td>1262</td><td>5.10</td></tr><tr><td>Middle frontal gyrus</td><td>Right</td><td>9</td><td>45</td><td>12</td><td>36</td><td>2422</td><td>5.18</td></tr><tr><td>Middle frontal gyrus</td><td>Left</td><td>9</td><td>−41</td><td>29</td><td>37</td><td>67</td><td>4.72</td></tr><tr><td>Middle temporal gyrus</td><td>Right</td><td>21</td><td>56</td><td>−25</td><td>−5</td><td>191</td><td>4.86</td></tr><tr><td>Inferior parietal lobe</td><td>Right</td><td>40</td><td>48</td><td>−44</td><td>37</td><td>2744</td><td>5.42</td></tr><tr><td>Inferior parietal lobe</td><td>Left</td><td>40</td><td>−46</td><td>−37</td><td>41</td><td>595</td><td>5.05</td></tr><tr><td>Precuneus</td><td>Right</td><td>7</td><td>10</td><td>−68</td><td>39</td><td>299</td><td>5.01</td></tr><tr><td>Nucleus caudatus</td><td>Right</td><td></td><td>13</td><td>8</td><td>12</td><td>224</td><td>5.38</td></tr><tr><td>Thalamus</td><td>Right</td><td></td><td>10</td><td>−12</td><td>10</td><td>113</td><td>4.82</td></tr><tr><td>Thalamus</td><td>Left</td><td></td><td>−7</td><td>−16</td><td>9</td><td>131</td><td>5.01</td></tr><tr><td colspan="8">REGION OF DEACTIVATION</td></tr><tr><td>Anterior cingulate gyrus</td><td>Left/Right</td><td>32</td><td>−2</td><td>36</td><td>−3</td><td>3226</td><td>−5.23</td></tr><tr><td>Superior frontal gyrus</td><td>Left</td><td>8</td><td>−17</td><td>26</td><td>45</td><td>315</td><td>−4.90</td></tr><tr><td>Posterior cingulate gyrus</td><td>Left/Right</td><td>30</td><td>−2</td><td>−53</td><td>20</td><td>560</td><td>−5.21</td></tr></table> |
373bd179cde589d235a1acc2d0bd4c3ca6869601b94cc55cf31f54a66362021e.png | complex | <table><tr><td rowspan="2">Variable</td><td>Rater</td><td colspan="2">Group activity</td><td>Control</td><td></td><td rowspan="2"><i>t</i></td><td rowspan="2">df</td><td rowspan="2"><i>p</i> (two-tailed)</td><td rowspan="2">Effect size</td></tr><tr><td></td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td></tr><tr><td rowspan="2">'Engagement'</td><td>TR</td><td>3.55</td><td>1.41</td><td>2.72</td><td>1.96</td><td>4.84</td><td>92</td><td>0.000</td><td>0.71</td></tr><tr><td>Observer</td><td>3.73</td><td>1.35</td><td>3.31</td><td>1.7</td><td>3.43</td><td>96</td><td>0.001</td><td>0.49</td></tr><tr><td rowspan="2">Positive mood</td><td>TR</td><td>2.48</td><td>1.07</td><td>1.76</td><td>1.28</td><td>6.04</td><td>91</td><td>0.000</td><td>0.89</td></tr><tr><td>Observer</td><td>1.52</td><td>1.07</td><td>1.24</td><td>1.29</td><td>3.12</td><td>96</td><td>0.002</td><td>0.45</td></tr><tr><td rowspan="2">Asleep</td><td>TR</td><td>1.14</td><td>1.62</td><td>1.87</td><td>2.15</td><td>−3.87</td><td>89</td><td>0.000</td><td>−0.58</td></tr><tr><td>Observer</td><td>1.19</td><td>1.63</td><td>1.48</td><td>2.09</td><td>−1.94</td><td>94</td><td>0.056</td><td>−0.28</td></tr></table> |
19cebeeb2bd32d32ded4a4e6ee831b4b71f561e287b449769d0c262d934f2ca5.png | simple | <table><tr><td>Protein</td><td>BQ00140 [49473701]</td><td>BQ00720 [49473755]</td><td>BQ03880 [49474026]</td><td>BQ12030 [49474691]</td><td>BQ07670 [49474353]</td><td>BQ11900 [49474679]</td></tr><tr><td>Length</td><td>222</td><td>83</td><td>198</td><td>91</td><td>336</td><td>172</td></tr><tr><td><i>Bra. jap</i>.</td><td>5e-18 (1.10)</td><td>2e-09 (1.08)</td><td>2e-20 (0.97)</td><td>2e-07 (1.05)</td><td>5e-46 (1.06)</td><td>1e-17 (0.98)</td></tr><tr><td><i>Rho. pal</i>.</td><td>3e-14 (1.11)</td><td>3e-09 (1.06)</td><td>2e-18 (0.97)</td><td>1e-07 (1.37)</td><td>-</td><td>-</td></tr><tr><td><i>Agr. tum</i>.</td><td>5e-13 (1.06)</td><td>6e-11 (1.02)</td><td>1e-26 (0.98)</td><td>2e-12 (1.03)</td><td>7e-66 (0.97)</td><td>2e-24 (1.37)</td></tr><tr><td><i>Sino. meli</i>.</td><td>3e-20 (1.00)</td><td>2e-13 (1.02)</td><td>7e-23 (0.98)</td><td>2e-14 (0.98)</td><td>5e-62 (1.02)</td><td>-</td></tr><tr><td><i>Bru. mel</i>.</td><td>9e-39 (0.98)</td><td>4e-19 (1.04)</td><td>1e-38 (0.97)</td><td>3e-13 (0.54)</td><td>8e-70 (0.96)</td><td>2e-26 (1.02)</td></tr><tr><td><i>Bru. suis</i></td><td>4e-39 (0.98)</td><td>4e-19 (0.96)</td><td>1e-38 (1.03)</td><td>6e-20 (0.99)</td><td>8e-70 (0.98)</td><td>6e-27 (0.98)</td></tr><tr><td><i>Meso. loti</i></td><td>3e-25 (1.07)</td><td>2e-13 (1.18)</td><td>1e-25 (0.98)</td><td>4e-16 (0.99)</td><td>2e-67 (0.95)</td><td>1e-26 (1.03)</td></tr><tr><td><i>Meso. sp</i>.</td><td>7e-18 (1.06)</td><td>2e-13 (1.02)</td><td>2e-25 (0.98)</td><td>2e-14 (1.02)</td><td>3e-61 (0.93)</td><td>7e-31 (1.02)</td></tr><tr><td><i>B. henselae</i></td><td>1e-92 (0.97)</td><td>6e-43 (1.00)</td><td>5e-92 (1.00)</td><td>2e-39 (1.00)</td><td>e-158 (1.01)</td><td>3e-81 (1.00)</td></tr><tr><td><i>B. Quintana</i></td><td>e-127 (1.00)</td><td>4e-43 (1.00)</td><td>e-107 (1.00)</td><td>1e-43 (1.00)</td><td>0.0 (1.00)</td><td>1e-91 (1.00)</td></tr><tr><td>Non – Rizobiale</td><td><i>Bdell. bacter</i>. 0.25 (1.77)</td><td><i>Sil. sp</i>. 0.46 (0.82)</td><td><i>Vibrio fischeri </i>0.005 (2.49)</td><td><i>St. pyogenes </i>0.12 (0.86)</td><td><i>St. agalactiae </i>0.38 (2.65)</td><td><i>Croc. watsonii </i>6.1 (2.85)</td></tr></table> |
c6e09cc56bc17b01ad008df595ec5455672a2d489569ee7a4fe9400a09f4c90f.png | simple | <table><tr><td></td><td><i>B. subtilis</i></td><td><i>S. aureus</i></td><td><i>A. niger</i></td><td><i>S. cerevisiae</i></td></tr><tr><td><i>(a) Activity per full feces sample</i></td><td></td><td></td><td></td><td></td></tr><tr><td>Feces producer (FP)</td><td>P = 0.440</td><td>P = 0.098</td><td>P = 0.005</td><td>P <0.0001</td></tr><tr><td>Mother-offspring interactions (MO)</td><td>P = 0.808</td><td>P = 0.104</td><td>P = 0.342</td><td>P = 0.051</td></tr><tr><td>FP : MO</td><td>P = 0.553</td><td>P = 0.934</td><td>P = 0.068</td><td>P = 0.215</td></tr><tr><td><i>(b) Activity per mg of feces</i></td><td></td><td></td><td></td><td></td></tr><tr><td>Feces producer (FP)</td><td>P <0.0001</td><td>P = 0.008</td><td>P = 0.095</td><td>P = 0.080</td></tr><tr><td>Mother-offspring interactions (MO)</td><td>P = 0.813</td><td>P = 0.575</td><td>P = 0.052</td><td>P = 0.078</td></tr><tr><td>FP : MO</td><td>P = 0.812</td><td>P = 0.731</td><td>P = 0.037</td><td>P = 0.089</td></tr></table> |
9391e6b33f6c749d886e01a3beb9bfa0a2a1a19e1a3e3aef27a4cfed409c3dd6.png | simple | <table><tr><td>Disease stage</td><td>Number of patients</td><td>HU, IFN or combination pretreatment months from diagnosis median (range)</td><td>Months on imatinib median (range)</td><td>WBC x10<sup>9</sup>/L PB median (range) PLT x10<sup>9</sup>/L PB median (range)</td><td>Blasts in PB (%) median (range)</td><td>Ph+ cells (%) median (range)</td><td>BCR-ABL (%) median (range)</td><td>BCR-ABL KD mutation Number of patients</td></tr><tr><td>Dg</td><td>13</td><td>NA</td><td>NA</td><td>67 (22-457)</td><td>2 (1-5)</td><td>100</td><td>132 (61-312)</td><td>NA</td></tr><tr><td></td><td></td><td></td><td></td><td>481 (130-824)</td><td></td><td></td><td></td><td></td></tr><tr><td>AP/BC</td><td>12</td><td>24 (2-106)</td><td>24 (8-55)</td><td>34 (1.17-147)</td><td>18 (8-76)</td><td>100</td><td>510 (103-2500)</td><td>3</td></tr><tr><td></td><td></td><td></td><td></td><td>81 (14-562)</td><td></td><td></td><td></td><td></td></tr><tr><td>Hr</td><td>15</td><td>18 (1-66)</td><td>22 (10-54)</td><td>16 (6-28)</td><td>10; 12</td><td>100 (32-100)</td><td>80 (23-827)</td><td>15</td></tr><tr><td></td><td></td><td></td><td></td><td>448 (71-1779)</td><td></td><td></td><td></td><td></td></tr><tr><td>TF</td><td>14</td><td>14 (1-68)</td><td>18 (12-67)</td><td>Phy</td><td>0</td><td>100 (40-100)</td><td>32 (11-91)</td><td>4</td></tr><tr><td></td><td></td><td></td><td></td><td>Phy</td><td></td><td></td><td></td><td></td></tr><tr><td>MMR</td><td>16</td><td>3 (1-11)</td><td>16 (7-24)</td><td>Phy</td><td>0</td><td>0</td><td>0.02 (0.001-0.1)</td><td>NA</td></tr><tr><td></td><td></td><td></td><td></td><td>Phy</td><td></td><td></td><td></td><td></td></tr></table> |
3a258a73db7699eb473b3fc2aef096a2d7b061c50a0d87cca907dc9187f7fc33.png | complex | <table><tr><td rowspan="2">threshold</td><td colspan="4">Geuvadis data</td><td colspan="4">GenoExp data</td></tr><tr><td>Lasso</td><td>ENET</td><td>LMM</td><td>BSLMM</td><td>Lasso</td><td>ENET</td><td>LMM</td><td>BSLMM</td></tr><tr><td>0.05</td><td>2252</td><td>2262</td><td>2447</td><td>2567</td><td>1785</td><td>1414</td><td>1560</td><td>1758</td></tr><tr><td>0.10</td><td>1144</td><td>1145</td><td>1145</td><td>1266</td><td>831</td><td>788</td><td>734</td><td>826</td></tr><tr><td>0.20</td><td>420</td><td>422</td><td>383</td><td>466</td><td>315</td><td>309</td><td>276</td><td>323</td></tr><tr><td>0.30</td><td>161</td><td>162</td><td>152</td><td>178</td><td>156</td><td>148</td><td>124</td><td>160</td></tr><tr><td>0.40</td><td>75</td><td>75</td><td>65</td><td>76</td><td>70</td><td>70</td><td>56</td><td>70</td></tr><tr><td>0.50</td><td>33</td><td>33</td><td>25</td><td>32</td><td>36</td><td>32</td><td>27</td><td>37</td></tr><tr><td>0.60</td><td>14</td><td>14</td><td>12</td><td>14</td><td>25</td><td>21</td><td>20</td><td>24</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.